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Biological and Phenotypic Complexity in Autism Spectrum Disorders 
Autism is behaviorally defined by severe deficits in some of our most human 
abilities: social understanding and engagement, an elaborate repertoire of 
language and communication skills, and flexibility of thought, behavior and 
interests (Volkmar, Lord, Bailey, Schultz, & Klin, 2004). In an original and seminal 
case series in 1943, Leo Kanner first reported on a collection of impairments in 
11 children, describing what he termed “autistic disturbances of affective contact” 
(Kanner, 1943). Kanner’s rich descriptions of these children included both the 
common triad of impairments that now define autism spectrum disorders (ASDs) 
— such as a failure to develop appropriate social relationships with caregivers or 
peers, profoundly affected language abilities including abject mutism, echolalia, 
literalness, and first-/third-person pronoun reversal, and an insistence on 
sameness manifest as strong aversion to changes in daily routines — as well as 
idiosyncratic complexity in each child, with each case presenting, in his words, 
“individual differences in the degree of their disturbance, the manifestation of 
specific features, the family constellation, and the step-by-step development in 
the course of years.” 
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In the seven decades since Kanner’s original report, our understanding of 
ASDs as neurodevelopmental disorders has grown a great deal. As defined by 
the 4th Edition of the Diagnostic and Statistical Manual of Mental Disorders, 
Pervasive Developmental Disorders include Autistic Disorder, Asperger’s 
Syndrome (AS), Pervasive Developmental Disorder — Not Otherwise Specified 
(PDD-NOS), Rett’s Syndrome, and Childhood Disintegrative Disorder (American 
Psychiatric Association, 1994). ASDs in particular, however, are the focus of this 
thesis and include only autism, AS and PDD-NOS. Current estimates of 
prevalence of ASDs are 0.9 to 1.1% in the US (Autism and Developmental 
Disabilities Monitoring Network, 2009; Kogan et al., 2009), and a recent report 
found a prevalence of 2.6% in a South Korean community (Kim et al., 2011) — 
placing ASDs among the most common neuropsychiatric disorders worldwide. 
The annual societal cost for caring with individuals with ASDs in the US was 
estimated to be $34.8 billion (including medical and non-medical needs, and lost 
productivity; using 2003 dollars and prevalence data) (Ganz, 2006); extrapolating 
to contemporary prevalence estimates (i.e., 1.1% (Kogan, et al., 2009)) suggests 
the cost to in fact be near $139 billion (in 2003 dollars) each year. As a lifelong 
condition, these costs are relatively consistent from childhood through adulthood 
(Ganz, 2007). Heritability of ASDs has been estimated at approximately 92% 
(Bailey et al., 1995), strongly implicating genetic risk as a primary etiology. The 
advent of ASDs-specific diagnostic instruments with high sensitivity, specificity, 
and both inter-rater and test-retest reliability (the Autism Diagnostic Observation 
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Schedule, ADOS (Lord et al., 1989) and the Autism Diagnostic Interview — 
Revised, ADI-R (Lord, Rutter, & Le Couteur, 1994)), highlights the homogeneity 
of the core triad of ASD impairments. Although individuals with ASDs, as a 
spectrum, vary in degrees of impairment (Volkmar & Pauls, 2003), the core 
features remain true to Kanner’s original description. 
Yet Kanner’s appreciation of individual differences in his original case series 
has proven prophetic, for our modern, nuanced understanding of ASDs reveals a 
far more complex and heterogeneous disorder. In search of biomarkers and 
endophenotypes, a number of studies have reported various neuro-centric 
findings. Macroscopic brain over-growth in the first years of life, measured 
grossly by head circumference or in more neuroanatomical detail with structural 
magnetic resonance imaging (MRI), showed group effects of ASD enlargement 
relative to controls, but importantly, a variable distribution within individuals with 
ASDs such that some affected individuals were within the normative range 
(Courchesne, Carper, & Akshoomoff, 2003; Hazlett et al., 2005). Macrocephaly, 
defined by head circumference greater than the age- and sex-normed 97th 
percentile, has been reported in approximately 15 to 17% of individuals with 
ASDs (Fombonne, Rogé, Claverie, Courty, & Frémolle, 1999; Lainhart et al., 
2006). Functional MRI studies showed focal hypoactivation of the “fusiform face 
area” (i.e. the fusiform gyrus of the ventral temporal lobe) in passive viewing 
tasks of static faces by individuals with ASDs compared to controls (Schultz et 
al., 2000), although interestingly more recent findings suggest only for unknown 
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(stranger) faces but not familiar (caretaker) faces (Pierce & Redcay, 2008). 
Looking at the long-range functional connectivity of different regions, numerous 
studies have shown hypoconnectivity across brains of individuals with ASDs 
(Geschwind & Levitt, 2007; Just, Cherkassky, Keller, & Minshew, 2004). For 
example, resting-state, interhemispheric-correlated activity is decreased in 
individuals with ASDs compared to controls, in ASDs-relevant regions, including 
the fusiform gyrus and anterior insula (Anderson et al., 2011). These functional 
data are supported by structural data, such as reduced volume and fractional 
anisotropy (measured by diffusion tensor imaging) of the corpus callosum in 
some individuals with ASDs (Alexander et al., 2007). Abnormalities at the 
microscopic level have also been reported in ASDs. Although inherently limited 
by small sample sizes, multiple reports have shown abnormalities in the post-
mortem cytoarchitecture of neocortical minicolumns, including increased number, 
decreased size and altered spacing, suggesting local hyperconnectivity in the 
ASD brain (Casanova, Buxhoeveden, Switala, & Roy, 2002; Casanova, El-Baz, 
Vanbogaert, Narahari, & Switala, 2010; Casanova et al., 2006). This seeming 
contradiction of simultaneous hyper- and hypoconnectivity in the ASD brain has 
been synthesized in unifying hypotheses regarding brain dysfunction in the 
ASDs, hypothesizing that local and overactive networks become disconnected 
from distant cortical areas which would, in individuals without ASDs, allow for 
higher order integration of information (Casanova & Trippe, 2009; Geschwind & 
Levitt, 2007). Biomarkers for ASDs have also been examined outside of the 
4
  
brain. Hyperserotonemia has been reported in approximately 35 to 60% of 
individuals with ASDs (Cook & Leventhal, 1996; Mulder et al., 2004). Various 
genetic findings (discussed in detail below) have been increasingly reported in 
recent years. Finally, the preponderance of males (a male-to-female ratio of 
4.3:1) affected with ASDs is perhaps the oldest — and yet, still unexplained — 
biomarker in ASDs(Fombonne, 2003). 
The biological complexity of ASDs is met with equally vexing clinical and 
behavioral heterogeneity (Geschwind, 2009; Gillberg & Billstedt, 2000; Levy, 
Mandell, & Schultz, 2009). ASDs vary in degrees and domains of impairment. For 
example, individuals with AS may have no intellectual disability, intact functional 
language capacities, and good outcomes; whereas greater than 50% of 
individuals with prototypical autism have intellectual disability, are often 
nonverbal, and have poor outcomes (Volkmar & Pauls, 2003). In fact, there is 
evidence that the triad of impairments fractionate along heritability, with each 
core deficit being, by itself, highly heritable, but correlating only modestly with 
each of the other two deficits (i.e., pairwise correlation coefficients ranging from 
0.23 to 0.38) (Ronald et al., 2006). Individuals with ASDs are often diagnosed 
with co-occurring mental health and behavioral disorders (Levy et al., 2010), 
including anxiety (42% (Simonoff et al., 2008)), aggression (22% (Hartley, Sikora, 
& McCoy, 2008), and obsessive-compulsive disorder (37% (Leyfer et al., 2006)). 
High prevalences of various medical comorbidities have also been reported in 
ASDs (Boulet, Boyle, & Schieve, 2009; Gurney, McPheeters, & Davis, 2006). 
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Seizure disorders have been reported in 21% of individuals with ASDs, a 
significant increase compared to a non-ASD population (Volkmar & Nelson, 
1990), with some estimates ranging as high as 38% prevalence (reviewed in 
(Tuchman & Rapin, 2002)). Sleep problems have been reported in 53% of 
children with ASDs (Krakowiak, Goodlin-Jones, Hertz-Picciotto, Croen, & 
Hansen, 2008; Malow et al., 2006). Gastrointestinal problems have also been 
reported in some individuals with ASDs, discussed in depth below. 
The preceding survey of biological and phenotypic heterogeneity serves to 
illustrate a key, foundational point: individuals with ASDs are highly complex, and 
this complexity has important implications. Aside from the triad of core 
impairments (which, by definition, must be present for a diagnosis of an ASD), no 
other feature is invariant and completely penetrant in all individuals with ASDs. 
This heterogeneity has ramifications for the diagnosis and treatment of 
individuals with ASDs (Bauman, 2010b). It has been reported that children with 
co-occurring medical conditions and ASDs are diagnosed later than children with 
only an ASD diagnosis, suggesting that co-occurring conditions can mask core 
impairments and delay accurate ASD diagnosis (Levy, et al., 2010). Moreover, 
this heterogeneity has hindered efforts to understand the genetic basis of risk for 
ASDs, discussed below.  
Pleiotropy — defined as a single genetic element affecting multiple 
phenotypes — is one possible explanation for this heterogeneity (Bill & 
Geschwind, 2009). Genes can be expressed in diverse cells and tissues across 
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an organism, at different times in those tissues during development, and in 
response to different stimuli in a cell-specific manner. A pathogenic or 
susceptibility genetic variant, therefore, can affect multiple organ systems in a 
single individual (i.e., the DSCR1 gene is implicated in both congenital heart 
defects and Down Syndrome (Fuentes et al., 1995)). An appreciation of this 
simple fact affords an opportunity to gain insight into the ASDs: by better 
understanding the complexity of ASDs, heterogeneity can be leveraged for 
benefit. It has been proposed that genetic variants conferring risk for ASDs are 
enriched in populations stratified by pleiotropic phenotypes (Campbell et al., 
2009). Investigating biological differences in stratified populations can therefore 
enable insight into ASD risk and pathogenesis. With a richer understanding of 
such differences, a natural extension is an appreciation for — and hopefully 
insight into — individualized strategies for clinical care. As a case study for this 
paradigm, the work reported in this thesis focuses on co-occurring 
gastrointestinal dysfunction (GID) in ASDs. The remainder of this chapter will 
proceed with a survey of the genetics of ASDs, highlighting progress and 
challenges. Then the focus will turn to one particular ASD susceptibility candidate 
gene, MET, examining supporting evidence for its role in risk for ASDs, as well as 
GID. Finally, this chapter will conclude with an in-depth description of GID in 
ASDs, returning to the clinical aspects of this disorder, and providing the 




The Genetics of Autism Spectrum Disorders: Progress and Challenges 
As a profound, prevalent and highly heritable condition, the interrogation of 
the genetics of ASDs has a rich history. Classic studies of concordance for ASDs 
in monozygotic (MZ) compared to dizygotic (DZ) twins established the strong 
heritability of the disorders. Using a less-stringent definition of ASDs (including 
broader cognitive and social deficits), DZ twin pairs were 10% concordant for 
diagnoses, compared to 92% of MZ pairs; using a strict definition of autism, 60% 
of MZ pairs compared to 0% of DZ pairs were concordant (Bailey, et al., 1995; 
Folstein & Rutter, 1977). Sibling recurrence risk for autism is high, reported at 
4.5% (Jorde et al., 1991). Building on this foundation, numerous studies in recent 
years have implicated a variety of genetic insults contributing to risk for ASDs 
(Abrahams & Geschwind, 2008). 
However, before moving to an examination of more recent genetic findings in 
the ASDs, a discussion of the two major, prevailing hypotheses regarding the 
genetic architecture of ASDs must be elaborated to provide necessary context. 
The two hypotheses that serve as framework for ASD risk and pathogenesis, 
which are neither necessarily mutually exclusive nor specific to ASDs, are the 
Common Variant-Common Disease (CVCD) and the Rare Variant-Common 
Disease (RVCD) hypotheses (El-Fishawy & Matthew W State MD, 2010). The 
CVCD hypothesis proposes that multiple common genetic variants (greater than 
1% prevalence in a population), each with small effect sizes, interact in an 
oligogenic manner to contribute to disease risk (Chakravarti, 1999; Reich & 
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Lander, 2001). The out-of-Africa theory of evolution is key to the CVCD 
hypothesis, for the theory proposes that a relatively small population of ancestral 
humans (on the order of 10,000 individuals) rapidly grew into the current world 
population over a relatively brief evolutionary period (on the order of 100,000 
years). In this ancestral population, the small size presumably allowed for only a 
small diversity of variants at any genetic locus, and therefore disease alleles for 
common diseases were common, whereas disease alleles for rare diseases were 
rare. With a rapid population expansion, although new mutations were introduced 
into the larger population’s collective genome, the original relative frequencies 
(common versus rare) were maintained during expansion, leaving common 
alleles as the prime source of variation for common diseases in the current 
human population. A secondary hypothesis consistent with the CVCD hypothesis 
is that a sub-threshold number of disease-associated common variants will be 
present in family members of probands, with subclinical manifestations of 
disease in these family members. Studies on the broad autism phenotype (BAP 
(Piven, 2001)) support such a hypothesis, for example reporting increased social 
and communication impairment in the undiagnosed parents and siblings of 
probands (Bishop et al., 2004; Constantino et al., 2006). 
In contrast, the RVCD hypothesis posits that rare polymorphisms (less than 
1% population prevalence), each with much larger effects than is seen in the 
CVCD hypothesis, are the predominant contributors to disease risk. A primary 
rationale for the RVCD hypothesis is that early-onset disorders (such as the 
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ASDs) which negatively affect an individual’s reproductive fitness (i.e., social, 
communicative, and often cognitive, impairments in the ASDs) would be subject 
to negative selection over evolutionary timescales, therefore only allowing such 
deleterious variants to exist, maximally, at low frequency in a population (El-
Fishawy & Matthew W State MD, 2010). Rare variants can be inherited or occur 
de novo, and recent reports (discussed below) provide support for both 
categories. Additional support for the RVCD hypothesis comes from, 
unexpectedly, reports that used the CVCD hypothesis as an intellectual 
foundation. Recent studies in search of common variants have found relatively 
few significant findings, with modest effect sizes and explaining a small fraction 
of disease variability, suggesting that common variants may not play a large role 
in risk, and thus implicating, indirectly, rare variants. However, although the two 
hypotheses represent contrasting models of allelic architecture, one hypothesis 
does not necessarily preclude the other’s existence. While a recent report stated 
that “the hypothesis that autism results from an unfortunate combination of 
common low-risk variants can be safely rejected,” this conclusion seems myopic 
(Levy et al., 2011). Instead, a more balanced view is one which appreciates 
biology’s complexity, and seeks to gain insight into disease by integrating 
findings grounded in both CVCD and RVCD hypotheses, transcending the 
historical dichotomy (and sometimes antagonism (Levy, et al., 2011)) (Iyengar & 
Elston, 2007). Additionally, an implicit concept in this discussion of genetic risk 
for complex disorders is that genes do not operate in a biological vacuum; 
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epistatic, epigenetic, experiential, environmental, and stochastic modifiers can all 
exert significant effects. 
In recent years, multiple genome-wide association (GWA) studies of ASDs, 
explicitly designed to test the CVCD hypothesis, have been reported. One allele 
of a single nucleotide polymorphism (SNP) in a 300 kilobase (kb) intronic region 
of the MACRO domain containing 2 (MACROD2) gene on chromosome 20p12.1 
was reported as significantly associated with an ASD diagnosis (Anney et al., 
2010). Other variants on chromosome 5p15.2, approximately 80 kb upstream 
from the semaphorin 5A (SEMA5A) gene, were also reported (Weiss, Arking, 
Daly, & Chakravarti, 2009). Another report implicated chromosome 5p14.1, with 
loci in a 2.2 megabase (Mb) intergenic region between the cadherin 10 (CDH10) 
and cadherin 9 (CDH9) genes (Wang et al., 2009). The 5p14.1 association was 
reported again by the same group (Ma et al., 2009). Interestingly, a subsequent 
report based on the 5p14.1 findings showed significant association of the 
rs4307059 risk allele with lower social communication functionality in a general 
population sample, consistent with the CVCD hypothesis (St Pourcain et al., 
2010).  
In a critical appraisal of these GWA studies, several points are worth noting. 
Although the 5p14.1 findings were initially replicated, subsequent studies have 
failed to replicate the associations with 5p14.1, 20p12.1 or 5p15.2. The loci 
implicated are often presented without rigorous empirical data that clarifies the 
biological roles or implications of the disease-associated variant, leaving a void 
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where a reader would hope to find a biological context that could ground further 
studies of the locus. Instead, the nearest annotated gene is reported, guilty-by-
proximity. In these reports, it remains to be demonstrated that a locus 80, 300, or 
2,200 kb away from an exon of a nearby gene can have an effect on that 
particular gene’s transcription or function, with concomitant biological implications 
for the resulting disease. With thousands of subjects in these GWA studies, only 
a small number of loci, with modest effect sizes (ranging from 1.2 to 1.9 (Anney, 
et al., 2010; Ma, et al., 2009; Wang, et al., 2009; Weiss, et al., 2009)), have been 
identified. These criticisms, however, are opportunities for improvement in future 
studies and highlights of the difficulties inherent in GWA studies. Although 
modest, the findings are presumably valid, and consistent with some contribution 
of common variants to risk for ASDs. As unbiased, non-hypothesis-driven 
investigations, they serve as starting points for further studies that may reveal 
aspects of the pathobiology of ASDs.  
Additional insight into risk for and pathogenesis of the ASDs has also come 
from study of rare variants. One approach to studying low frequency genetic 
insults is to focus on monogenic disorders with large phenotypic overlap with 
ASDs. In these rare disorders, such as fragile X syndrome (FXS) and tuberous 
sclerosis (TSC), as high as 25% of individuals with the syndrome also have a 
diagnosable ASD (Muhle, Trentacoste, & Rapin, 2004). These disorders are rare 
(approximately 1 in 6,000 for TSC (O'Callaghan, Shiell, Osborne, & Martyn, 
1998) and 1 in 2,500 for FXS (Crawford et al., 2002)), and each disorder 
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accounts for only 1-2% of ASD cases (Abrahams & Geschwind, 2008). Although 
some have expressed concern regarding the relevance of cases of so-called 
syndromic ASDs to the understanding of core pathogenesis in non-syndromic, 
idiopathic ASDs (particularly in the context of severe intellectual disability) (Moss 
& Howlin, 2009), as highlighted below, elucidating the genes involved (FMR1 for 
FXS; TSC1 and TSC2 for TSC) in these monogenic disorders may provide 
insight into molecular mechanisms of pathogenesis in the ASDs.  
Other rare variant findings are also important contributions to understanding 
the genetics of ASDs. Maternal duplications of the 15q11-15q13 chromosomal 
region, with the maternally-expressed UBE3A gene thought to be critically 
involved, are common cytogenetic and chromosomal microarray findings in the 
ASDs (Abrahams & Geschwind, 2008; Cook et al., 1997; Matsuura et al., 1997). 
Deletions involving 22q13 have also been reported, with the SHANK3 gene now 
implicated in pathogenesis (Durand et al., 2007; Manning et al., 2004; Moessner 
et al., 2007). Other studies have reported major effects of rare mutations in the 
NLGN3, NLGN4, and NRXN1 genes (Feng et al., 2006; Jamain et al., 2003). 
Although each of these rare sequence and structural abnormalities are present in 
no more than 1 to 2 % of individuals with ASDs, collectively they account for an 
estimated total of 15% of cases (Abrahams & Geschwind, 2010). 
The field has recently focused on larger structural variants (greater than 1,000 
bp, including both gains and losses) across the genome, collectively referred to 
as copy-number variants (CNVs) (Merikangas, Corvin, & Gallagher, 2009). 
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Noteworthy findings include CNVs at 16p11.2, initially reported to account for 
approximately 1% of cases of ASD (Kumar et al., 2008; Weiss et al., 2008). In a 
recent meta-analysis of seven studies of 16p11.2 in the ASDs, prevalence was 
found to be a more modest 0.76% (with deletions approximately two-fold more 
common than duplications at the locus) (Walsh & Bracken, 2011). Other studies 
have replicated some genes and regions that were already implicated in risk for 
ASD, including UBE3A, NRXN1, and 16p11.2 (Glessner et al., 2009), and 15q11-
13 (Christian et al., 2008), while also suggesting novel loci to be further studied. 
Some research groups have developed a particular focus on de novo, and thus 
presumed pathogenic, CNVs. Multiple studies have reported increased frequency 
of de novo CNVs in simplex (7-10%; only one child affected with an ASD) 
compared to multiplex (2-3%; more than one child affected with an ASD) families, 
or compared to controls (1%) (Marshall et al., 2008; Pinto et al., 2010; Sebat et 
al., 2007). This enrichment of signal in simplex families served as a strong 
rationale for focusing exclusively on simplex families in larger cohorts and with 
state-of-the-art assay arrays, as two recent reports did (Levy, et al., 2011; 
Sanders et al., 2011). As the most current CNV data published, these two studies 
suggest a range of 100 to 400 genes and loci are implicated in risk and 
pathogenesis for ASDs, and account for approximately 5% of simplex cases. 
However, as a still-developing method of inquiry, the CNV literature has 
unresolved issues of specificity and presumed pathogenicity. Otherwise normal 
and unaffected individuals have, on average, 11 CNVs each (Sebat et al., 2004), 
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strongly suggesting that presence of a CNV is, by itself, insufficient for causing 
disease. Moreover, association between a recurrent CNV and ASDs as a specific 
phenotype, is variable. For example, 16p11.2 deletions have been reported to 
also be associated with obesity and intellectual disability, irrespective of social 
disability (Walters et al., 2010). 
Although the field has learned a great deal about genetic susceptibility for 
ASDs, two conspicuous points persist, with particular relevance to case-control 
studies of association. Namely, the vast majority of idiopathic cases of disease 
remain unexplained (by neither putatively pathogenic de novo mutations, rare 
mutations of large effect, nor monogenic insults) (Schaaf & Zoghbi, 2011), and 
large consortia-based studies have often not replicated previous findings for 
genome-wide analyses (Anney, et al., 2010; Weiss, et al., 2009). Pointing to 
underlying genetic heterogeneity as the root cause, calls for larger samples sizes 
in response — to detect even lower frequency rare variants, and common 
variants with even smaller effect sizes — have been made (Anney, et al., 2010; 
Marshall, et al., 2008; Wang, et al., 2009). However, although the phenotypic 
heterogeneity of ASDs is often mentioned in reports of genetic studies, curiously, 
it is mentioned seemingly only as a formality, without giving the concept much 
attention in the study (Wang, et al., 2009). As a field, it is an improvement to have 
consensus that gold standard diagnostic instruments (i.e., ADOS and/or ADI-R) 
must be used to confirm a categorical diagnosis of an ASD, facilitating inter- and 
intra-study comparisons of ASD case status. However, by including all subjects 
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meeting ASD categorical criteria, and given the deep heterogeneity of ASDs, 
genetic studies of association are, possibly, diluting disease-associated signal, 
as that signal may only be present in a subset of the study’s entire population. 
For example, in a recent GWA study, a significant association was found for 
rs4141463 on chromosome 20p12.1 (Anney, et al., 2010). However, this 
association was only significant when considering cases that met strict criteria for 
ASD diagnosis and were of European ancestry (P = 2.10x 10-8; i.e., meeting the 
conventional Bonferroni-corrected GWA threshold for significance of P < 5 x 10-
8). For all cases, including those meeting a less strict diagnosis for the broader 
autism spectrum, and those of all ancestries, this locus was no longer significant 
(P = 4.30 x 10-5). Unfortunately, the current practice is to report minimal 
phenotypic information on study subjects (and, when more detailed information is 
offered, it is relegated to a publication’s online supplement, seemingly as an 
afterthought (Marshall, et al., 2008; Wang, et al., 2009)). Phenotype is not 
supplemental; phenotype is substantive. However, hopefully representative of the 
field’s evolving priorities, a recent report does look at relationships between de 
novo CNVs and more nuanced phenotypes beyond categorical ASD diagnoses, 
such as IQ and externalizing behaviors (Sanders, et al., 2011). Broad support for, 
and NIH-mandated compliance with, data-sharing in the National Database for 
Autism Research (NDAR, (National Institute of Mental Health)) may help move 
the field in a positive direction, as granular phenotype data will be available to 
investigators through this centralized database and enable follow-up phenotype 
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analyses even if such analyses were not included in original reports. As the field 
quickly progresses towards exome (O'Roak et al., 2011) and whole genome 
sequencing, there is an opportunity to move beyond the challenges of categorical 
diagnoses in ASDs, by leveraging phenotypic differences in stratified 
subpopulations to enrich for, potentially, a more genetically homogenous subset 
of individuals. The calls for larger sample sizes, therefore, may in fact prove 
useful, as they will allow for stratifying of populations based on phenotype. 
In a broader view, the variety of loci now implicated in the ASDs — common 
and rare, single sequence variants and larger CNVs, de novo and inherited — 
suggest an emerging, central hypothesis for risk and pathogenesis. Proteins of 
several of the loci implicated in the ASDs, including NLGN3, NLGN4, NRXN1, 
and SHANK3, share a common neuroanatomical geography: the excitatory 
synapse (Gilman et al., 2011; Penzes, Cahill, Jones, VanLeeuwen, & Woolfrey, 
2011; Zoghbi, 2003). Extending the model from synapse structure genes to 
downstream intracellular signaling molecules, the PI3 Kinase-AKT pathway is 
further implicated, which integrates the monogenic, syndromic ASD genetic 
defects (such as FMR1, TSC1 and TSC2, NF1, and PTEN) (Bill & Geschwind, 
2009; Levitt & Campbell, 2009). As discussed in the following section, a key 
player involved in upstream signaling of this pathway, MET, is a receptor tyrosine 
kinase with multiple, convergent lines of evidence in support of its role in ASD 




The Genetics of Autism Spectrum Disorders: Focus on MET Signaling 
An association between a common polymorphism in the MET gene, and risk 
for developing an ASD, was first reported in 2006 (Campbell et al., 2006). The 
reasons for first investigating MET as an ASD candidate risk gene were 
numerous. A broad linkage peak on chromosome 7q — encompassing many 
genes, including MET — had been reported multiple times (International 
Molecular Genetic Study of Autism Consortium, 1998, 2001; Lamb et al., 2005; 
Philippe et al., 1999; Schellenberg et al., 2006). At the time, although MET 
signaling was primarily known to be involved in the biology of cancer due to its 
original discovery as a proto-oncogene (Cooper et al., 1984; Trusolino, Bertotti, & 
Comoglio, 2010), there was a growing literature which implicated MET signaling 
in neurodevelopment. Using mouse models and cell culture assays (in which the 
mouse form is indicated by Met instead of MET), multiple studies had 
demonstrated in vitro evidence of Met signaling’s involvement in both axonal and 
dendritic outgrowth of cultured neurons (Gutierrez, Dolcet, Tolcos, & Davies, 
2004; Powell, Mühlfriedel, Bolz, & Levitt, 2003), as well as regulation and 
functioning of synapses (Akimoto et al., 2004; Tyndall & Walikonis, 2006). 
Moreover, it was also reported that Met signaling increased motility of cells 
migrating out of the ganglionic eminence en route to the neocortex (Powell, Mars, 
& Levitt, 2001). Implicating Met signaling in interneuron migration, and thus 
potentially the overall inhibitory tone of the developed cortex, was consistent with 
hypotheses of imbalanced excitation-inhibition as a possible etiology of the ASDs 
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(Casanova, Buxhoeveden, & Gomez, 2003; Levitt, Eagleson, & Powell, 2004; 
Rubenstein & Merzenich, 2003). Although at the time this was an additional 
rationale for exploring MET as an ASD candidate gene, more recent findings, it 
should be noted, have suggested that in fact Met signaling does not have a direct 
effect on interneuron motility in vivo, and that initial findings reported in 2001 
were possibly confounded by ectopic expression of Met induced by cell culture 
conditions (Eagleson, Campbell, Thompson, Bergman, & Levitt, 2010). Finally, 
beyond the central nervous system, Met signaling is also implicated in immune 
and gastrointestinal processes, abnormalities of which are both reported in the 
ASDs (Beilmann et al., 1997; Beilmann, Vande Woude, Dienes, & Schirmacher, 
2000; Numata et al., 2005; Tahara et al., 2003). The role of Met in 
gastrointestinal function, as well as gastrointestinal issues in ASDs, will be 
discussed below in greater detail. 
Since the original report in 2006 of association between a functional common 
polymorphism in MET and risk for ASDs, additional findings on the 
neurobiological roles played by Met have corroborated the initial rationale and 
hypothesis of MET signaling playing an important role in the ASDs (reviewed in 
(Judson, et al., 2011)). Comprehensive and detailed neuroanatomical mapping 
studies of Met expression during neurodevelopment suggest Met signaling is 
involved in the development of forebrain and limbic circuits involved in various 
aspects of social and emotional behavior and which are thought to play important 
roles in the etiology of the ASDs. In the mouse, Met mRNA transcript is detected 
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in neocortical projection neurons of cingulate, prefrontal, temporal and sensory 
cortices and traditional limbic structures such as the amygdala, hippocampus, 
and septum, whereas protein is detected in axon fiber tracts connecting those 
regions (such as the cingulum, fornix, and internal capsule) (Judson, Bergman, 
Campbell, Eagleson, & Levitt, 2009). Moreover, peak expression of Met is during 
the second postnatal week in the mouse, which corresponds to extensive neurite 
outgrowth and synaptogenesis, suggesting Met signaling plays important roles in 
developing appropriate wiring connections in these circuits (Judson, et al., 2009). 
A subsequent study comparing Met expression in the developing mouse to MET 
expression in the developing rhesus macaque brain provides additional support 
for the receptor’s roles in development of particular circuits. The timing of MET 
protein expression was found to be highly conserved between mouse and 
macaque, with the primate expression also coinciding with synaptogenesis 
(Judson, Amaral, & Levitt, 2010a). Although expression in limbic structures was 
also conserved, there was a difference in neocortical expression between mouse 
and macaque, with restricted expression of MET in cortical areas of species-
specific relevance (such as the posterior cingulate, inferior temporal, posterior 
parietal and visual cortices) (Judson, et al., 2010a). Although divergent, these 
findings are consistent with the hypothesis that MET signaling is involved in the 
ontogeny of limbic and neocortical circuits implicated in species-specific 
communication and social behavior. Along with developmental expression 
studies that increased understanding of the normative roles played by Met/MET 
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signaling, there have also been reports of the implications of a specific loss of 
Met signaling in a mutant model system. In Met conditional null mice (in which 
the kinase domain, critical for proper receptor signaling, is ablated specifically in 
forebrain excitatory neurons arising from the dorsal pallium), dendrite and spine 
morphology changes have been reported and are presumed to be cell-
nonautonomous (Judson, Eagleson, Wang, & Levitt, 2010b). Using the same 
conditional mutant model, the physiological impact of loss of Met signaling in 
neurons derived from the dorsal pallium was studied. In Met null mice, local 
excitatory input from layer 2/3 to layer 5 pyramidal neurons was two-fold stronger 
compared to controls (Qiu, Anderson, Levitt, & Shepherd, 2011). This specific 
alteration of local circuit connectivity is consistent with hypotheses of 
differentially-altered local versus long-range connectivity in the ASDs (Casanova 
& Trippe, 2009; Geschwind & Levitt, 2007). Together, these reports on dendritic, 
synaptic and connectivity findings all suggest that MET signaling may be an 
important component to include in synaptic models of ASD pathobiology (Gilman, 
et al., 2011; Penzes, et al., 2011; Zoghbi, 2003). In summary, the experimental 
data elucidating the developmental and neurobiological roles of the MET 
signaling system provide multiple lines of convergent evidence to support MET 
as an ASD risk gene. 
Multiple reports of human genetic findings complement the basic 
neurobiological data implicating MET signaling in ASD pathobiology. The original 
study of an association between a common variant, the C allele of rs1858830, in 
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the promoter of the MET gene and risk for ASDs reported a relative risk of 2.27 
(Campbell, et al., 2006). The rs1858830 G/C SNP resides in the 5’ untranslated 
region (UTR), 20 bp upstream of the transcriptional start site of MET. The 
association between rs1858830 and risk for ASDs was replicated in two 
independent cohorts, one by another research group (Campbell, Li, Sutcliffe, 
Persico, & Levitt, 2008; Jackson et al., 2009). Using gel-shift and cell-based 
transcriptional assays, it was also reported that the C allele at rs1858830 
resulted in altered transcription factor binding to the MET promoter and 
decreased transcription of a reporter signal (Campbell, et al., 2006). These in 
vitro data were consistent with previous reports of the functional significance of 
promoter variants (Masotti et al., 2005). A subsequent study reported a two-fold 
reduction in MET protein in post-mortem temporal cortex of ASD compared to 
matched control brains (Campbell et al., 2007), data which was suggestive of the 
in vivo functional consequence of rs1858830. These data, combined with the 
neurobiology of Met/MET signaling discussed above, support the hypothesis that 
the rs1858830 C allele is a common variant which predisposes specific neural 
circuitry to an altered developmental trajectory and functional capacity, which 
ultimately places the individual at risk for developing an ASD.  
In addition to the rs1858830 findings, additional reports have implicated 
altered MET signaling in risk for ASDs. Two other SNPs in MET, rs38841 and 
rs38845, have also been reported to be significantly associated with risk for 
ASDs, in independent cohorts and by separate research groups (Sousa et al., 
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2009; Thanseem et al., 2010). Both SNPs reside in intron 1 of MET, and although 
direct evidence of functional significance of either SNP has not been reported, a 
bioinformatics analysis of rs38845 alleles suggests the sequence variation may 
impact transcription factor binding (Sousa, et al., 2009). Additionally, two rare 
missense variants in exon 14 of MET, rs56391007 and rs34589476, were 
reported with increased prevalence in cases (1.8%) versus controls (0.6%), 
although not to a statistically significant degree (Campbell, et al., 2006). These 
variants reside in the juxtamembrane domain of the protein and have been 
reported to increase protein function (Ma et al., 2003). The linkage disequilibrium 
(LD) block structure of the 5’ region of MET is shown in Figure 1, with relative 
positions of rs1858830, rs38841, and rs38845. Each 5’ SNP, according to this 
block structure, resides in a distinct block in Caucasians. Figure 2 shows a 
schematic representation of the 5’ and exon 14 rare variants. Multiple research 
groups using independent sample data, with different races and ethnicities, in 
both case-control and family-based (thereby addressing concerns of population 
stratification) study designs have reported significant association between 
polymorphisms in the 5’ region of MET and risk for ASDs. Moreover, rare de 
novo CNVs of chromosome 7 that encompass MET have been observed in ASD 
(Marshall, et al., 2008; Pinto, et al., 2010). Variants of two other genes with 
protein products that are involved in the MET signaling cascade, PLAUR and 
SERPINE1, have also been associated with risk for ASDs (Campbell, et al., 
2008). Finally, a recent gene expression study using a large sample of  
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Figure 1. Structure of ASD-associated loci in the MET gene. LD block 
structure of 5ʼ region of MET in Caucasians, showing 3 ASD-associated SNPs 
(rs1858830, rs38841, and rs38845) and their locations in three distinct blocks. 
Figure modified from output generated in Haploview 4.2 <Barrett Bioinfor 2005>
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Figure 2. Schematic structure of ASD-associated loci in the MET gene. 
Schematic representation of MET, showing relative locations of common SNPs in 
the 5ʼ UTR (rs1858830) and intron 1 (rs38841 and rs38845), and rare variants 












postmortem brains reported decreased expression of MET in temporal neocortex 
of individuals with ASD (Voineagu et al., 2011). In sum, the data and reports 
linking altered MET signaling to ASDs are comprehensive, rigorous, and 
replicated — and taken together, make a strong and compelling case for MET as 
a risk gene for ASDs. 
 
Met as a Pleiotropic Signaling Receptor in the Gastrointestinal System 
In addition to the neurobiological and genetic findings discussed above, MET 
signaling is also important in the development and functioning of cells and tissues 
outside of the nervous system. In the mouse, Met signaling has been implicated 
in cell proliferation, migration, differentiation and survival (Beilmann, et al., 2000; 
Birchmeier, Birchmeier, Gherardi, & Vande Woude, 2003; Bladt, Riethmacher, 
Isenmann, Aguzzi, & Birchmeier, 1995; Dignass, Lynch-Devaney, & Podolsky, 
1994; Giacobini et al., 2007). Of particular relevance to this thesis, Met signaling 
is also implicated in the development and function of the gastrointestinal system. 
Met expression in mouse gastrointestinal tissue has been reported during 
development and in the adult, but these studies generally have lacked adequate 
resolution to determine cell specificity. Expression at embryonic day 9 (E9) is 
detected in the hindgut (the anatomical precursor of the distal third of the colon 
and rectum) (Andermarcher, Surani, & Gherardi, 1996), and later at E15 and E17 
in the immature intestines (Sonnenberg, Meyer, Weidner, & Birchmeier, 1993). 
Met expression is detectable in the adult small and large intestine, although at a 
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low basal level (Boon et al., 2006). Rodent studies are paralleled by human 
expression studies, showing MET to be expressed in various gastrointestinal 
tissues along the developing alimentary canal throughout development 
(Kermorgant et al., 1997) and in the adult colon (Crepaldi et al., 1994). 
Presuming the expression is not superfluous, these studies suggest that the 
expression of Met/MET is functional, playing a role in gastrointestinal 
development and physiology. Some insight into the role of MET in the large 
intestine may be gleaned from a series of studies which report that administration 
of exogenous hepatocyte growth factor (HGF), Met’s endogenous ligand, can 
augment epithelial repair processes in acute gastrointestinal injury paradigms. 
These findings have been demonstrated in mice (Oh et al., 2005) and rats 
(Numata, et al., 2005; Tahara, et al., 2003), in two different injury paradigms and 
methods of delivering HGF, by independent research groups, strongly supporting 
the hypothesis that Met signaling is important in physiological repair processes in 
the rodent large intestine. These findings are consistent with a study of MET 
expression in human colonic tissue which showed increased expression in 
inflamed tissue of patients with ulcerative colitis, compared to control tissue 
(Kitamura et al., 2000). 
These additional biological roles played by MET in the gastrointestinal system 
demonstrate the pleiotropic biology of MET, a concept which served as the 
intellectual framework for a follow-up study of the reported associations between 
MET and risk for ASDs. A subpopulation of individuals with ASDs also have co-
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occurring gastrointestinal dysfunction (discussed in the following section). It was 
therefore hypothesized that those with co-occurring GID and ASDs represented a 
more etiologically-homogenous subgroup of individuals compared to a 
phenotypically-diverse population of cases of idiopathic ASD, and that this 
subgroup may share a common biology which places them at parallel risk for 
both gastrointestinal and brain dysfunction (Campbell, et al., 2009). Campbell 
and colleagues found the rs1858830 C allele — a common variant previously 
associated with risk for ASDs — to be significantly overtransmitted in individuals 
with co-occurring GID and ASDs, compared to ASDs-only (Campbell, et al., 
2009). The field of genetics of ASDs has generally shifted its focus away from 
study of common variants to that of rare variants as prime suspects for risk and 
pathogenesis, with some claiming that common variants play no role at all (Levy, 
et al., 2011). However, the evidence in support of the common variant rs1858830 
(and thereby altered MET signaling in general) as a risk factor for ASDs is 
substantial and makes for a compelling rationale to further study this fascinating 
intersection of biology and disease. 
 
Co-Occurring Gastrointestinal Dysfunction in Autism Spectrum Disorders 
As part of the heterogeneity of ASDs, a subgroup of individuals with ASDs 
present with co-occurring gastrointestinal dysfunction (Buie et al., 2010a; Buie et 
al., 2010b). Although reports on the prevalence of GID in the ASDs vary widely, 
from 9% (Black, Kaye, & Jick, 2002) to 24% (Molloy & Manning-Courtney, 2003) 
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to 54% (Levy et al., 2007) to 70% (Valicenti-McDermott et al., 2006), it is 
important to note that overall prevalence of GID in the ASDs is irrelevant to the 
biological study of specifically those individuals with co-occurring GID and ASDs. 
The lack of replication or agreement regarding prevalence estimates suggests 
the true rate of GID in the ASDs has not yet been accurately determined, and a 
critical review of epidemiological studies of GID in ASDs concluded that they are 
hindered by serious flaws, including small sample sizes, reporting biases, and 
lack of proper comparison groups (Erickson et al., 2005). However, whatever the 
prevalence might be, it is a truism that there is a subpopulation of individuals with 
GID. For these individuals, in addition to the difficulties inherent in their overall 
ASD, the presence of co-occurring GID may have implications for their clinical 
care, including delayed diagnosis (Levy, et al., 2010) or negatively-impacted 
behavioral interventions and management (Bauman, 2010a). A recent consensus 
report by clinicians and investigators noted that the consistent theme among 
reports on GID in ASDs is a lack of quantity and quality — that what is needed 
most in this field is methodological rigor, adequate sample sizes, and cross-
disciplinary integration (Buie, et al., 2010a).  
Several mechanisms have been proposed to underlie co-occurring GID in 
ASD. There may be distinct genetic and biological differences between 
individuals with or without co-occurring GID (Campbell, et al., 2009). Behavioral 
rigidity may lead individuals with ASDs to choose a restricted diet which induces 
GID (Ibrahim, Voigt, Katusic, Weaver, & Barbaresi, 2009). Medications commonly 
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prescribed to individuals with ASDs may induce weight gain or suppress appetite 
in general, thus leading to GID (Ibrahim, et al., 2009). Psychotropic medications 
with adverse side effects on the gastrointestinal system may induce 
gastrointestinal symptoms directly (Ibrahim, et al., 2009). Finally, the “leaky gut” 
hypothesis suggested by Andrew Wakefield and colleagues, proposed that the 
measles-mumps-rubella (MMR) vaccine induced a chronic colitis in children, 
which increased intestinal permeability and thereby allowed increased absorption 
of neurotoxic compounds which ultimately caused the behaviors of ASD 
(Wakefield et al., 1998).  
A full examination of research on GID in ASDs must address the historical 
legacy of Wakefield’s report. In 1998, Wakefield and colleagues proposed a link 
between autism, the MMR vaccine, and gastrointestinal abnormalities (including 
lymphoid-nodular hyperplasia and colitis) (Wakefield, et al., 1998). The majority 
of the original authors subsequently retracted their interpretation and conclusions 
(Murch et al., 2004). It is now clear the extent to which Wakefield egregiously 
violated scientific and ethical principles (Deer, 2011), and the damage his claims 
have inflicted on public health vaccination programs (Freed, Clark, Butchart, 
Singer, & Davis, 2010; Jansen et al., 2003; Parker et al., 2006; Smith, Ellenberg, 
Bell, & Rubin, 2008). The current consensus among professionals, and current 
data, do not support the “leaky gut” hypothesis (Buie, et al., 2010a; Hornig et al., 
2008). Importantly and without any ambiguity, the present thesis is biologically 
and intellectually unrelated to Wakefield’s line of investigation. Moreover, another 
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important consequence of Wakefield’s work is a deep stigma has been attached 
to research on GID in ASDs, deterring investigators and prompting suspicion of 
those who do study GID. Anecdotally, many clinicians and researchers view GID 
in the ASDs with skepticism, which is in contrast to what parents report, often 
resulting in a tension between parents and providers involved in the clinical care 
of children with ASDs. Without high quality studies of GID, the field is left with 
many unexplored clinical and biological issues regarding GID in ASDs (Buie, et 
al., 2010a).  
This thesis sought to address some of the unanswered questions regarding 
GID in ASDs. Building on work previously reported by Campbell and colleagues 
(Campbell, et al., 2009), the biological framework for this thesis is pleiotropic 
consequences of altered MET signaling and thus shared genetic risk for co-
occurring GID in ASDs. The aims of this thesis were as follows: 1) to describe the 
specific clinical and behavioral phenotype of children with co-occurring GID and 
ASDs, examining relationships between proposed causes of GID and GID 
outcomes, comparing parent versus clinician evaluations of GID, and exploring 
the functional implications of GID in ASDs (Chapter II); 2) to replicate previous 
genetic findings in an independent cohort with higher quality phenotype data and 
extend these findings to additional biomarkers (Chapter III); and 3) to elucidate 
the specific contribution of Met signaling to gastrointestinal biology in a 
conditional knockout mouse model (Chapter IV). Through these aims, the larger 
goals of this thesis were to improve clinical care, and possibly gain insight into 
31
  






Abrahams, B. S., & Geschwind, D. H. (2008). Advances in autism genetics: On 
the threshold of a new neurobiology. Nature reviews Genetics, 9(5), 341-
355. 
Abrahams, B. S., & Geschwind, D. H. (2010). Connecting genes to brain in the 
autism spectrum disorders. Arch Neurol, 67(4), 395-399. 
Akimoto, M., Baba, A., Ikeda-Matsuo, Y., Yamada, M. K., Itamura, R., Nishiyama, 
N., Ikegaya, Y., & Matsuki, N. (2004). Hepatocyte growth factor as an 
enhancer of nmda currents and synaptic plasticity in the hippocampus. 
Neuroscience, 128(1), 155-162. 
Alexander, A. L., Lee, J. E., Lazar, M., Boudos, R., DuBray, M. B., Oakes, T. R., 
Miller, J. N., Lu, J., Jeong, E.-K., Mcmahon, W. M., Bigler, E. D., & 
Lainhart, J. E. (2007). Diffusion tensor imaging of the corpus callosum in 
autism. NeuroImage, 34(1), 61-73. 
American Psychiatric Association. (1994). Diagnostic and statistical manual of 
mental disorders. Washington, DC: American Psychiatric Association. 
Andermarcher, E., Surani, M. A., & Gherardi, E. (1996). Co-expression of the 
hgf/sf and c-met genes during early mouse embryogenesis precedes 
reciprocal expression in adjacent tissues during organogenesis. 
Developmental genetics, 18(3), 254-266. 
Anderson, J. S., Druzgal, T. J., Froehlich, A., DuBray, M. B., Lange, N., 
Alexander, A. L., Abildskov, T., Nielsen, J. A., Cariello, A. N., Cooperrider, 
J. R., Bigler, E. D., & Lainhart, J. E. (2011). Decreased interhemispheric 
functional connectivity in autism. Cerebral cortex (New York, NY : 1991), 
21(5), 1134-1146. 
Anney, R., Klei, L., Pinto, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, 
C., Abrahams, B. S., Sykes, N., Pagnamenta, A. T., Almeida, J., Bacchelli, 
E., Bailey, A. J., Baird, G., Battaglia, A., Berney, T., Bolshakova, N., Bölte, 
S., Bolton, P. F., Bourgeron, T., Brennan, S., Brian, J., Carson, A. R., 
Casallo, G., Casey, J., Chu, S. H., Cochrane, L., Corsello, C., Crawford, E. 
L., Crossett, A., Dawson, G., de Jonge, M., Delorme, R., Drmic, I., Duketis, 
E., Duque, F., Estes, A., Farrar, P., Fernandez, B. A., Folstein, S. E., 
Fombonne, E., Freitag, C. M., Gilbert, J., Gillberg, C., Glessner, J. T., 
Goldberg, J., Green, J., Guter, S. J., Hakonarson, H., Heron, E. A., Hill, 
M., Holt, R., Howe, J. L., Hughes, G., Hus, V., Igliozzi, R., Kim, C., Klauck, 
S. M., Kolevzon, A., Korvatska, O., Kustanovich, V., Lajonchere, C. M., 
Lamb, J. A., Laskawiec, M., Leboyer, M., Le Couteur, A., Leventhal, B. L., 
Lionel, A. C., Liu, X.-Q., Lord, C., Lotspeich, L., Lund, S. C., Maestrini, E., 
33
  
Mahoney, W., Mantoulan, C., Marshall, C. R., McConachie, H., Mcdougle, 
C. J., Mcgrath, J., Mcmahon, W. M., Melhem, N. M., Merikangas, A., 
Migita, O., Minshew, N. J., Mirza, G. K., Munson, J., Nelson, S. F., 
Noakes, C., Noor, A., Nygren, G., Oliveira, G., Papanikolaou, K., Parr, J. 
R., Parrini, B., Paton, T., Pickles, A., Piven, J., Posey, D. J., Poustka, A., 
Poustka, F., Prasad, A., Ragoussis, J., Renshaw, K., Rickaby, J., Roberts, 
W., Roeder, K., Rogé, B., Rutter, M. L., Bierut, L. J., Rice, J. P., Salt, J., 
Sansom, K., Sato, D., Segurado, R., Senman, L., Shah, N., Sheffield, V. 
C., Soorya, L., Sousa, I., Stoppioni, V., Strawbridge, C., Tancredi, R., 
Tansey, K., Thiruvahindrapduram, B., Thompson, A. P., Thomson, S., 
Tryfon, A., Tsiantis, J., Van Engeland, H., Vincent, J. B., Volkmar, F., 
Wallace, S., Wang, K., Wang, Z., Wassink, T. H., Wing, K., Wittemeyer, 
K., Wood, S., Yaspan, B. L., Zurawiecki, D., Zwaigenbaum, L., Betancur, 
C., Buxbaum, J. D., Cantor, R. M., Cook, E. H., Coon, H., Cuccaro, M. L., 
Gallagher, L., Geschwind, D. H., Gill, M., Haines, J. L., Miller, J., Monaco, 
A. P., Nurnberger, J. I., Paterson, A. D., Pericak-Vance, M. A., 
Schellenberg, G. D., Scherer, S. W., Sutcliffe, J. S., Szatmari, P., Vicente, 
A. M., Vieland, V. J., Wijsman, E. M., Devlin, B., Ennis, S., & Hallmayer, J. 
(2010). A genome-wide scan for common alleles affecting risk for autism. 
Human Molecular Genetics, 19(20), 4072-4082. 
Autism and Developmental Disabilities Monitoring Network. (2009). Prevalence of 
autism spectrum disorders --- autism and developmental disabilities 
monitoring network, united states, 2006. MMWR Surveillance summaries : 
Morbidity and mortality weekly report Surveillance summaries / CDC, 
58(10), 1-20. 
Bailey, A., Le Couteur, A., Gottesman, I., Bolton, P., Simonoff, E., Yuzda, E., & 
Rutter, M. (1995). Autism as a strongly genetic disorder: Evidence from a 
british twin study. Psychological medicine, 25(1), 63-77. 
Bauman, M. L. (2010a). Medical comorbidities in autism: Challenges to diagnosis 
and treatment. Neurotherapeutics : the journal of the American Society for 
Experimental NeuroTherapeutics, 7(3), 320-327. 
Bauman, M. L. (2010b). Medical comorbidities in autism: Challenges to diagnosis 
and treatment. Neurotherapeutics, 7(3), 320-327. 
Beilmann, M., Odenthal, M., Jung, W., Vande Woude, G. F., Dienes, H. P., & 
Schirmacher, P. (1997). Neoexpression of the c-met/hepatocyte growth 
factor-scatter factor receptor gene in activated monocytes. Blood, 90(11), 
4450-4458. 
Beilmann, M., Vande Woude, G. F., Dienes, H. P., & Schirmacher, P. (2000). 




Bill, B., & Geschwind, D. H. (2009). Genetic advances in autism: Heterogeneity 
and convergence on shared pathways. Current Opinion in Genetics &amp; 
Development. 
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, 
metastasis, motility and more. Nature Reviews Molecular Cell Biology, 
4(12), 915-925. 
Bishop, D. V. M., Maybery, M., Maley, A., Wong, D., Hill, W., & Hallmayer, J. 
(2004). Using self-report to identify the broad phenotype in parents of 
children with autistic spectrum disorders: A study using the autism-
spectrum quotient. Journal of child psychology and psychiatry, and allied 
disciplines, 45(8), 1431-1436. 
Black, C., Kaye, J. A., & Jick, H. (2002). Relation of childhood gastrointestinal 
disorders to autism: Nested case-control study using data from the uk 
general practice research database. BMJ (Clinical research ed), 
325(7361), 419-421. 
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., & Birchmeier, C. (1995). 
Essential role for the c-met receptor in the migration of myogenic 
precursor cells into the limb bud. Nature, 376(6543), 768-771. 
Boon, E. M. J., Pouwels, W., Redeker, S., Joosten, S. P. J., Hamann, J., Van Der 
Neut, R., & Pals, S. T. (2006). Activation of wnt signaling in the intestinal 
mucosa of apc +/min mice does not cause overexpression of the receptor 
tyrosine kinase met. Cancer Science, 97(8), 710-715. 
Boulet, S. L., Boyle, C. A., & Schieve, L. A. (2009). Health care use and health 
and functional impact of developmental disabilities among us children, 
1997-2005. Archives of Pediatrics &amp; Adolescent Medicine, 163(1), 
19-26. 
Buie, T. M., Campbell, D. B., Fuchs, G. J., Furuta, G. T., Levy, J., Vandewater, 
J., Whitaker, A. H., Atkins, D., Bauman, M. L., Beaudet, A. L., Carr, E. G., 
Gershon, M. D., Hyman, S. L., Jirapinyo, P., Jyonouchi, H., Kooros, K., 
Kushak, R., Levitt, P., Levy, S. E., Lewis, J. D., Murray, K. F., Natowicz, 
M. R., Sabra, A., Wershil, B. K., Weston, S. C., Zeltzer, L., & Winter, H. 
(2010a). Evaluation, diagnosis, and treatment of gastrointestinal disorders 
in individuals with asds: A consensus report. PEDIATRICS, 125 Suppl 1, 
S1-18. 
Buie, T. M., Fuchs, G. J., Furuta, G. T., Kooros, K., Levy, J., Lewis, J. D., 
Wershil, B. K., & Winter, H. (2010b). Recommendations for evaluation and 
35
  
treatment of common gastrointestinal problems in children with asds. 
PEDIATRICS, 125 Suppl 1, S19-29. 
Campbell, D. B., Buie, T. M., Winter, H., Bauman, M., Sutcliffe, J. S., Perrin, J. 
M., & Levitt, P. (2009). Distinct genetic risk based on association of met in 
families with co-occurring autism and gastrointestinal conditions. 
PEDIATRICS, 123(3), 1018-1024. 
Campbell, D. B., D&apos;Oronzio, R., Garbett, K., Ebert, P. J., Mirnics, K., Levitt, 
P., & Persico, A. M. (2007). Disruption of cerebral cortex met signaling in 
autism spectrum disorder. Annals of neurology, 62(3), 243-250. 
Campbell, D. B., Li, C., Sutcliffe, J. S., Persico, A. M., & Levitt, P. (2008). Genetic 
evidence implicating multiple genes in the met receptor tyrosine kinase 
pathway in autism spectrum disorder. Autism research : official journal of 
the International Society for Autism Research, 1(3), 159-168. 
Campbell, D. B., Sutcliffe, J. S., Ebert, P. J., Militerni, R., Bravaccio, C., Trillo, S., 
Elia, M., Schneider, C., Melmed, R., Sacco, R., Persico, A. M., & Levitt, P. 
(2006). A genetic variant that disrupts met transcription is associated with 
autism. Proceedings of the National Academy of Sciences of the United 
States of America, 103(45), 16834-16839. 
Casanova, M., & Trippe, J. (2009). Radial cytoarchitecture and patterns of 
cortical connectivity in autism. Philosophical transactions of the Royal 
Society of London. Series B, Biological sciences, 364(1522), 1433-1436. 
Casanova, M. F., Buxhoeveden, D., & Gomez, J. (2003). Disruption in the 
inhibitory architecture of the cell minicolumn: Implications for autism. The 
Neuroscientist : a review journal bringing neurobiology, neurology and 
psychiatry, 9(6), 496-507. 
Casanova, M. F., Buxhoeveden, D. P., Switala, A. E., & Roy, E. (2002). 
Minicolumnar pathology in autism. Neurology, 58(3), 428-432. 
Casanova, M. F., El-Baz, A., Vanbogaert, E., Narahari, P., & Switala, A. (2010). 
A topographic study of minicolumnar core width by lamina comparison 
between autistic subjects and controls: Possible minicolumnar disruption 
due to an anatomical element in-common to multiple laminae. Brain 
pathology (Zurich, Switzerland), 20(2), 451-458. 
Casanova, M. F., van Kooten, I. A. J., Switala, A. E., Van Engeland, H., Heinsen, 
H., Steinbusch, H. W. M., Hof, P. R., Trippe, J., Stone, J., & Schmitz, C. 




Chakravarti, A. (1999). Population genetics--making sense out of sequence. 
Nature genetics, 21(1 Suppl), 56-60. 
Christian, S. L., Brune, C. W., Sudi, J., Kumar, R. A., Liu, S., Karamohamed, S., 
Badner, J. A., Matsui, S., Conroy, J., McQuaid, D., Gergel, J., Hatchwell, 
E., Gilliam, T. C., Gershon, E. S., Nowak, N. J., Dobyns, W. B., & Cook, E. 
H. (2008). Novel submicroscopic chromosomal abnormalities detected in 
autism spectrum disorder. Biological Psychiatry, 63(12), 1111-1117. 
Constantino, J. N., Lajonchere, C., Lutz, M., Gray, T., Abbacchi, A., McKenna, K., 
Singh, D., & Todd, R. D. (2006). Autistic social impairment in the siblings 
of children with pervasive developmental disorders. The American journal 
of psychiatry, 163(2), 294-296. 
Cook, E. H., & Leventhal, B. L. (1996). The serotonin system in autism. Current 
Opinion in Pediatrics, 8(4), 348-354. 
Cook, E. H., Lindgren, V., Leventhal, B. L., Courchesne, R., Lincoln, A., Shulman, 
C., Lord, C., & Courchesne, E. (1997). Autism or atypical autism in 
maternally but not paternally derived proximal 15q duplication. American 
journal of human genetics, 60(4), 928-934. 
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & 
Vande Woude, G. F. (1984). Molecular cloning of a new transforming gene 
from a chemically transformed human cell line. Nature, 311(5981), 29-33. 
Courchesne, E., Carper, R., & Akshoomoff, N. (2003). Evidence of brain 
overgrowth in the first year of life in autism. JAMA : the journal of the 
American Medical Association, 290(3), 337-344. 
Crawford, D. C., Meadows, K. L., Newman, J. L., Taft, L. F., Scott, E., Leslie, M., 
Shubek, L., Holmgreen, P., Yeargin-Allsopp, M., Boyle, C., & Sherman, S. 
L. (2002). Prevalence of the fragile x syndrome in african-americans. 
American journal of medical genetics, 110(3), 226-233. 
Crepaldi, T., Pollack, A. L., Prat, M., Zborek, A., Mostov, K., & Comoglio, P. M. 
(1994). Targeting of the sf/hgf receptor to the basolateral domain of 
polarized epithelial cells. The Journal of cell biology, 125(2), 313-320. 
Deer, B. (2011). How the case against the mmr vaccine was fixed. BMJ (Clinical 
research ed), 342, c5347. 
Dignass, A. U., Lynch-Devaney, K., & Podolsky, D. K. (1994). Hepatocyte growth 
factor/scatter factor modulates intestinal epithelial cell proliferation and 




Durand, C. M., Betancur, C., Boeckers, T. M., Bockmann, J., Chaste, P., 
Fauchereau, F., Nygren, G., Råstam, M., Gillberg, I. C., Anckarsäter, H., 
Sponheim, E., Goubran-Botros, H., Delorme, R., Chabane, N., Mouren-
Simeoni, M.-C., de Mas, P., Bieth, E., Rogé, B., Heron, D., Burglen, L., 
Gillberg, C., Leboyer, M., & Bourgeron, T. (2007). Mutations in the gene 
encoding the synaptic scaffolding protein shank3 are associated with 
autism spectrum disorders. Nature genetics, 39(1), 25-27. 
Eagleson, K. L., Campbell, D. B., Thompson, B. L., Bergman, M. Y., & Levitt, P. 
(2010). The autism risk genes met and plaur differentially impact cortical 
development. Autism research : official journal of the International Society 
for Autism Research. 
El-Fishawy, P., & Matthew W State MD, P. (2010). The genetics of autism: Key 
issues, recent findings, and clinical implications. Psychiatric Clinics of NA, 
33(1), 83-105. 
Erickson, C. A., Stigler, K. A., Corkins, M. R., Posey, D. J., Fitzgerald, J. F., & 
Mcdougle, C. J. (2005). Gastrointestinal factors in autistic disorder: A 
critical review. Journal of Autism and Developmental Disorders, 35(6), 
713-727. 
Feng, J., Schroer, R., Yan, J., Song, W., Yang, C., Bockholt, A., Cook, E. H., 
Skinner, C., Schwartz, C. E., & Sommer, S. S. (2006). High frequency of 
neurexin 1beta signal peptide structural variants in patients with autism. 
Neuroscience letters, 409(1), 10-13. 
Folstein, S., & Rutter, M. (1977). Genetic influences and infantile autism. Nature, 
265(5596), 726-728. 
Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive 
developmental disorders: An update. Hum Genet, 33(4), 365-382. 
Fombonne, E., Rogé, B., Claverie, J., Courty, S., & Frémolle, J. (1999). 
Microcephaly and macrocephaly in autism. Hum Genet, 29(2), 113-119. 
Freed, G. L., Clark, S. J., Butchart, A. T., Singer, D. C., & Davis, M. M. (2010). 
Parental vaccine safety concerns in 2009. PEDIATRICS. 
Fuentes, J. J., Pritchard, M. A., Planas, A. M., Bosch, A., Ferrer, I., & Estivill, X. 
(1995). A new human gene from the down syndrome critical region 
encodes a proline-rich protein highly expressed in fetal brain and heart. 
Human Molecular Genetics, 4(10), 1935-1944. 




Ganz, M. L. (2007). The lifetime distribution of the incremental societal costs of 
autism. Archives of Pediatrics &amp; Adolescent Medicine, 161(4), 343-
349. 
Geschwind, D. H. (2009). Advances in autism. Annual review of medicine, 60, 
367-380. 
Geschwind, D. H., & Levitt, P. (2007). Autism spectrum disorders: Developmental 
disconnection syndromes. Current opinion in neurobiology, 17(1), 103-
111. 
Giacobini, P., Messina, A., Wray, S., Giampietro, C., Crepaldi, T., Carmeliet, P., 
& Fasolo, A. (2007). Hepatocyte growth factor acts as a motogen and 
guidance signal for gonadotropin hormone-releasing hormone-1 neuronal 
migration. Journal of Neuroscience, 27(2), 431-445. 
Gillberg, C., & Billstedt, E. (2000). Autism and asperger syndrome: Coexistence 
with other clinical disorders. Acta Psychiatrica Scandinavica, 102(5), 321-
330. 
Gilman, S. R., Iossifov, I., Levy, D., Ronemus, M., Wigler, M., & Vitkup, D. (2011). 
Rare de novo variants associated with autism implicate a large functional 
network of genes involved in formation and function of synapses. Neuron, 
70(5), 898-907. 
Glessner, J., Wang, K., Cai, G., Korvatska, O., Kim, C., Wood, S., Zhang, H., 
Estes, A., Brune, C., Bradfield, J., Imielinski, M., Frackelton, E., Reichert, 
J., Crawford, E., Munson, J., Sleiman, P., Chiavacci, R., Annaiah, K., 
Thomas, K., Hou, C., Glaberson, W., Flory, J., Otieno, F., Garris, M., 
Soorya, L., Klei, L., Piven, J., Meyer, K., Anagnostou, E., Sakurai, T., 
Game, R., Rudd, D., Zurawiecki, D., McDougle, C., Davis, L., Miller, J., 
Posey, D., Michaels, S., Kolevzon, A., Silverman, J., Bernier, R., Levy, S., 
Schultz, R., Dawson, G., Owley, T., McMahon, W., Wassink, T., Sweeney, 
J., Nurnberger, J., Coon, H., Sutcliffe, J. S., Minshew, N., Grant, S., 
Bucan, M., Cook, E. H., Buxbaum, J. D., Devlin, B., Schellenberg, G., & 
Hakonarson, H. (2009). Autism genome-wide copy number variation 
reveals ubiquitin and neuronal genes. Nature. 
Gurney, J. G., McPheeters, M. L., & Davis, M. M. (2006). Parental report of 
health conditions and health care use among children with and without 
autism: National survey of children&apos;s health. Archives of Pediatrics 
&amp; Adolescent Medicine, 160(8), 825-830. 
Gutierrez, H., Dolcet, X., Tolcos, M., & Davies, A. (2004). Hgf regulates the 
development of cortical pyramidal dendrites. Development (Cambridge, 
England), 131(15), 3717-3726. 
39
  
Hartley, S. L., Sikora, D. M., & McCoy, R. (2008). Prevalence and risk factors of 
maladaptive behaviour in young children with autistic disorder. Journal of 
intellectual disability research : JIDR, 52(10), 819-829. 
Hazlett, H. C., Poe, M., Gerig, G., Smith, R. G., Provenzale, J., Ross, A., 
Gilmore, J., & Piven, J. (2005). Magnetic resonance imaging and head 
circumference study of brain size in autism: Birth through age 2 years. 
Archives of general psychiatry, 62(12), 1366-1376. 
Hornig, M., Briese, T., Buie, T. M., Bauman, M. L., Lauwers, G., Siemetzki, U., 
Hummel, K., Rota, P. A., Bellini, W. J., O&apos;leary, J. J., Sheils, O., 
Alden, E., Pickering, L., & Lipkin, W. I. (2008). Lack of association 
between measles virus vaccine and autism with enteropathy: A case-
control study. PLoS ONE, 3(9), e3140. 
Ibrahim, S. H., Voigt, R. G., Katusic, S. K., Weaver, A. L., & Barbaresi, W. J. 
(2009). Incidence of gastrointestinal symptoms in children with autism: A 
population-based study. PEDIATRICS, 124(2), 680-686. 
International Molecular Genetic Study of Autism Consortium. (1998). A full 
genome screen for autism with evidence for linkage to a region on 
chromosome 7q. International molecular genetic study of autism 
consortium. Human Molecular Genetics, 7(3), 571-578. 
International Molecular Genetic Study of Autism Consortium. (2001). A 
genomewide screen for autism: Strong evidence for linkage to 
chromosomes 2q, 7q, and 16p. American journal of human genetics, 
69(3), 570-581. 
Iyengar, S. K., & Elston, R. C. (2007). The genetic basis of complex traits: Rare 
variants or &quot;common gene, common disease&quot;? Methods in 
molecular biology (Clifton, NJ), 376, 71-84. 
Jackson, P., Boccuto, L., Skinner, C., Collins, J., Neri, G., Gurrieri, F., & 
Schwartz, C. (2009). Further evidence that the rs1858830 c variant in the 
promoter region of the met gene is associated with autistic disorder. 
Autism research : official journal of the International Society for Autism 
Research. 
Jamain, S., Quach, H., Betancur, C., Råstam, M., Colineaux, C., Gillberg, I. C., 
Soderstrom, H., Giros, B., Leboyer, M., Gillberg, C., Bourgeron, T., & 
Study, P. A. R. I. S. (2003). Mutations of the x-linked genes encoding 
neuroligins nlgn3 and nlgn4 are associated with autism. Nature genetics, 
34(1), 27-29. 
Jansen, V. A. A., Stollenwerk, N., Jensen, H. J., Ramsay, M. E., Edmunds, W. J., 
40
  
& Rhodes, C. J. (2003). Measles outbreaks in a population with declining 
vaccine uptake. Science (New York, N.Y.), 301(5634), 804. 
Jorde, L. B., Hasstedt, S. J., Ritvo, E. R., Mason-Brothers, A., Freeman, B. J., 
Pingree, C., McMahon, W. M., Petersen, B., Jenson, W. R., & Mo, A. 
(1991). Complex segregation analysis of autism. American journal of 
human genetics, 49(5), 932-938. 
Judson, M. C., Amaral, D. G., & Levitt, P. (2010a). Conserved subcortical and 
divergent cortical expression of proteins encoded by orthologs of the 
autism risk gene met. Cerebral cortex (New York, NY : 1991). 
Judson, M. C., Bergman, M. Y., Campbell, D. B., Eagleson, K. L., & Levitt, P. 
(2009). Dynamic gene and protein expression patterns of the autism-
associated met receptor tyrosine kinase in the developing mouse 
forebrain. The Journal of comparative neurology, 513(5), 511-531. 
Judson, M. C., Eagleson, K. L., & Levitt, P. (2011). A new synaptic player leading 
to autism risk: Met receptor tyrosine kinase. Journal of 
Neurodevelopmental Disorders. 
Judson, M. C., Eagleson, K. L., Wang, L., & Levitt, P. (2010b). Evidence of cell-
nonautonomous changes in dendrite and dendritic spine morphology in 
the met-signaling-deficient mouse forebrain. The Journal of comparative 
neurology, 518(21), 4463-4478. 
Just, M. A., Cherkassky, V. L., Keller, T. A., & Minshew, N. J. (2004). Cortical 
activation and synchronization during sentence comprehension in high-
functioning autism: Evidence of underconnectivity. Brain : a journal of 
neurology, 127(Pt 8), 1811-1821. 
Kanner, L. (1943). Autistic disturbances of affective contact. Nervous child, 
2(217.250). 
Kermorgant, S., Walker, F., Hormi, K., Dessirier, V., Lewin, M. J., & Lehy, T. 
(1997). Developmental expression and functionality of hepatocyte growth 
factor and c-met in human fetal digestive tissues. Gastroenterology, 
112(5), 1635-1647. 
Kim, Y. S., Leventhal, B. L., Koh, Y. J., Fombonne, E., Laska, E., Lim, E. C., 
Cheon, K. A., Kim, S. J., Kim, Y. K., Lee, H., Song, D. H., & Grinker, R. R. 
(2011). Prevalence of autism spectrum disorders in a total population 
sample. American Journal of Psychiatry. 
Kitamura, S., Kondo, S., Shinomura, Y., Isozaki, K., Kanayama, S., Higashimoto, 
Y., Minami, T., Kiyohara, T., Yasunaga, Y., Ishikawa, H., Ohtani, T., 
41
  
Ishiguro, S., & Matsuzawa, Y. (2000). Expression of hepatocyte growth 
factor and c-met in ulcerative colitis. Inflammation research : official journal 
of the European Histamine Research Society [et al], 49(7), 320-324. 
Kogan, M. D., Blumberg, S. J., Schieve, L. A., Boyle, C. A., Perrin, J. M., 
Ghandour, R. M., Singh, G. K., Strickland, B. B., Trevathan, E., & van 
Dyck, P. C. (2009). Prevalence of parent-reported diagnosis of autism 
spectrum disorder among children in the us, 2007. PEDIATRICS, 124(5), 
1395-1403. 
Krakowiak, P., Goodlin-Jones, B., Hertz-Picciotto, I., Croen, L. A., & Hansen, R. 
L. (2008). Sleep problems in children with autism spectrum disorders, 
developmental delays, and typical development: A population-based 
study. J Sleep Res, 17(2), 197-206. 
Kumar, R. A., Karamohamed, S., Sudi, J., Conrad, D. F., Brune, C., Badner, J. 
A., Gilliam, T. C., Nowak, N. J., Cook, E. H., Dobyns, W. B., & Christian, S. 
L. (2008). Recurrent 16p11.2 microdeletions in autism. Human Molecular 
Genetics, 17(4), 628-638. 
Lainhart, J. E., Bigler, E. D., Bocian, M., Coon, H., Dinh, E., Dawson, G., 
Deutsch, C. K., Dunn, M., Estes, A., Tager-Flusberg, H., Folstein, S., 
Hepburn, S., Hyman, S., Mcmahon, W., Minshew, N., Munson, J., Osann, 
K., Ozonoff, S., Rodier, P., Rogers, S., Sigman, M., Spence, M. A., 
Stodgell, C. J., & Volkmar, F. (2006). Head circumference and height in 
autism: A study by the collaborative program of excellence in autism. 
American journal of medical genetics Part A, 140(21), 2257-2274. 
Lamb, J. A., Barnby, G., Bonora, E., Sykes, N., Bacchelli, E., Blasi, F., Maestrini, 
E., Broxholme, J., Tzenova, J., Weeks, D., Bailey, A. J., Monaco, A. P., & 
IMGSAC, I. M. G. S. o. A. C. (2005). Analysis of imgsac autism 
susceptibility loci: Evidence for sex limited and parent of origin specific 
effects. Journal of medical genetics, 42(2), 132-137. 
Levitt, P., & Campbell, D. B. (2009). The genetic and neurobiologic compass 
points toward common signaling dysfunctions in autism spectrum 
disorders. The Journal of clinical investigation, 119(4), 747-754. 
Levitt, P., Eagleson, K. L., & Powell, E. M. (2004). Regulation of neocortical 
interneuron development and the implications for neurodevelopmental 
disorders. Trends in neurosciences, 27(7), 400-406. 
Levy, D., Ronemus, M., Yamrom, B., Lee, Y.-H., Leotta, A., Kendall, J., Marks, 
S., Lakshmi, B., Pai, D., Ye, K., Buja, A., Krieger, A., Yoon, S., Troge, J., 
Rodgers, L., Iossifov, I., & Wigler, M. (2011). Rare de novo and 




Levy, S. E., Giarelli, E., Lee, L.-C., Schieve, L. A., Kirby, R. S., Cunniff, C., 
Nicholas, J., Reaven, J., & Rice, C. E. (2010). Autism spectrum disorder 
and co-occurring developmental, psychiatric, and medical conditions 
among children in multiple populations of the united states. Journal of 
developmental and behavioral pediatrics : JDBP, 31(4), 267-275. 
Levy, S. E., Mandell, D. S., & Schultz, R. T. (2009). Autism. Lancet, 374(9701), 
1627-1638. 
Levy, S. E., Souders, M. C., Ittenbach, R. F., Giarelli, E., Mulberg, A. E., & Pinto-
Martin, J. A. (2007). Relationship of dietary intake to gastrointestinal 
symptoms in children with autistic spectrum disorders. Biological 
Psychiatry, 61(4), 492-497. 
Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., 
Tager-Flusberg, H., & Lainhart, J. E. (2006). Comorbid psychiatric 
disorders in children with autism: Interview development and rates of 
disorders. Hum Genet, 36(7), 849-861. 
Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., & 
Schopler, E. (1989). Autism diagnostic observation schedule: A 
standardized observation of communicative and social behavior. Hum 
Genet, 19(2), 185-212. 
Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: 
A revised version of a diagnostic interview for caregivers of individuals 
with possible pervasive developmental disorders. Hum Genet, 24(5), 659-
685. 
Ma, D., Salyakina, D., Jaworski, J. M., Konidari, I., Whitehead, P. L., Andersen, 
A. N., Hoffman, J. D., Slifer, S. H., Hedges, D. J., Cukier, H. N., Griswold, 
A. J., McCauley, J. L., Beecham, G. W., Wright, H. H., Abramson, R. K., 
Martin, E. R., Hussman, J. P., Gilbert, J. R., Cuccaro, M. L., Haines, J. L., 
& Pericak-Vance, M. A. (2009). A genome-wide association study of 
autism reveals a common novel risk locus at 5p14.1. Annals of human 
genetics, 73(3), 263-273. 
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. 
E., & Salgia, R. (2003). C-met mutational analysis in small cell lung 
cancer: Novel juxtamembrane domain mutations regulating cytoskeletal 
functions. Cancer research, 63(19), 6272-6281. 
Malow, B. A., Marzec, M. L., McGrew, S. G., Wang, L., Henderson, L. M., & 
Stone, W. L. (2006). Characterizing sleep in children with autism spectrum 
43
  
disorders: A multidimensional approach. Sleep, 29(12), 1563-1571. 
Manning, M. A., Cassidy, S. B., Clericuzio, C., Cherry, A. M., Schwartz, S., 
Hudgins, L., Enns, G. M., & Hoyme, H. E. (2004). Terminal 22q deletion 
syndrome: A newly recognized cause of speech and language disability in 
the autism spectrum. PEDIATRICS, 114(2), 451-457. 
Marshall, C. R., Noor, A., Vincent, J. B., Lionel, A. C., Feuk, L., Skaug, J., Shago, 
M., Moessner, R., Pinto, D., Ren, Y., Thiruvahindrapduram, B., Fiebig, A., 
Schreiber, S., Friedman, J., Ketelaars, C. E. J., Vos, Y. J., Ficicioglu, C., 
Kirkpatrick, S., Nicolson, R., Sloman, L., Summers, A., Gibbons, C. A., 
Teebi, A., Chitayat, D., Weksberg, R., Thompson, A., Vardy, C., Crosbie, 
V., Luscombe, S., Baatjes, R., Zwaigenbaum, L., Roberts, W., Fernandez, 
B., Szatmari, P., & Scherer, S. W. (2008). Structural variation of 
chromosomes in autism spectrum disorder. American journal of human 
genetics, 82(2), 477-488. 
Masotti, C., Armelin-Correa, L. M., Splendore, A., Lin, C. J., Barbosa, A., 
Sogayar, M. C., & Passos-Bueno, M. R. (2005). A functional snp in the 
promoter region of tcof1 is associated with reduced gene expression and 
yy1 DNA-protein interaction. Gene, 359, 44-52. 
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R. J., Jiang, Y. H., Benton, C. S., 
Rommens, J. M., & Beaudet, A. L. (1997). De novo truncating mutations in 
e6-ap ubiquitin-protein ligase gene (ube3a) in angelman syndrome. Nature 
genetics, 15(1), 74-77. 
Merikangas, A. K., Corvin, A. P., & Gallagher, L. (2009). Copy-number variants in 
neurodevelopmental disorders: Promises and challenges. Trends in 
genetics : TIG, 25(12), 536-544. 
Moessner, R., Marshall, C. R., Sutcliffe, J. S., Skaug, J., Pinto, D., Vincent, J., 
Zwaigenbaum, L., Fernandez, B., Roberts, W., Szatmari, P., & Scherer, S. 
W. (2007). Contribution of shank3 mutations to autism spectrum disorder. 
American journal of human genetics, 81(6), 1289-1297. 
Molloy, C. A., & Manning-Courtney, P. (2003). Prevalence of chronic 
gastrointestinal symptoms in children with autism and autistic spectrum 
disorders. Autism : the international journal of research and practice, 7(2), 
165-171. 
Moss, J., & Howlin, P. (2009). Autism spectrum disorders in genetic syndromes: 
Implications for diagnosis, intervention and understanding the wider 
autism spectrum disorder population. Journal of intellectual disability 
research : JIDR, 53(10), 852-873. 
44
  
Muhle, R., Trentacoste, S. V., & Rapin, I. (2004). The genetics of autism. 
PEDIATRICS, 113(5), e472-486. 
Mulder, E. J., Anderson, G. M., Kema, I. P., de Bildt, A., van Lang, N. D. J., den 
Boer, J. A., & Minderaa, R. B. (2004). Platelet serotonin levels in pervasive 
developmental disorders and mental retardation: Diagnostic group 
differences, within-group distribution, and behavioral correlates. Journal of 
the American Academy of Child and Adolescent Psychiatry, 43(4), 491-
499. 
Murch, S. H., Anthony, A., Casson, D. H., Malik, M., Berelowitz, M., Dhillon, A. 
P., Thomson, M. A., Valentine, A., Davies, S. E., & Walker-Smith, J. A. 
(2004). Retraction of an interpretation. Lancet, 363(9411), 750. 
National Institute of Mental Health. National database for autism research  
Retrieved June 19, 2011, from http://ndar.nih.gov 
Numata, M., Ido, A., Moriuchi, A., Kim, I., Tahara, Y., Yamamoto, S., Hasuike, S., 
Nagata, K., Miyata, Y., Uto, H., & Tsubouchi, H. (2005). Hepatocyte 
growth factor facilitates the repair of large colonic ulcers in 2,4,6-
trinitrobenzene sulfonic acid-induced colitis in rats. Inflammatory Bowel 
Diseases, 11(6), 551-558. 
O'Callaghan, F. J., Shiell, A. W., Osborne, J. P., & Martyn, C. N. (1998). 
Prevalence of tuberous sclerosis estimated by capture-recapture analysis. 
The Lancet, 351(9114), 1490. 
O'Roak, B. J., Deriziotis, P., Lee, C., Vives, L., Schwartz, J. J., Girirajan, S., 
Karakoc, E., MacKenzie, A. P., Ng, S. B., Baker, C., Rieder, M. J., 
Nickerson, D. A., Bernier, R., Fisher, S. E., Shendure, J., & Eichler, E. E. 
(2011). Exome sequencing in sporadic autism spectrum disorders 
identifies severe de novo mutations. Nature genetics. 
Oh, K., Iimuro, Y., Takeuchi, M., Kaneda, Y., Iwasaki, T., Terada, N., Matsumoto, 
T., Nakanishi, K., & Fujimoto, J. (2005). Ameliorating effect of hepatocyte 
growth factor on inflammatory bowel disease in a murine model. American 
journal of physiology Gastrointestinal and liver physiology, 288(4), G729-
735. 
Parker, A. A., Staggs, W., Dayan, G. H., Ortega-Sánchez, I. R., Rota, P. A., 
Lowe, L., Boardman, P., Teclaw, R., Graves, C., & LeBaron, C. W. (2006). 
Implications of a 2005 measles outbreak in indiana for sustained 
elimination of measles in the united states. The New England journal of 
medicine, 355(5), 447-455. 
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. 
45
  
(2011). Dendritic spine pathology in neuropsychiatric disorders. Nature 
Neuroscience, 14(3), 285-293. 
Philippe, A., Martinez, M., Guilloud-Bataille, M., Gillberg, C., Råstam, M., 
Sponheim, E., Coleman, M., Zappella, M., Aschauer, H., Van Maldergem, 
L., Penet, C., Feingold, J., Brice, A., Leboyer, M., & van Malldergerme, L. 
(1999). Genome-wide scan for autism susceptibility genes. Paris autism 
research international sibpair study. Human Molecular Genetics, 8(5), 
805-812. 
Pierce, K., & Redcay, E. (2008). Fusiform function in children with an autism 
spectrum disorder is a matter of &quot;who&quot;. Biological Psychiatry, 
64(7), 552-560. 
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, 
J., Magalhaes, T. R., Correia, C., Abrahams, B. S., Almeida, J., Bacchelli, 
E., Bader, G. D., Bailey, A. J., Baird, G., Battaglia, A., Berney, T., 
Bolshakova, N., Bölte, S., Bolton, P. F., Bourgeron, T., Brennan, S., Brian, 
J., Bryson, S. E., Carson, A. R., Casallo, G., Casey, J., Chung, B. H. Y., 
Cochrane, L., Corsello, C., Crawford, E. L., Crossett, A., Cytrynbaum, C., 
Dawson, G., de Jonge, M., Delorme, R., Drmic, I., Duketis, E., Duque, F., 
Estes, A., Farrar, P., Fernandez, B. A., Folstein, S. E., Fombonne, E., 
Freitag, C. M., Gilbert, J., Gillberg, C., Glessner, J. T., Goldberg, J., 
Green, A., Green, J., Guter, S. J., Hakonarson, H., Heron, E. A., Hill, M., 
Holt, R., Howe, J. L., Hughes, G., Hus, V., Igliozzi, R., Kim, C., Klauck, S. 
M., Kolevzon, A., Korvatska, O., Kustanovich, V., Lajonchere, C. M., 
Lamb, J. A., Laskawiec, M., Leboyer, M., Le Couteur, A., Leventhal, B. L., 
Lionel, A. C., Liu, X.-Q., Lord, C., Lotspeich, L., Lund, S. C., Maestrini, E., 
Mahoney, W., Mantoulan, C., Marshall, C. R., McConachie, H., Mcdougle, 
C. J., Mcgrath, J., Mcmahon, W. M., Merikangas, A., Migita, O., Minshew, 
N. J., Mirza, G. K., Munson, J., Nelson, S. F., Noakes, C., Noor, A., 
Nygren, G., Oliveira, G., Papanikolaou, K., Parr, J. R., Parrini, B., Paton, 
T., Pickles, A., Pilorge, M., Piven, J., Ponting, C. P., Posey, D. J., Poustka, 
A., Poustka, F., Prasad, A., Ragoussis, J., Renshaw, K., Rickaby, J., 
Roberts, W., Roeder, K., Rogé, B., Rutter, M. L., Bierut, L. J., Rice, J. P., 
Salt, J., Sansom, K., Sato, D., Segurado, R., Sequeira, A. F., Senman, L., 
Shah, N., Sheffield, V. C., Soorya, L., Sousa, I., Stein, O., Sykes, N., 
Stoppioni, V., Strawbridge, C., Tancredi, R., Tansey, K., 
Thiruvahindrapduram, B., Thompson, A. P., Thomson, S., Tryfon, A., 
Tsiantis, J., Van Engeland, H., Vincent, J. B., Volkmar, F., Wallace, S., 
Wang, K., Wang, Z., Wassink, T. H., Webber, C., Weksberg, R., Wing, K., 
Wittemeyer, K., Wood, S., Wu, J., Yaspan, B. L., Zurawiecki, D., 
Zwaigenbaum, L., Buxbaum, J. D., Cantor, R. M., Cook, E. H., Coon, H., 
Cuccaro, M. L., Devlin, B., Ennis, S., Gallagher, L., Geschwind, D. H., Gill, 
M., Haines, J. L., Hallmayer, J., Miller, J., Monaco, A. P., Nurnberger, J. I., 
46
  
Paterson, A. D., Pericak-Vance, M. A., Schellenberg, G. D., Szatmari, P., 
Vicente, A. M., Vieland, V. J., Wijsman, E. M., Scherer, S. W., Sutcliffe, J. 
S., & Betancur, C. (2010). Functional impact of global rare copy number 
variation in autism spectrum disorders. Nature, 466(7304), 368-372. 
Piven, J. (2001). The broad autism phenotype: A complementary strategy for 
molecular genetic studies of autism. American journal of medical genetics, 
105(1), 34-35. 
Powell, E. M., Mars, W. M., & Levitt, P. (2001). Hepatocyte growth factor/scatter 
factor is a motogen for interneurons migrating from the ventral to dorsal 
telencephalon. Neuron, 30(1), 79-89. 
Powell, E. M., Mühlfriedel, S., Bolz, J., & Levitt, P. (2003). Differential regulation 
of thalamic and cortical axonal growth by hepatocyte growth factor/scatter 
factor. Developmental Neuroscience, 25(2-4), 197-206. 
Qiu, S., Anderson, C. T., Levitt, P., & Shepherd, G. M. G. (2011). Circuit-specific 
intracortical hyperconnectivity in mice with deletion of the autism-
associated met receptor tyrosine kinase. Journal of Neuroscience, 31(15), 
5855-5864. 
Reich, D. E., & Lander, E. S. (2001). On the allelic spectrum of human disease. 
Trends in genetics : TIG, 17(9), 502-510. 
Ronald, A., Happé, F., Bolton, P., Butcher, L. M., Price, T. S., Wheelwright, S., 
Baron-Cohen, S., & Plomin, R. (2006). Genetic heterogeneity between the 
three components of the autism spectrum: A twin study. Journal of the 
American Academy of Child and Adolescent Psychiatry, 45(6), 691-699. 
Rubenstein, J. L. R., & Merzenich, M. M. (2003). Model of autism: Increased ratio 
of excitation/inhibition in key neural systems. Genes, brain, and behavior, 
2(5), 255-267. 
Sanders, S. J., Ercan-Sencicek, A. G., Hus, V., Luo, R., Murtha, M. T., Moreno-
De-Luca, D., Chu, S. H., Moreau, M. P., Gupta, A. R., Thomson, S. A., 
Mason, C. E., Bilguvar, K., Celestino-Soper, P. B. S., Choi, M., Crawford, 
E. L., Davis, L., Wright, N. R. D., Dhodapkar, R. M., DiCola, M., DiLullo, N. 
M., Fernandez, T. V., Fielding-Singh, V., Fishman, D. O., Frahm, S., 
Garagaloyan, R., Goh, G. S., Kammela, S., Klei, L., Lowe, J. K., Lund, S. 
C., McGrew, A. D., Meyer, K. A., Moffat, W. J., Murdoch, J. D., 
O&apos;Roak, B. J., Ober, G. T., Pottenger, R. S., Raubeson, M. J., Song, 
Y., Wang, Q., Yaspan, B. L., Yu, T. W., Yurkiewicz, I. R., Beaudet, A. L., 
Cantor, R. M., Curland, M., Grice, D. E., Gunel, M., Lifton, R. P., Mane, S. 
M., Martin, D. M., Shaw, C. A., Sheldon, M., Tischfield, J. A., Walsh, C. A., 
Morrow, E. M., Ledbetter, D. H., Fombonne, E., Lord, C., Martin, C. L., 
47
  
Brooks, A. I., Sutcliffe, J. S., Cook Jr, E. H., Geschwind, D., Roeder, K., 
Devlin, B., & State, M. W. (2011). Multiple recurrent de novo cnvs, 
including duplications of the 7q11.23 williams syndrome region, are 
strongly associated with autism. Neuron, 70(5), 863-885. 
Schaaf, C. P., & Zoghbi, H. Y. (2011). Solving the autism puzzle a few pieces at 
a time. Neuron, 70(5), 806-808. 
Schellenberg, G. D., Dawson, G., Sung, Y. J., Estes, A., Munson, J., Rosenthal, 
E., Rothstein, J., Flodman, P., Smith, M., Coon, H., Leong, L., Yu, C.-E., 
Stodgell, C., Rodier, P. M., Spence, M. A., Minshew, N., McMahon, W. M., 
& Wijsman, E. M. (2006). Evidence for multiple loci from a genome scan of 
autism kindreds. Molecular Psychiatry, 11(11), 1049-1060, 1979. 
Schultz, R. T., Gauthier, I., Klin, A., Fulbright, R. K., Anderson, A. W., Volkmar, 
F., Skudlarski, P., Lacadie, C., Cohen, D. J., & Gore, J. C. (2000). 
Abnormal ventral temporal cortical activity during face discrimination 
among individuals with autism and asperger syndrome. Archives of 
general psychiatry, 57(4), 331-340. 
Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C. L., Walsh, T., 
Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J., Leotta, A., Pai, D., Zhang, 
R., Lee, Y.-H., Hicks, J., Spence, S. J., Lee, A. T., Puura, K., Lehtimäki, T., 
Ledbetter, D., Gregersen, P. K., Bregman, J., Sutcliffe, J. S., Jobanputra, 
V., Chung, W., Warburton, D., King, M.-C., Skuse, D., Geschwind, D. H., 
Gilliam, T. C., Ye, K., & Wigler, M. (2007). Strong association of de novo 
copy number mutations with autism. Science (New York, N.Y.), 316(5823), 
445-449. 
Sebat, J., Lakshmi, B., Troge, J., Alexander, J., Young, J., Lundin, P., Månér, S., 
Massa, H., Walker, M., Chi, M., Navin, N., Lucito, R., Healy, J., Hicks, J., 
Ye, K., Reiner, A., Gilliam, T. C., Trask, B., Patterson, N., Zetterberg, A., & 
Wigler, M. (2004). Large-scale copy number polymorphism in the human 
genome. Science (New York, N.Y.), 305(5683), 525-528. 
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. 
(2008). Psychiatric disorders in children with autism spectrum disorders: 
Prevalence, comorbidity, and associated factors in a population-derived 
sample. J Am Acad Child Adolesc Psychiatry, 47(8), 921-929. 
Smith, M. J., Ellenberg, S. S., Bell, L. M., & Rubin, D. M. (2008). Media coverage 
of the measles-mumps-rubella vaccine and autism controversy and its 
relationship to mmr immunization rates in the united states. PEDIATRICS, 
121(4), e836-843. 
Sonnenberg, E., Meyer, D., Weidner, K. M., & Birchmeier, C. (1993). Scatter 
48
  
factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, 
can mediate a signal exchange between mesenchyme and epithelia 
during mouse development. The Journal of cell biology, 123(1), 223-235. 
Sousa, I., Clark, T. G., Toma, C., Kobayashi, K., Choma, M., Holt, R., Sykes, N. 
H., Lamb, J. A., Bailey, A. J., Battaglia, A., Maestrini, E., & Monaco, A. P. 
(2009). Met and autism susceptibility: Family and case-control studies. Eur 
J Hum Genet, 17(6), 749-758. 
St Pourcain, B., Wang, K., Glessner, J. T., Golding, J., Steer, C., Ring, S. M., 
Skuse, D. H., Grant, S. F. A., Hakonarson, H., Smith, G. D., & Davey 
Smith, G. (2010). Association between a high-risk autism locus on 5p14 
and social communication spectrum phenotypes in the general population. 
American Journal of Psychiatry, 167(11), 1364-1372. 
Tahara, Y., Ido, A., Yamamoto, S., Miyata, Y., Uto, H., Hori, T., Hayashi, K., & 
Tsubouchi, H. (2003). Hepatocyte growth factor facilitates colonic mucosal 
repair in experimental ulcerative colitis in rats. The Journal of 
pharmacology and experimental therapeutics, 307(1), 146-151. 
Thanseem, I., Nakamura, K., Miyachi, T., Toyota, T., Yamada, S., Tsujii, M., 
Tsuchiya, K. J., Anitha, A., Iwayama, Y., Yamada, K., Hattori, E., 
Matsuzaki, H., Matsumoto, K., Iwata, Y., Suzuki, K., Suda, S., Kawai, M., 
Sugihara, G.-i., Takebayashi, K., Takei, N., Ichikawa, H., Sugiyama, T., 
Yoshikawa, T., & Mori, N. (2010). Further evidence for the role of met in 
autism susceptibility. Neuroscience Research. 
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010). Met signalling: Principles and 
functions in development, organ regeneration and cancer. Nature Reviews 
Molecular Cell Biology, 11(12), 834-848. 
Tuchman, R., & Rapin, I. (2002). Epilepsy in autism. The Lancet Neurology, 1(6), 
352-358. 
Tyndall, S. J., & Walikonis, R. S. (2006). The receptor tyrosine kinase met and its 
ligand hepatocyte growth factor are clustered at excitatory synapses and 
can enhance clustering of synaptic proteins. Cell cycle (Georgetown, Tex), 
5(14), 1560-1568. 
Valicenti-McDermott, M. D., McVicar, K., Rapin, I., Wershil, B. K., Cohen, H., & 
Shinnar, S. (2006). Frequency of gastrointestinal symptoms in children 
with autistic spectrum disorders and association with family history of 
autoimmune disease. Journal of developmental and behavioral pediatrics : 
JDBP, 27(2 Suppl), S128-136. 
Voineagu, I., Wang, X., Johnston, P., Lowe, J. K., Tian, Y., Horvath, S., Mill, J., 
49
  
Cantor, R. M., Blencowe, B. J., & Geschwind, D. H. (2011). Transcriptomic 
analysis of autistic brain reveals convergent molecular pathology. Nature, 
474(7351), 380-384. 
Volkmar, F. R., Lord, C., Bailey, A., Schultz, R. T., & Klin, A. (2004). Autism and 
pervasive developmental disorders. Journal of child psychology and 
psychiatry, and allied disciplines, 45(1), 135-170. 
Volkmar, F. R., & Nelson, D. S. (1990). Seizure disorders in autism. Journal of 
the American Academy of Child and Adolescent Psychiatry, 29(1), 127-
129. 
Volkmar, F. R., & Pauls, D. (2003). Autism. The Lancet, 362(9390), 1133-1141. 
Wakefield, A., Murch, S. H., Anthony, A., Linnell, J., Casson, D. M., Malik, M., 
Berelowitz, M., Dhillon, A. P., Thomson, M. A., Harvey, P., Valentine, A., 
Davies, S. E., & Walker-Smith, J. A. (1998). Ileal-lymphoid-nodular 
hyperplasia, non-specific colitis, and pervasive developmental disorder in 
children. Lancet, 351(9103), 637-641. 
Walsh, K. M., & Bracken, M. B. (2011). Copy number variation in the dosage-
sensitive 16p11.2 interval accounts for only a small proportion of autism 
incidence: A systematic review and meta-analysis. Genetics in medicine : 
official journal of the American College of Medical Genetics, 13(5), 377-
384. 
Walters, R. G., Jacquemont, S., Valsesia, A., de Smith, A. J., Martinet, D., 
Andersson, J., Falchi, M., Chen, F., Andrieux, J., Lobbens, S., Delobel, B., 
Stutzmann, F., El-Sayed Moustafa, J. S., Chèvre, J.-C., Lecoeur, C., Vatin, 
V., Bouquillon, S., Buxton, J. L., Boute, O., Holder-Espinasse, M., Cuisset, 
J.-M., Lemaitre, M.-P., Ambresin, A.-E., Brioschi, A., Gaillard, M., Giusti, 
V., Fellmann, F., Ferrarini, A., Hadjikhani, N., Campion, D., Guilmatre, A., 
Goldenberg, A., Calmels, N., Mandel, J.-L., Le Caignec, C., David, A., 
Isidor, B., Cordier, M.-P., Dupuis-Girod, S., Labalme, A., Sanlaville, D., 
Béri-Dexheimer, M., Jonveaux, P., Leheup, B., Ounap, K., Bochukova, E. 
G., Henning, E., Keogh, J., Ellis, R. J., Macdermot, K. D., van Haelst, M. 
M., Vincent-Delorme, C., Plessis, G., Touraine, R., Philippe, A., Malan, V., 
Mathieu-Dramard, M., Chiesa, J., Blaumeiser, B., Kooy, R. F., Caiazzo, 
R., Pigeyre, M., Balkau, B., Sladek, R., Bergmann, S., Mooser, V., 
Waterworth, D., Reymond, A., Vollenweider, P., Waeber, G., Kurg, A., 
Palta, P., Esko, T., Metspalu, A., Nelis, M., Elliott, P., Hartikainen, A.-L., 
Mccarthy, M. I., Peltonen, L., Carlsson, L., Jacobson, P., Sjöström, L., 
Huang, N., Hurles, M. E., O&apos;Rahilly, S., Farooqi, I. S., Männik, K., 
Jarvelin, M.-R., Pattou, F., Meyre, D., Walley, A. J., Coin, L. J. M., 
Blakemore, A. I. F., Froguel, P., & Beckmann, J. S. (2010). A new highly 
50
  
penetrant form of obesity due to deletions on chromosome 16p11.2. 
Nature, 463(7281), 671-675. 
Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., 
Salyakina, D., Imielinski, M., Bradfield, J. P., Sleiman, P. M. A., Kim, C. E., 
Hou, C., Frackelton, E., Chiavacci, R., Takahashi, N., Sakurai, T., 
Rappaport, E., Lajonchere, C. M., Munson, J., Estes, A., Korvatska, O., 
Piven, J., Sonnenblick, L. I., Retuerto, A. I. A., Herman, E. I., Dong, H., 
Hutman, T., Sigman, M., Ozonoff, S., Klin, A., Owley, T., Sweeney, J. A., 
Brune, C. W., Cantor, R. M., Bernier, R., Gilbert, J. R., Cuccaro, M. L., 
Mcmahon, W. M., Miller, J., State, M. W., Wassink, T. H., Coon, H., Levy, 
S. E., Schultz, R. T., Nurnberger, J. I., Haines, J. L., Sutcliffe, J. S., Cook, 
E. H., Minshew, N. J., Buxbaum, J. D., Dawson, G., Grant, S. F. A., 
Geschwind, D. H., Pericak-Vance, M. A., Schellenberg, G. D., & 
Hakonarson, H. (2009). Common genetic variants on 5p14.1 associate 
with autism spectrum disorders. Nature, 459(7246), 528-533. 
Weiss, L. A., Arking, D. E., Daly, M. J., & Chakravarti, A. (2009). A genome-wide 
linkage and association scan reveals novel loci for autism. Nature, 
461(7265), 802-808. 
Weiss, L. A., Shen, Y., Korn, J. M., Arking, D. E., Miller, D. T., Fossdal, R., 
Saemundsen, E., Stefansson, H., Ferreira, M. A. R., Green, T., Platt, O. 
S., Ruderfer, D. M., Walsh, C. A., Altshuler, D. A., Chakravarti, A., Tanzi, 
R. E., Stefansson, K., Santangelo, S. L., Gusella, J. F., Sklar, P., Wu, B.-
L., Daly, M. J., & Consortium, A. (2008). Association between 
microdeletion and microduplication at 16p11.2 and autism. The New 
England journal of medicine, 358(7), 667-675. 
Zoghbi, H. Y. (2003). Postnatal neurodevelopmental disorders: Meeting at the 






Gastrointestinal Dysfunction in Autism: 
Parental Report, Clinical Evaluation, & Associated Factors 
 
Introduction 
Autism spectrum disorder (ASD) is defined by deficits in social interaction and 
communication, and a restricted repertoire of activities and interests (Volkmar, 
2005). ASD is heterogeneous and complex, often presenting with behavioral and 
medical comorbidities, including mood disorders, sleep abnormalities, and 
gastrointestinal dysfunction (GID) (Geschwind, 2009). However, a recent 
consensus report highlighted many unexplored issues in GID and ASD that have 
important implications for clinical care (Buie et al., 2010). 
The absence of rigorous, prospective clinical phenotyping in children with 
ASD and parent-suspected GID has impeded understanding potential 
relationships between GID and ASD. Research on GID in ASD has largely been 
limited to studies relying on parental reports (Smith, Farnworth, Wright, & Allgar, 
2009; Valicenti-McDermott et al., 2006) or retrospective review of records (Black, 
Kaye, & Jick, 2002; Xue, Brimacombe, Chaaban, Zimmerman-Bier, & Wagner, 
2008), lacking comparison groups (Molloy & Manning-Courtney, 2003; Nikolov et 
al., 2009), or focused on the prevalence of GID in ASD compared to non-ASD 
populations (Ibrahim, Voigt, Katusic, Weaver, & Barbaresi, 2009; Mouridsen, 
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Rich, & Isager, 2010). It has been suggested that GID in children with ASD does 
not have a biological basis but rather results from behavior, medications or 
dietary habits (Ibrahim, et al., 2009). 
Our laboratory has previously identified genetic differences between 
individuals with ASD with and without comorbid GID (Campbell et al., 2009), 
reframing questions of GID in a biologically-reasoned context in which subgroups 
of individuals with ASD may be at greater risk for GID because of pleiotropic 
expression of risk-associated genes in both the brain and gastrointestinal 
system. Here we report findings of an ongoing study that further explores this 
hypothesis. Our objectives were to characterize GID in children with ASD, to 
compare parental reports of GID symptoms on a validated instrument to results 
of clinical evaluations by a pediatric gastroenterologist, and to evaluate the 





Children were recruited into three groups: co-occurring ASD and GID (ASD-
GID); ASD without any GID (ASD-only); and GID without any ASD (GID-only). At 
enrollment, parents of children with ASD were queried in a structured interview to 
assess for ongoing GI complaints and assign GID group status. The ASD-GID 
and GID-only groups were evaluated by a pediatric gastroenterologist. The ASD-
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GID and ASD-only groups were assessed with the Autism Diagnostic 
Observation Schedule (ADOS). Parents in all groups completed questionnaires 
about their child’s behavior and GI symptoms, and a dietary journal. The 
research protocol was approved by the Vanderbilt University Institutional Review 
Board, and written informed consent was obtained from parents of participants. 
 
Participants 
Children were recruited at Vanderbilt University in Nashville, Tennessee, 
between 2009 and 2011. Children in both ASD groups were recruited primarily 
through the hospital’s ASD medical clinic, although some families self-referred 
after seeing study flyers in other locations, such as family resource events. 
Children in the GID-only group were recruited through the pediatric 
gastroenterology outpatient clinic. Exclusion criteria included severe sensory or 
motor impairment, neurodevelopmental disorders of known etiology (e.g. Fragile 
X Syndrome), gestational age less than 36 or greater than 42 weeks, and birth 
weight less than 2500 grams. Inclusion criteria included age between 5 and 18 
years, meeting ASD criteria on the ADOS (for the ASD groups), and GI 
symptoms that had lasted more than a month (for the GID groups).  
 
Measures 
Clinical evaluation: Children in both GID groups were evaluated by one of six 
pediatric gastroenterologists; one of those six (K.C.W.) evaluated 78.9% of 
54
participants. The evaluation included a medical history, gastrointestinal 
symptoms review, and physical examination; laboratory tests and procedures 
were pursued at the physician’s discretion when non-functional GI disease was 
suspected. Because of pronounced behavioral manifestations, blinding the 
gastroenterologist to ASD status was not possible. 
ADOS: Children in both ASD groups had ASD clinical diagnoses at 
enrollment, that were confirmed by assessment with the ADOS, a standardized 
instrument for diagnosing ASD (Lord, Rutter, DiLavore, & Risi, 1999). ADOSs 
were performed within two years of the study by a research-certified assessor 
who was blinded to GID status, and the revised scoring algorithm was used 
(Gotham, Risi, Pickles, & Lord, 2007). Item scores were not available for one 
participant, and one participant was assessed with a Module 4, which does not 
have a revised scoring algorithm; for these two participants, the original scoring 
algorithm was used. 
Expressive language: Item A1 on Module 1 of the ADOS rates non-echoed 
language. A score of either 3 or 8 was considered nonverbal for analyses. 
Social Responsiveness Scale (SRS): The SRS is a 65-item, parent-report 
instrument that provides a validated continuous measure of social impairment 
(Constantino & Gruber, 2005). SRS data was not available for one participant. 
Questionnaire on Pediatric Gastrointestinal Symptoms - Rome III Version 
(QPGS): The QPGS is a 71-item parent-report instrument that assesses GI 
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symptoms, classifies functional GI disorders (FGIDs) according to Rome-III 
criteria (Drossman, 2006; Walker, Caplan-Dover, & Rasquin-Weber, 2000), and 
is widely used in research on pediatric GID (Baber, Anderson, Puzanovova, & 
Walker, 2008; Caplan, Walker, & Rasquin, 2005a, 2005b). While organic GI 
disorders result from a clear anatomic, metabolic or pathologic process that is 
readily identified clinically, FGIDs instead have no overt pathology which can be 
identified. For analysis, missing responses on the QPGS were interpreted as a 
lack of evidence for the assessed symptom. If eight or more items were missing, 
the QPGS was omitted from analysis; instrument data from two participants were 
excluded by this criterion. Three participants who were initially enrolled in the 
ASD-only group subsequently met criteria for one or more FGID classifications; 
these participants were moved to the ASD-GID group and evaluated by a 
pediatric gastroenterologist. Four participants who were enrolled in the ASD-only 
group subsequently met criteria for fecal incontinence on the QPGS, but no other 
FGID; we interpreted this to be a toilet-training issue, rather than indicative of 
GID, and thus these individuals remained in the ASD-only group. The instrument 
is available online at romecriteria.org. 
Dietary journal: Parents were asked to record all food eaten by the 
participating child for seven days, into 11 categories but without serving size 
information. For analysis, we required complete data from at least five days. Two 
journals were excluded based on this criterion, and 20 parents did not complete 
the journal. 
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Medication classification: Medications were queried in the Micromedex 
database (Thomson Reuters, New York, NY) and classified as having potential 
GI side effects if adverse effects of abdominal pain, constipation, indigestion, 
nausea, vomiting, or diarrhea were reported in greater than 10% of patients. 
Supplemental Table 1 lists medications and corresponding classifications.  
 
Data Analysis 
Study data were managed using REDCap, a secure, research-oriented, web-
based application (Harris et al., 2009). Statistical analyses were computed using 
SPSS version 18.0.3 (IBM, Somers, NY). Participant characteristics were 
described by mean and standard deviation for continuous measures (age and 
BMI percentile) and by percent for nonparametric measures (sex, ethnicity, race, 
ADOS classification, and nonverbal status). ADOS classification and nonverbal 
status were compared using χ2 tests; BMI percentiles were compared by a one-
way analysis of variance (ANOVA). Prevalences of GI diagnoses were reported 
as percentages. Kappa coefficients (κ) were calculated to assess parent-
physician agreement for a diagnosis of constipation, and parent-physician 
percent agreement for presence of any GID was compared with a χ2 test. SRS T-
scores were plotted as boxplots and compared with an ANOVA; T-scores of 
nonverbal versus verbal subgroups were compared with a two-tailed t-test. 
Dietary habits were plotted as group means of percent of food category eaten 
with 95% confidence intervals (CI), and compared with an ANOVA. The 
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proportion of subgroups taking medications with potential GI side effects was 
compared with a χ2 test. To examine factors associated with the outcome of 
constipation, an exploratory logistic regression model was developed to test the 
additive effect of factors with potential clinical relevance (SRS T-score, nonverbal 
status, BMI percentile, and medication status). After univariate logistic regression 
models were tested, factors with significant unadjusted odds ratios (ORs) were 
retained and then entered into a final model, with sex and age as covariates. 
Adjusted ORs for constipation are reported. For all statistical tests, a P value of 
less than 0.05 was considered significant. When applicable, Tukey’s HSD post 





121 children were enrolled into three groups (ASD-GID = 40; ASD-only = 45; 
GID-only 36; Table 1). Participants were predominantly male (range: 63.9 to 
86.7%) and of non-Hispanic white racial and ethnic origin (range: 77.5 to 88.9%), 
and ranged in age from 5.1 to 17.9 years. There was no difference in ADOS 
classification between the ASD groups (proportion who met criteria for autism: 











Age in years, mean (SD) 10.8 (3.7) 12.4 (3.4) 11.0 (3.4)
Male sex, % (n) 72.5 (29) 86.7 (39) 63.9 (23)
Ethnicity and race, % (n)
Hispanic 12.5 (5)   0 (0)   2.8 (1)
Non-Hispanic white 77.5 (31) 86.7 (39) 88.9 (32)
Non-Hispanic black   7.5 (3)   8.9 (4)   8.3 (3)
Non-Hispanic other   2.5 (1)   4.4 (2)   0 (0)
ADOS Classification, % (n)
Autism 95.0 (38) 91.1 (41)   n/a
Autism Spectrum   5.0 (2)   8.9 (4)   n/a
Nonverbal, % (n)A 30.0 (12)   6.7 (3)   0 (0)
BMI-for-age percentile, mean 
(SD)B 76.2 (30.2) 68.9 (31.0) 57.2 (36.3)
A ASD-GID versus other groups, P < 0.01
B ASD-GID versus GID-only, P = 0.03
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Gastrointestinal Diagnoses 
Functional constipation (FC) was the most common diagnosis of GID in ASD 
(85.0%; Figure 1) when evaluated by a pediatric gastroenterologist. Although FC 
was also common in the GID-only group (44.4%), a comparison of prevalence of 
FC in ASD versus non-ASD was not appropriate, as this study was not designed 
to be epidemiologically representative. Instead, the diagnoses in the GID-only 
group show that this group had primarily FGIDs and was thus similar to the ASD-
GID group in nature of GID, to enable subsequent comparisons across groups for 
other factors. Reflux was the next most common diagnosis in the ASD-GID group 
(20.0%), and three children were found to have non-functional, organic disease 
underlying their GI symptoms (one case each of eosinophilic esophagitis, H. 
pylori, and celiac disease). 
FC by the parent-reported QPGS was also the most common diagnosis in the 
ASD-GID group (44.7%). Parent-physician agreement for a diagnosis of FC was 
fair for the ASD-GID group (κ = 0.26) and moderate for the GID-only group (κ = 
0.42) (Landis & Koch, 1977). However, percent agreement between a physician’s 
diagnosis for any GID and a parent’s report yielding any diagnosis on the QPGS 

























































































































































































































































































































































































































Language & Social Impairments 
To explore the functional significance of comorbid GID, we investigated group 
differences in language and social function. The percentage of nonverbal children 
was larger in the ASD-GID group, compared to the ASD-only group (Table 1; 
ASD-GID 30.0%; ASD-only 6.7%; P < 0.01).  
Children in the GID-only group did not show an elevated SRS T-score above 
that in typically-developing children (normed with mean 50 and SD 10 
(Constantino & Gruber, 2005); GID-only mean 51.3; Figure 2). As expected 
(Constantino et al., 2003), children in the ASD-only group showed an elevated T-
score compared to the GID-only group (ASD-only mean 77.7; GID-only mean 
51.3; P < 0.001). Interestingly, children in the ASD-GID group showed an 
elevated T-score compared to children in both ASD-only and GID-only groups, 
indicating the most severe social impairment in the co-occurring group (ASD-GID 
mean 89.2; ASD-only 77.7; P = 0.001). The elevated SRS T-score in the ASD-
GID group was not associated with impaired language, as scores of nonverbal 
and verbal children in this group were not different (nonverbal mean 86.2; verbal 






Figure 2. Social Impairment Measured by T-Scores on the 
Social Responsiveness Scale. Social impairment was significantly 
greater in both ASD groups, compared to the GID-only group; the 




















To explore whether GID in ASD was associated with a restricted or limited 
diet, parents were asked to record 11 categories of food that their child ate during 
the course of seven days (Figure 3). Comparison of the relative distributions of 
food categories showed no significant differences across groups.  
 
Factors Associated with Constipation 
Logistic regression was used to determine what factors were associated with 
functional constipation, the most prevalent GI diagnosis in our sample. Elevated 
BMI has been associated with FGIDs in typically-developing children (Pashankar 
& Loening-Baucke, 2005; Teitelbaum, Sinha, Micale, Yeung, & Jaeger, 2009), 
and obesity prevalence in ASD has been reported to be 30% (Curtin, Anderson, 
Must, & Bandini, 2010). Mean BMI-for-age percentile (Kuczmarski et al., 2002) 
was not statistically different between ASD-GID and ASD-only children (Table 1), 
and in univariate logistic regression, BMI was not significantly associated with a 
diagnosis of constipation in ASD (OR 1.01, 95% CI 0.99 − 1.02). There were no 
differences among ASD subgroups in the proportion taking medications with 
potential constipating side effects (67.6% of ASD-GID with constipation; 83.3% of 
ASD-GID with GID other than constipation; 64.4% of ASD-only; P = 0.65). Table 
2 lists medications and corresponding classifications. In univariate logistic 
regression, potentially constipating medications were not associated with  
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Figure 3. Percent of food categories eaten during 
seven days. Parents recorded foods eaten by their 
children for seven days, in 11 different food categories. 
Relative distributions of food categories eaten did not 
differ significantly across any of the three groups.












ASD-GID (n = 34)
GID-only (n = 26)




Table 2. Classification of Medications by Potential Gastrointestinal 
Side Effects
Without potential GI side effects
amitriptyline, atenolol, benztropine, chlorpromazine, clonazepam, 
clonidine, diazepam, doxazosin, eszopiclone, haloperidol, hydroxyzine, 
levothyroxine, lithium, lorazepam, melatonin, zonisamide
With potential GI side effects, except constipation
albuterol, amphetamine-dextroamphetamine, atomoxetine, baclofen, 
desmopressin, dexmethylphenidate, escitalopram, fluoxetine, 
lamotrigine, levetiracetam, lisdexamfetamine, methylphenidate, 
oxcarbazepine, sertraline, somatropin, topiramate, trazodone, valproic 
acid-divalproex sodium, ziprasidone
With potential GI side effects, including constipation
aripiprazole, citalopram, clomipramine, clozapine, fluvoxamine, 
guanfacine, olanzapine, oxybutynin, paroxetine, pregabalin, quetiapine, 
risperidone
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Table 3. Factors Associated With a Diagnosis of 
Constipation in Children With ASD (n = 85)
Adjusted 
Odds Ratio 95% CI P Value
Sex   0.79 0.20 - 3.11 NS
Age   0.81 0.69 - 0.94 0.01
SRS T-score   1.05 1.01 - 1.09 0.02
Nonverbal 11.98 2.54 - 56.57 0.002
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constipation in ASD (OR 1.04, 95% CI 0.42 − 2.64). Thus, in our final multivariate 
logistic regression model, we adjusted for age and sex (due to the large 
developmental age range and preponderance of males in our sample), and 
included SRS T-score and nonverbal status, as those were different between 
ASD-GID and ASD-only groups. Table 3 reports adjusted ORs, showing that 
younger (OR 0.81, 95% CI 0.69 − 0.94; P = 0.01), more socially impaired (OR 
1.05, 95% CI 1.01 − 1.09; P = 0.02), and nonverbal (OR 11.98, 95% CI 2.54 – 




For the first time, data obtained from clinical specialists and parents were 
integrated in the same study to address gaps in understanding GID in ASD (Buie, 
et al., 2010). A number of unique findings address what we suggest are 
misconceptions of GID in ASD. The majority of children in the ASD-GID group 
had functional, rather than organic, GID; children with ASD had the same types 
of GID as children without ASD. For constipation, the most common diagnosis in 
the ASD-GID group, we saw fair parent-physician agreement (κ = 0.26), which is 
similar to reported agreement among pediatric gastroenterologists (κ = 0.36) 
(Saps, Chogle, Sztainberg, Dhroove, & Di Lorenzo, 2010). Percent agreement 
between any type of parent-reported GID and any physician diagnosis, however, 
was high (92.1% in ASD-GID), and no different than that in the GID-only group. 
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This suggests that parents of children with ASD are similar to parents of children 
without ASD in reporting GID, and parents from both groups are limited in their 
ability to discriminate subtypes of GID. Moreover, parental report of GI symptoms 
in a child requires inference that may by limited by communication deficits in 
ASD. The parental report data in Figure 1 suggest a variety of FGIDs are present 
in ASD, whereas by a physician’s evaluation, most children were given a working 
diagnosis of functional constipation. This suggests that in children with ASD the 
manifestations of functional constipation can be variable and the expertise of a 
gastroenterologist is needed to determine the nature of the GID. 
Interestingly, some children were initially enrolled into the ASD-only group, as 
parents did not report ongoing GID. However, upon completing the QPGS, 19 
children met criteria for one or more FGIDs. To properly re-assign them to the 
ASD-GID group, we requested that the children be evaluated by a pediatric 
gastroenterologist. Several families could no longer be contacted and other 
families chose not to be evaluated; thus, no data from these 19 children are 
included in this report. This finding, combined with high parent-physician 
concordance of GID presence, suggests that parents of children with ASD do not 
over-report GID, and in fact may under-report GID. 
We suggest that comorbid GID has implications beyond medical status for 
children with ASD. Our data show a large portion of children with co-occurring 
ASD and GID lack expressive language; as a novel finding, this association 
warrants further study. This study did not assess for behavioral problems, such 
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as aggression or self-injurious acts. However, it will be important to clarify the 
relationship between externalizing behaviors, language level, and GI disorders, in 
a rigorous manner. Children in the ASD-GID group also showed increased social 
impairment on the SRS, compared to the ASD-only group. Because GID-only 
children did not show increased SRS scores, this suggests an interaction 
between ASD and GID statuses. Additional insight may derive from monitoring 
SRS scores or other behaviors during GID treatment, to determine whether 
improved medical status can enhance child responsiveness to established ASD 
behavioral treatments or decrease problematic behaviors (Bauman, 2010). In 
addition, observation of parent-child communication regarding the toileting needs 
of nonverbal children with ASD will clarify the extent to which lack of expressive 
language may itself contribute to constipation by limiting appropriate toileting 
behavior. 
We were surprised to find no differences in dietary habits between the three 
groups. Previous studies have reported increased food selectivity in younger 
children with ASD (Bandini et al., 2010; Emond, Emmett, Steer, & Golding, 2010). 
The data reported here focus on older children, and do not show evidence of 
food selectivity beyond that seen in a non-ASD population. We suggest that it is 
unlikely that dietary habits play a large causal role in GID status in our study 
population.  
Potential medication side effects and BMI did not contribute to a diagnosis of 
constipation. Although it has been suggested that constipation in ASD is caused 
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by such factors (Ibrahim, et al., 2009), our data do not support this conclusion. 
For any given child, medications may contribute to GID. However, group-level 
analysis did not detect an association between potential medication side effects 
and GID in ASD. Associations between impaired language and social function 
remained after adjustment for age and sex. Although the OR for the SRS is 
modest (1.05), this indicates a 5% increase in odds of constipation for each point 
increase in the SRS T-score. The OR for nonverbal status is large (11.98), and 
has important implications for those involved in the clinical care of children with 
ASD who lack traditional communication abilities. Consistent with the recent 
consensus report (Buie, et al., 2010), the data presented here affirm the need for 
healthcare providers to evaluate their patients for latent constipation, and to 
consider empiric treatment of constipation in nonverbal children. 
An important limitation of this study was that the physician's evaluation was 
often limited to a single encounter. Tests and procedures were ordered as 
needed to determine if organic disease was underlying a child's GID, thus it is 
likely that the diagnoses presented here are functional. As FGIDs are symptom-
based diagnoses of exclusion, working through the differential diagnosis may 
require multiple visits to determine the specific underlying FGID (for example, 
determining if intermittent abdominal pain is due to functional constipation or 
functional abdominal pain). The diagnoses presented here are the most likely 
diagnoses given the child's clinical presentation at study enrollment. Future 
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studies will benefit from follow-up evaluations of participants to determine 
whether original diagnoses are confirmed after subsequent clinical evaluations. 
An additional potential limitation of this study is possible ascertainment bias. 
Although some study participants self-referred to the study by responding to 
community flyers, the majority of participants were recruited from medical clinics 
at a large academic medical center. The data presented here may not generalize 
to a diverse community-based sample, as the participants in this study may be 
more severely impaired than the average child in the community. However, with 
this potential limitation taken into consideration, the data presented here still 
provide insight into the population studied. 
 
Conclusion 
This report characterized GID in children with ASD, evaluated by pediatric 
gastroenterologists and compared to parental report of GI symptoms, for the first 
time in comparison to ASD-only and GID-only groups. Parental report of 
presence of any GID in ASD was highly concordant with a physician’s diagnosis 
of any GID, validating parental concerns for GID in children with ASD. Parents 
were sensitive to the existence, although not necessarily the nature, of GID. 
Functional constipation was the most prevalent GID in ASD. Odds for 
constipation were significantly associated with younger age, increased social 
impairment, and lack of expressive language. Factors previously suggested as 
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causes of GID in ASD, diet and medications, were not associated with GID. 
These data support our evolving hypothesis (Campbell, et al., 2009) that GID in 
ASD represents pleiotropic expression of genetic risk factors, and thus a 




Baber, K. F., Anderson, J., Puzanovova, M., & Walker, L. S. (2008). Rome ii 
versus rome iii classification of functional gastrointestinal disorders in 
pediatric chronic abdominal pain. J Pediatr Gastroenterol Nutr, 47(3), 299-
302. 
Bandini, L. G., Anderson, S. E., Curtin, C., Cermak, S., Evans, E. W., Scampini, 
R., Maslin, M., & Must, A. (2010). Food selectivity in children with autism 
spectrum disorders and typically developing children. J Pediatr, 157(2), 
259-264. 
Bauman, M. L. (2010). Medical comorbidities in autism: Challenges to diagnosis 
and treatment. Neurotherapeutics : the journal of the American Society for 
Experimental NeuroTherapeutics, 7(3), 320-327. 
Black, C., Kaye, J. A., & Jick, H. (2002). Relation of childhood gastrointestinal 
disorders to autism: Nested case-control study using data from the uk 
general practice research database. BMJ (Clinical research ed), 
325(7361), 419-421. 
Buie, T., Campbell, D. B., Fuchs, G. J., 3rd, Furuta, G. T., Levy, J., Vandewater, 
J., Whitaker, A. H., Atkins, D., Bauman, M. L., Beaudet, A. L., Carr, E. G., 
Gershon, M. D., Hyman, S. L., Jirapinyo, P., Jyonouchi, H., Kooros, K., 
Kushak, R., Levitt, P., Levy, S. E., Lewis, J. D., Murray, K. F., Natowicz, 
M. R., Sabra, A., Wershil, B. K., Weston, S. C., Zeltzer, L., & Winter, H. 
(2010). Evaluation, diagnosis, and treatment of gastrointestinal disorders 
in individuals with asds: A consensus report. Pediatrics, 125 Suppl 1, S1-
18. 
Campbell, D. B., Buie, T. M., Winter, H., Bauman, M., Sutcliffe, J. S., Perrin, J. 
M., & Levitt, P. (2009). Distinct genetic risk based on association of met in 
families with co-occurring autism and gastrointestinal conditions. 
PEDIATRICS, 123(3), 1018-1024. 
Caplan, A., Walker, L., & Rasquin, A. (2005a). Development and preliminary 
validation of the questionnaire on pediatric gastrointestinal symptoms to 
assess functional gastrointestinal disorders in children and adolescents. J 
Pediatr Gastroenterol Nutr, 41(3), 296-304. 
Caplan, A., Walker, L., & Rasquin, A. (2005b). Validation of the pediatric rome ii 
criteria for functional gastrointestinal disorders using the questionnaire on 
pediatric gastrointestinal symptoms. J Pediatr Gastroenterol Nutr, 41(3), 
305-316. 
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., 
74
Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. 
(2003). Validation of a brief quantitative measure of autistic traits: 
Comparison of the social responsiveness scale with the autism diagnostic 
interview-revised. J Autism Dev Disord, 33(4), 427-433. 
Constantino, J. N., & Gruber, C. P. (2005). Social responsiveness scale: Manual: 
Western Psychological Services. 
Curtin, C., Anderson, S. E., Must, A., & Bandini, L. (2010). The prevalence of 
obesity in children with autism: A secondary data analysis using nationally 
representative data from the national survey of children's health. BMC 
Pediatr, 10, 11. 
Drossman, D. A. (2006). The functional gastrointestinal disorders and the rome iii 
process. Gastroenterology, 130(5), 1377-1390. 
Emond, A., Emmett, P., Steer, C., & Golding, J. (2010). Feeding symptoms, 
dietary patterns, and growth in young children with autism spectrum 
disorders. Pediatrics, 126(2), e337-342. 
Geschwind, D. H. (2009). Advances in autism. Annu Rev Med, 60, 367-380. 
Gotham, K., Risi, S., Pickles, A., & Lord, C. (2007). The autism diagnostic 
observation schedule: Revised algorithms for improved diagnostic validity. 
J Autism Dev Disord, 37(4), 613-627. 
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. 
(2009). Research electronic data capture (redcap)--a metadata-driven 
methodology and workflow process for providing translational research 
informatics support. J Biomed Inform, 42(2), 377-381. 
Ibrahim, S. H., Voigt, R. G., Katusic, S. K., Weaver, A. L., & Barbaresi, W. J. 
(2009). Incidence of gastrointestinal symptoms in children with autism: A 
population-based study. PEDIATRICS, 124(2), 680-686. 
Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Grummer-Strawn, L. M., Flegal, K. 
M., Mei, Z., Wei, R., Curtin, L. R., Roche, A. F., & Johnson, C. L. (2002). 
2000 cdc growth charts for the united states: Methods and development. 
Vital Health Stat 11(246), 1-190. 
Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for 
categorical data. Biometrics, 33(1), 159-174. 
Lord, C., Rutter, M., DiLavore, P., & Risi, S. (1999). Autism diagnostic 
observation schedule: Manual: Western Psychological Services. 
75
Molloy, C. A., & Manning-Courtney, P. (2003). Prevalence of chronic 
gastrointestinal symptoms in children with autism and autistic spectrum 
disorders. Autism : the international journal of research and practice, 7(2), 
165-171. 
Mouridsen, S. E., Rich, B., & Isager, T. (2010). A longitudinal study of 
gastrointestinal diseases in individuals diagnosed with infantile autism as 
children. Child Care Health Dev, 36(3), 437-443. 
Nikolov, R. N., Bearss, K. E., Lettinga, J., Erickson, C., Rodowski, M., Aman, M. 
G., McCracken, J. T., McDougle, C. J., Tierney, E., Vitiello, B., Arnold, L. 
E., Shah, B., Posey, D. J., Ritz, L., & Scahill, L. (2009). Gastrointestinal 
symptoms in a sample of children with pervasive developmental disorders. 
J Autism Dev Disord, 39(3), 405-413. 
Pashankar, D. S., & Loening-Baucke, V. (2005). Increased prevalence of obesity 
in children with functional constipation evaluated in an academic medical 
center. Pediatrics, 116(3), e377-380. 
Saps, M., Chogle, A., Sztainberg, M. O., Dhroove, G., & Di Lorenzo, C. (2010). 
Inter-rater reliability of the rome iii criteria in children. Gastroenterology, 
138(5), S-109-S-110. 
Smith, R. A., Farnworth, H., Wright, B., & Allgar, V. (2009). Are there more bowel 
symptoms in children with autism compared to normal children and 
children with other developmental and neurological disorders?: A case 
control study. Autism, 13(4), 343-355. 
Teitelbaum, J. E., Sinha, P., Micale, M., Yeung, S., & Jaeger, J. (2009). Obesity 
is related to multiple functional abdominal diseases. J Pediatr, 154(3), 
444-446. 
Valicenti-McDermott, M., McVicar, K., Rapin, I., Wershil, B. K., Cohen, H., & 
Shinnar, S. (2006). Frequency of gastrointestinal symptoms in children 
with autistic spectrum disorders and association with family history of 
autoimmune disease. J Dev Behav Pediatr, 27(2 Suppl), S128-136. 
Volkmar, F. R. (2005). Handbook of autism and pervasive developmental 
disorders (3rd ed.). Hoboken: John Wiley & Sons. 
Walker, L. S., Caplan-Dover, A., & Rasquin-Weber, A. (2000). Manual for the 
questionnaire on pediatric gastrointestinal symptoms. 
Xue, M., Brimacombe, M., Chaaban, J., Zimmerman-Bier, B., & Wagner, G. C. 
(2008). Autism spectrum disorders: Concurrent clinical disorders. J Child 





Biological Stratification Of Individuals With ASD  
Shows Subpopulation Enrichment Of 15-F2t-Isoprostane 
 
Introduction 
Progress in understanding the etiology and prognosis of individuals with 
autism spectrum disorders (ASDs) has been, to date, modest. It has been 
proposed that profound heterogeneity across individuals — both in underlying 
pathogenic mechanism and in phenotypic manifestation of the disorder — has 
been a significant source of this limited progress (Campbell et al., 2009). 
However, viewed through an optimistic lens, this heterogeneity is an opportunity 
to stratify affected individuals, thereby leveraging complexity to yield 
subpopulations with greater intra-group homogeneity and potentially enriching for 
a disease-specific signal within a subpopulation. Consistent with this view, a 
recent report demonstrated that, using genome-wide association (GWA) data, a 
variant association with ASD surpassed the Bonferroni-corrected GWA threshold 
of significance only when sex of cases was incorporated as a modifying factor; 
without sex included, the association did not meet criteria for significance (Lu & 
Cantor, 2010). 
Another example of the power of stratifying cases to enrich for signal 
detection was reported recently in individuals with ASDs and co-occurring 
gastrointestinal dysfunction (ASD-GID) compared to those without co-occurring 
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GID (ASD-only) (Campbell, et al., 2009). As discussed in Chapters I and II, GID 
is a co-occurring condition for a subpopulation of individuals with ASDs. 
Campbell and colleagues hypothesized that given the expression of the MET 
receptor tyrosine kinase in multiple organ systems, including the brain and 
gastrointestinal (GI) system, that pleiotropic effects of a previously-described 
ASD-associated functional risk variant in the gene, rs1858830, could mediate 
shared risk for dysfunction in parallel organ systems. To this end, they reported 
data demonstrating that the risk allele of rs1858830 was over-transmitted to 
individuals with ASD-GID, compared to ASD-only. Allelic frequency for the risk 
variant was enriched in the co-occurring group, consistent with the hypothesis 
that stratified populations are an important strategy for addressing the difficulties 
imposed by disease heterogeneity. 
The genetic signal enrichment in a GID-stratified population reported by 
Campbell and colleagues suggested two important future studies to undertake. 
First, a previous report had demonstrated significantly decreased MET protein 
expression in postmortem temporal cortex of ASD cases versus matched 
controls (Campbell et al., 2007). Given the genetic signal enrichment in 
individuals with ASD-GID (Campbell, et al., 2009), a subsequent hypothesis was 
that protein expression in peripheral blood would show similar differences as 
seen in postmortem brain. Second, it was hypothesized that genetic differences 
between ASD-GID and ASD-only groups may coincide with other biological 
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differences between groups, independent of MET signaling system biology, per 
se. 
Metabolic dysfunction is one potential biological abnormality in ASD that has 
recently been investigated by a number of investigators. One report concluded 
that 7.2% of individuals with ASDs have mitochondrial dysfunction (Oliveira et al., 
2005). More recently, an examination of 10 cases with ASD compared to 10 
controls showed decreased mitochondrial activity levels and elevated pyruvate 
levels in ASD cases (Giulivi et al., 2010). Variants in several genes involved in 
the pyruvate metabolic pathway have been associated with ASD (Anney et al., 
2011). Dysfunctional mitochondrial metabolism can produce free radicals and 
reactive oxygen species. Normally, cellular homeostatic and antioxidant systems 
(such as glutathione metabolism) accommodate free radical production. Variants 
in genes of the glutathione metabolic pathway and altered blood levels of 
glutathione have been reported in ASD (Bowers et al., 2011; James et al., 2006; 
Melnyk et al., 2011). Under conditions of oxidative stress, however, abundant 
free radicals can mediate damage to cellular components, including DNA, 
proteins and lipids (Milne, Sanchez, Musiek, & Morrow, 2007). 
Of the diverse strategies for quantifying oxidative stress and metabolic 
dysfunction, some of which were used in the studies described above, the 
measurement of urinary or plasma 15-F2t-isoprostane (isoP; also known as 8-iso-
PGF2α) is widely considered to be the gold standard measure of oxidative stress 
(Milne, et al., 2007). The NIH-commissioned Biomarkers of Oxidative Stress 
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Study found isoP measurement to be the most sensitive and specific metric of 
oxidative stress (Kadiiska et al., 2005a; Kadiiska et al., 2005b). F2-isoprostanes 
are formed by the non-enzymatic free radical-catalyzed oxidation of arachidonic 
acid, which is present in all fatty acid membranes (Milne, et al., 2007). Increased 
isoprostane levels, resulting from increased free radicals, have been associated 
with many diseases, including Crohn’s disease (Cracowski et al., 2002), kidney 
disease (Oberg et al., 2004), and stroke severity (Zeiger et al., 2009), suggesting 
elevated isoprostanes represent a high-level measure of systemic oxidative 
stress that is not specific to a particular disease. Two previous studies, with 
modest sample sizes, have reported increased urinary isoP levels in children with 
ASD compared to controls (Ming et al., 2005; Yao, Walsh, McGinnis, & Praticò, 
2006). 
Building on the previous work demonstrating enrichment of a genetic signal 
(Campbell, et al., 2009), the objectives of this study were threefold. The first 
objective was to replicate the previous genetic findings, using more detailed 
phenotype information. The second objective was to extend the genetic findings 
to peripheral blood expression of MET mRNA. The final objective was to examine 
differences in isoP levels between groups, as a potential biomarker parallel to the 








Participants and Study Procedures 
Children were recruited at Vanderbilt University in Nashville, Tennessee into 
three groups: co-occurring ASD and GID (ASD-GID); ASD without any GID (ASD-
only); and GID without any ASD (GID-only). All children in the ASD groups were 
assessed with the Autism Diagnostic Observation Schedule (ADOS). Children in 
the GID groups were assessed by either parental report on a research-validated 
instrument that categorizes GI complaints into functional gastrointestinal 
disorders according to Rome-III criteria (the Questionnaire on Pediatric 
Gastrointestinal Symptoms, or QPGS; (Drossman, 2006; Walker, Caplan-Dover, 
& Rasquin-Weber, 2000)), or by a clinician who specializes in caring for children 
with GID. Details of these GID evaluations are articulated in the Methods section 
of Chapter II, with the only difference being that participants included here in 
Chapter III were not required to have data from both parental report and clinical 
evaluation. The concordance for presence of any type of functional GID in 
children when reported by parents on the QPGS compared to physician 
examination exceeds 90% (see Chapter II).  Additionally, parents in the ASD-only 
group completed the same GID parental report instrument as the other two 
groups, to ensure the ASD-only group was devoid of any latent GID that was not 
identified at study enrollment. All children donated a blood or saliva sample. 
Exclusion criteria included severe sensory or motor impairment, 
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neurodevelopmental disorders of known etiology (Rett Syndrome, Tuberous 
Sclerosis, Down Syndrome, Phenylketonuria, 22Q Deletion Syndrome, Fragile X 
Syndrome and Neurofibromatosis), gestational age less than 36 or greater than 
42 weeks, and birth weight less than 2500 grams. Inclusion criteria included age 
between 5 and 18 years at enrollment, meeting ASD criteria on the ADOS (for the 
ASD groups), and GI symptoms that had lasted more than a month (for the GID 
groups). The research protocol was approved by the Vanderbilt University 
Institutional Review Board, and written informed consent was obtained from 
parents of participants. 
 
Specimen Collection and Nucleic Acid Extraction 
Blood or saliva was collected from study participants. Blood was collected into 
both EDTA-coated (for DNA) and PAXgene Blood (for RNA) tubes (both from BD, 
Franklin Lakes, NJ). For participants who opted not to donate blood, saliva was 
collected into Oragene-DNA collection kits (DNA Genotek, Kanata, Ontario, 
Canada). Genomic DNA was extracted using the QIAamp DNA Kit (Qiagen, 
Valencia, CA). Total RNA was isolated from whole blood collected into PAXgene 
tubes using the PAXgene 96 Blood RNA Kit (BD) according to the manufacturer’s 
protocol, which included a DNase I treatment. RNA was assessed for purity with 
a ND-1000 Nanodrop (Thermo Scientific, Wilmington, DE). Nearly all RNA 
samples had A260/A280 ratios of approximately 2.0; two samples had 
absorbance ratios below 1.90 and were thus excluded. Multiple RNA samples 
82
  
were randomly chosen for integrity assessment using RNA 6000 Nano chips on 
an Agilent 2100 Bioanalyzer system (Agilent Technologies, Santa Clara, CA). 
RNA Integrity Number was consistently greater than 9.0 across samples. 
 
Genotypes of the ASD-Associated MET Variant rs1858830 
Genotypes at rs1858830 were determined by direct sequencing, as described 
elsewhere ((Campbell, et al., 2007)). In brief, genomic DNA was extracted from 
blood or saliva specimens, and 20 ng was used as template for a polymerase 
chain reaction (PCR) amplification of a 652 bp amplicon which includes 
rs1858830, using the KOD Xtreme Hot Start DNA Polymerase kit (EMD 
Chemicals, Gibbstown, NJ) by the manufacturer’s protocol. Primer sequences 
were: forward primer, GATTTCCCTCTGGGTGGTG; reverse primer, 
CAAGCCCCATTCTAGTTTCG. Thermal cycling conditions were as follows: 94º 
for 2 m, followed by 35 cycles of 98º for 10 s then 58º for 30 s then 68º for 1 m, 
and a final extension at 68º for 7 m. Agarose gel electrophoresis of the PCR 
product from a random sampling of reactions confirmed specific amplification of 
the 652 bp amplicon. A 2 μl aliquot of PCR product was diluted 1:10 in water, and 
direct sequencing off the reverse primer was performed using a 3730xl DNA 
Analyzer (Applied Biosystems, Foster City, CA). Sequences were aligned to the 
reference sequence of the plus strand of chromosome 7 and chromatograms 
were visually inspected to determine genotypes using Sequencher version 4.10.1 
(Gene Codes, Ann Arbor, MI). Genotypes were called while blinded to sample 
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identity and case status, and heterozygote calls were required to have a 
secondary peak on the chromatogram with at least 50% the height of the primary 
peak. Observed genotypes at rs1858830 were in Hardy–Weinberg equilibrium 
(χ2; P = 0.97). 
 
Measurement of MET mRNA Expression in Blood 
For each sample, complementary DNA (cDNA) was reverse transcribed from 
8 μl of input DNase-treated total RNA, using the SuperScript III First-Strand 
Synthesis kit primed with random hexamers in a 20 μl reaction, according to the 
manufacturer’s protocol (Invitrogen, Carlsbad, CA). Quantitative reverse 
transcriptase-polymerase chain reaction (qPCR) was performed using 2 μl of 
input cDNA in a 20 μl reaction, with TaqMan Gene Expression Master Mix and 
TaqMan Gene Expression assays, according to the manufacturer’s protocol (both 
from Applied Biosystems). Assay IDs were as follows: GAPDH, 
Hs99999905_m1; MET, Hs01565584_m1; NOD2, Hs00223394_m1; POLR2A, 
Hs00172187_m1. Assays were manufacturer-validated, highly efficient, and 
amplified regions spanning exon-exon junctions. Each sample was run in 
triplicate and average values were used for analysis, with all four assays run for a 
given sample on the same 96-well plate. Each plate contained multiple no-
template negative control wells and reactions were run on a CFX96 real-time 
system (Bio-Rad, Hercules, CA). Thermal cycling conditions were as follows: 
50ºC for 2 m, 95ºC for 10 m, and 50 cycles of 95ºC for 15 s and 60ºC for 1 m. For 
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data analysis, raw amplification plots were visually inspected for wells that failed 
amplification and were subsequently manually excluded. Threshold cycle number 
(Ct) values were then exported for further analysis. Individual triplicate Ct values 
were compared for deviation from the replicate series mean, and if any replicate 
varied from the mean by more than 2 Ct values, it was excluded and the mean of 
the remaining duplicates was used as the average Ct value for that sample. After 
these exclusions, each sample had at least duplicates remaining for each target 
gene. Using the ΔCt method, MET Ct expression values were normalized to 
POLR2A, GAPDH, and NOD2 Ct values separately.  
 
Measurement of 15-F2t-Isoprostane in Plasma 
Whole blood was collected into EDTA-coated blood tubes (BD) and 
centrifuged at 1000 g for 10 m at 4ºC. Plasma was drawn off the sample and 
aliquoted before freezing at −80ºC. If blood was not centrifuged immediately, it 
was placed on ice within 15 m of blood draw. Plasma was frozen within 1 h of 
blood draw, and kept at −80ºC until further processing for measurement of isoP. 
IsoP levels were measured by gas chromatography-negative ion chemical 
ionization-mass spectrometry (GC-NICI-MS) at the Vanderbilt University Medical 
Center Eicosanoid Core (Milne, et al., 2007). Samples were processed in 
batches of 21, with each batch containing an aliquot of an inter-batch normalizing 
standard. For analysis, samples within a batch were normalized to the inter-batch 
standard; normalized data are presented here. Additionally, 10 unaffected control 
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plasma samples were contributed by the laboratory of Dr. BethAnn McLaughlin 
(Vanderbilt University). These control samples came from male subjects who 
were all of non-Hispanic white ethnicity and race, and between 5 and 15 years 
old, making them similar to the experimental groups. Control participants were all 
assessed for the absence of seizures, neurodevelopmental delay, and GID. 
 
Analyses 
Study data were managed using REDCap, a secure, research-oriented, web-
based application (Harris et al., 2009). Statistical analyses were computed using 
SPSS version 18.0.3 (IBM, Somers, NY) and Prism version 5.0d (GraphPad, La 
Jolla, CA). Prism was also used for generating plots. Categorical values 
(genotype and allele frequencies at rs1858830) were compared with a χ2 test. 
Continuous measures (average ΔCt and isoP levels) were compared with a one-
way ANOVA with Tukey post-hoc tests. IsoP levels were plotted as mean and 
95% confidence intervals (CIs). For all statistical tests, a P value of less than 




Characteristics of Study Participants 
162 children were recruited for this study (Table 1; group sizes: ASD-GID = 
74, ASD-only = 40, GID-only = 48), with characteristics similar to the cohort  
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Present in Chapter II cohort, % (n) 54.1 (40) 97.5 (39) 72.9 (35)
Age in years, mean (SD) 11.2 (3.5) 12.8 (3.2) 11.2 (3.3)
Male sex, % (n) 75.7 (56) 87.5 (35) 62.5 (30)
Ethnicity and race, % (n)
Hispanic   8.1 (6)   2.5 (1)   6.2 (3)
Non-Hispanic white 78.4 (58) 82.5 (33) 89.6 (43)
Non-Hispanic black 10.8 (8) 10.0 (4)   4.2 (2)
Non-Hispanic other   2.7 (2)   5.0 (2)   0 (0)
ADOS classification, % (n)
Autism 95.9 (71) 92.5 (37) n/a
Autism Spectrum   4.1 (3)   7.5 (3) n/a
Specimen availability, % (n)
DNA 100 (74) 100 (40) 100 (48)
RNA 71.6 (53) 75.0 (30) 68.8 (33)
Plasma 40.5 (30) 72.5 (29) 41.7 (20)
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described in Chapter II. On average, children were young adolescents (range of 
mean ages among groups: 11.2 − 12.8 y). The majority of participants were male 
(range among groups: 62.5 − 75.7%) and of non-Hispanic white self-reported 
ethnicity and race (range among groups: 78.4 − 89.6%). The vast majority of 
children in both ASD groups met ADOS criteria for autism (ASD-GID: 95.9%; 
ASD-only: 92.5%), with the remaining children in each group meeting criteria for 
autism spectrum. 100% of participants had DNA available for genetic analyses; 
RNA and plasma availability was incomplete for all groups, ranging from 40.5% 
to 75% available within a group. There was substantial overlap between children 
included in this study, and those included in Chapter II (ranging from 54.1% for 
ASD-GID to 97.5% for ASD-only). Nineteen children included in the current study 
were excluded from the ASD-GID group in Chapter II because they had a 
complete GI parent report, but did not have a clinical GI evaluation. The high 
concordance seen in Chapter II between parent report and clinical evaluation of 
presence of GI complaints (92% agreement) justified inclusion of these 19 
children in the ASD-GID group for this study. Children in the ASD-only group 
were required to have a complete parent report of GI complaints, and 
subsequently not meet criteria for any GID classification (except fecal 
incontinence, which as discussed in Chapter II, is confounded by toilet training; 
four children met criteria for incontinence, but were still included in the ASD-only 
group), to ensure no latent or undiagnosed GID was present in the ASD-only 
group. Finally, gastrointestinal dysfunction, for this study, is treated as a binary 
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variable (yes or no), without distinction for type of GID. There is, however, 
substantial homogeneity of type of GID within this group (i.e., 85% constipation 
seen in Chapter II). 
 
Genotypes at MET rs1858830 
All samples were genotyped at the ASD-associated MET variant rs1858830 
(Table 2). No significant differences were seen between ASD-GID and ASD-only 
groups for either genotypic or allelic frequencies. With an increased prevalence 
of C/C homozygotes, genotypic frequencies in the ASD-GID group were 
significantly different from those in the GID-only group (P = 0.007). This 
difference was not found for allelic frequencies (P = 0.111), however. 
 
MET Expression in Peripheral Blood 
RNA was available for a subset of participants in each group, and used to 
measure MET expression in peripheral blood by qPCR. Using the ΔCt method of 
relative quantification, MET mRNA expression was normalized to three different 
reference genes. The genes encoding housekeeping proteins GAPDH and 
POLR2A are standard normalizing genes. Peripheral blood expression of MET is 
primarily in monocytes (Beilmann, Vande Woude, Dienes, & Schirmacher, 2000). 
Thus, NOD2, which is a specific marker for monocytes, was also used for 
normalization (Ogura et al., 2001). Tables 3 and 4 show average ΔCt values, 
relative to these three normalization genes. Table 3 shows MET expression  
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Table 2. Genotype and Allele Frequencies at MET rs1858830
n C/C C/G G/G P C G P
ASD-GID 74 0.432 0.392 0.176 Ref. 0.628 0.372 Ref.
ASD-only 40 0.500 0.400 0.100 0.532 0.700 0.300 0.309
GID-only 48 0.188 0.667 0.146 0.007 0.521 0.479 0.111
MET Genotype MET Allele
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Table 3. Comparison of MET Expression in Peripheral Blood 






(n = 33) P
MET ΔCt, mean (SD)
relative to POLR2A 10.6 (1.0) 11.0 (0.9) 10.7 (0.9) NS
relative to GAPDH 14.8 (0.9) 15.2 (1.0) 14.8 (0.9) NS







(n = 18) P
MET ΔCt, mean (SD)
relative to POLR2A 10.9 (0.9) 10.5 (1.0) 11.1 (0.8) NS
relative to GAPDH 14.8 (0.9) 14.9 (1.0) 15.1 (0.9) NS
relative to NOD2   9.6 (1.0)   9.4 (1.0)   9.9 (0.8) NS
Table 4. Comparison of MET Expression in Peripheral Blood 
Measured by qPCR, Stratified by rs1858830 Genotype
92
  
stratified by study group, whereas Table 4 shows expression stratified by 
genotype at rs1858830. No significant differences were seen in MET expression 
among study groups or genotypes, for any of the three normalizations. 
 
IsoP Levels in Peripheral Blood Plasma 
Plasma was available for a subset of participants and was used to measure 
isoP (Figure 1). Interestingly, the ASD-GID group mean was significantly elevated 
above the ASD-only group mean (ASD-GID mean 0.173 ng/ml, 95% CI 0.145 – 
0.202; ASD-only mean 0.122 ng/ml, 95% CI 0.105 – 0.139). The ASD-only and 
GID-only group means were not significantly different (GID-only mean 0.135 
ng/ml, 95% CI 0.111 – 0.160). ASD-GID, ASD-only, and GID-only all had 
significantly elevated group mean isoP levels compared to unaffected control 
children (Unaffected mean 0.056 ng/ml, 95% CI 0.045 - 0.067). 
 
Discussion 
Three distinct biomarkers were examined in the current study of stratified 
ASD participants. The most significant finding of this study is the elevation of 
plasma isoP levels in the ASD-GID group. The isoP elevation in ASD-only 
compared to unaffected controls is consistent with two previous reports, which 
showed a similar elevation in urinary isoP relative to controls (Ming, et al., 2005; 
Yao, et al., 2006). However, neither study reported isoP levels stratified by GID. 
Ming and colleagues did in fact report on presence of GID in their cohort, so  
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Figure 1. Plasma 15-F2t-isoprostane levels among four study groups. 
Plasma was available for a subset of participants and IsoP was measured. ASD-
GID group mean was significantly elevated above the ASD-only group mean 
(ASD-GID mean 0.173, 95% CI 0.145 - 0.202; ASD-only mean 0.122, 95% CI 
0.105 - 0.139). ASD-only and GID-only group means were not significantly 
different (GID-only mean 0.135, 95% CI 0.111 - 0.160). All three experimental 
groups were significantly different from the unaffected group (Unaffected mean 
0.056, 95% CI 0.045 - 0.067). Data are plotted as mean and 95% CI around the 
mean.







(ng/mL) P = 0.005
P ! 0.01
n = 30 n = 29 n = 20 n = 10
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stratification would be possible in a re-analysis of their data. Yao and colleagues 
do not mention assessing for GID in their population, but, interestingly, their data 
show a subpopulation of ASD-diagnosed individuals with much higher isoP 
levels. In the context of the data reported here, assessing individuals in the Yao 
et al dataset for GID seems warranted. Given the findings reported in Chapter II 
(namely, high prevalence of nonverbal children with GID and possible under-
reporting of GID by parents), it is likely that some fraction of the Yao cohort has 
undiagnosed, or diagnosed but unreported, GID. Moreover, elevation of isoP 
levels in the ASD-GID group, above that in both GID-only and ASD-only groups, 
is consistent with a hypothesis that dysfunctional biology in parallel organ 
systems (in this case, oxidative stress in the brain and gastrointestinal system, 
both of which have high metabolic activity) will have additive effects apparent in 
biomarker measures of that dysfunctional biology.  
An additional primary objective of this study was to replicate the previously-
reported enrichment of rs1858830 signal in an ASD-GID population (Campbell, et 
al., 2009). While the data reported here are exploratory and limited by sample 
size, the trends in rs1858830 allele frequency are consistent with what was 
hypothesized and with previous reports (Campbell, et al., 2009; Campbell et al., 
2006). The ASD-associated C allele of rs1858830 was present at increased 
frequencies in both ASD groups (63 and 70%, which are even higher than that 
reported by Campbell et al (Campbell, et al., 2009)) relative to the GID-only group 
(52%), although this difference lacked statistical significance. Genotypic 
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frequencies, however, were significantly different between ASD-GID and GID-
only. While it is surprising to see a relatively high C allele frequency in the ASD-
only group, which would be inconsistent with the Campbell et al study (Campbell, 
et al., 2009), these data are inconclusive given the small sample size. 
Additionally, although case-control association studies can be confounded by 
population stratification, the cohort in this study was mostly self-reported non-
Hispanic white (and self-report correlates highly with genetically-defined ethnicity 
and race (Tang et al., 2005)), making it unlikely that these data are confounded 
by racial differences. To further understand and formally test for replication of 
rs1858830 enrichment, a larger cohort will need to be studied in the future.  
Given previous findings of MET expression differences in postmortem brain 
tissue of individuals with ASD (Campbell, et al., 2007), it was hypothesized that 
peripheral blood expression of MET would be different in cases versus controls, 
and potentially different within ASD cases when stratified by presence of GID. 
Postmortem brain MET protein expression differences were seen between ASD 
cases compared to controls, as well as differences within controls when stratified 
by rs1858830 genotype. There were no significant differences found in this study 
for MET mRNA expression in peripheral blood, when the cohort was stratified by 
group membership or by rs1858830 genotype. MET expression was normalized 
to both standard housekeeping genes, and a monocyte-specific marker, as MET 
expression in blood is primarily in monocytes, a cell population which could vary 
substantially between participants depending on immune status. The lack of 
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differences between groups reported here was initially surprising. Recent 
unpublished data, however, provides a useful context for interpreting these 
findings. In an exploratory study of over 120 samples from ASD, 
developmentally-delayed, and typically-developing children, measurement of 
MET protein expression in peripheral blood also showed no differences, by 
affected status or rs1858830 genotype (S. Spence, P. Gorrindo, D. Campbell, P. 
Levitt, and S. Swedo, unpublished observations). Replication of lack of 
expression differences in an independent cohort, and at the protein level, 
corroborates the mRNA findings reported here. However, in a cohort of over 70 
samples in which peripheral blood mononuclear cells (PBMCs) isolated from 
fresh blood were stimulated with lipopolysaccharides (LPS) to induce MET 
expression, rs1858830 genotype did correlate significantly with MET protein 
expression differences (D. Campbell, personal communication). Integrating these 
unpublished findings and the data reported here, one possible interpretation of 
our findings is that MET expression in peripheral blood is very low at basal levels, 
but when MET expression is induced, the functional variant rs1858830 
significantly affects transcriptional level of the gene. Thus, induced MET 
expression in PBMCs, altered by rs1858830 genotype, is consistent with the 
previously published postmortem brain expression findings (Campbell, et al., 
2007). 
These studies have a number of limitations, which are opportunities for 
improvement and subsequent studies. The genetic study would benefit from a 
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much larger sample. Additionally, family status (simplex versus multiplex) was 
not rigorously assessed in this cohort. Previous data on the rs1858830 ASD 
association demonstrates specific signal for multiplex, rather than simplex, 
families (Campbell, et al., 2006). Thus, a larger sample with additional recruiting 
resources and time may benefit from specifically recruiting multiplex families. The 
lack of MET expression differences, now clarified in the context of unpublished 
studies, was surprising. Future studies could test for MET expression differences 
in response to LPS stimulation. However, it should be noted that this is a 
nontrivial endeavor, as PBMC isolation and stimulation requires significant 
technical skills. Finally, while the isoP findings are exciting, characterizing lipid 
status (including low-density lipoprotein, LDL) in these samples will be required 
for a more complete understanding of the data. Oxidation of LDL can lead to isoP 
formation (Lynch, Morrow, Roberts, & Frei, 1994), and given the elevated mean 
body-mass index (BMI) seen in the ASD groups (Chapter II), it is possible that 
elevated LDL levels contributed to elevated isoP levels. Importantly, BMI was 
elevated in both ASD groups, with no significant difference between them, so it is 
unlikely that there is a ASD-GID group specific effect of LDL levels, however this 
remains to be formally tested in future studies. 
 
Conclusion 
The studies reported here were grounded in an original finding of genetic 
signal enrichment in a biologically-stratified subpopulation of individuals with 
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ASDs (Campbell, et al., 2009). The overall aim of these studies was to test the 
validity of biological stratification as a viable and powerful strategy to address 
heterogeneity within the ASDs. While the genetic and transcript expression data 
were inconclusive, the isoP findings provide strong support for stratification as a 
useful approach for studies of ASD. Future studies may benefit from analogous 
stratification on other readily assessed clinical and biological aspects of the 
ASDs, such as presence of seizures or immune dysfunction. Moreover, the 
elevated isoP levels in the ASD-GID group parallel clinical and behavioral 
differences in this group (increased language and social impairment reported in 
Chapter II). It remains to be tested if there is a direct relationship between these 
behavioral findings and isoP levels. Finally, changes in isoP levels can change 
rapidly within an individual in response to stimuli, which offers the possibility of 
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Met Signaling Is Involved In Gastrointestinal Repair  
After Acute Epithelial Injury 
 
Introduction 
The Met receptor tyrosine kinase, through activation by its endogenous ligand 
hepatocyte growth factor (HGF; also known as Scatter Factor), provides the 
molecular initiation signal for downstream intracellular pathways that underlie a 
variety of biological processes (Trusolino, Bertotti, & Comoglio, 2010). Met 
signaling is implicated in the development of multiple tissues and organ systems, 
including the placenta (Uehara et al., 1995), liver (Schmidt et al., 1995), and 
nervous system (Akimoto et al., 2004; Judson, Amaral, & Levitt, 2010a; Judson, 
Bergman, Campbell, Eagleson, & Levitt, 2009; Judson, Eagleson, Wang, & 
Levitt, 2010b; Tyndall & Walikonis, 2006). MET was originally discovered as a 
proto-oncogene (Cooper et al., 1984), and the data supporting MET’s 
involvement in cancer pathology is vast (Birchmeier, Birchmeier, Gherardi, & 
Vande Woude, 2003; Trusolino, et al., 2010). Acute injury paradigms have also 
demonstrated the importance of Met signaling for tissue repair and regeneration 
in multiple organs, including the liver (Borowiak et al., 2004; Huh et al., 2004) and 
skin (Chmielowiec et al., 2007). Of particular relevance to the studies described 
here, multiple reports have also implicated Met signaling in repair of the 
gastrointestinal (GI) epithelium after acute injury, as administration of exogenous 
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HGF bolsters repair of the damaged epithelium (Numata et al., 2005; Oh et al., 
2005; Tahara et al., 2003).  
Recent studies have implicated MET signaling in developmental 
neurobiology. As an increasing number of neurodevelopmental roles played by 
Met were reported (Akimoto, et al., 2004; Tyndall & Walikonis, 2006), and 
because the MET gene resides under a linkage peak on chromosome 7q that 
has been reported multiple times in studies of autism spectrum disorders (ASDs) 
(International Molecular Genetic Study of Autism Consortium, 1998, 2001; Lamb 
et al., 2005; Philippe et al., 1999; Schellenberg et al., 2006), MET was examined 
as a candidate risk gene for ASDs (Campbell et al., 2006). Multiple studies by 
independent investigators and using distinct cohorts have shown association 
between genetic variants in MET and ASD diagnosis (Campbell, Li, Sutcliffe, 
Persico, & Levitt, 2008; Campbell, et al., 2006; Jackson et al., 2009; Sousa et al., 
2009; Thanseem et al., 2010). As individuals with ASDs can have co-occurring 
gastrointestinal problems (Geschwind, 2009), and given the pleiotropic activity of 
Met signaling in both the nervous and GI systems, a subsequent study showed 
significant enrichment of a genetic variant in MET specifically in individuals with 
co-occurring ASDs and GI problems, compared to those with only ASDs 
(Campbell et al., 2009). This clinical context provides a compelling rationale for 




The objectives of the present study were threefold. The first objective was to 
study the developmental expression patterns of Met protein in the rodent GI 
system. These expression data informed the selection of a tissue-specific Cre 
recombinase line to specifically delete Met from the GI epithelium. Conditional 
null mice, in which a tissue-specific Cre line is leveraged to only delete a gene of 
interest in a subpopulation of cells, enable studies which are not subject to 
confounds of whole organism genetic deletion. In the case of Met, full knockout 
mice are embryonically lethal (Bladt, Riethmacher, Isenmann, Aguzzi, & 
Birchmeier, 1995) and thus a conditional deletion strategy is required for studying 
adult phenotypes. Thus, the second objective was to assess the consequences 
of loss of Met signaling in the GI epithelium in conditional null mice. Finally, the 
third objective was to assess conditional null mice for their susceptibility to acute 





Mice used in these studies were on the C57Bl/6 background and housed in a 
vivarium on a 12 h light/dark cycle. Water and chow were provided ad libitum. 
Gastrointestinal-specific Met conditional null mice (Villincre/+; Metfx/fx) were 
generated by mating mice homozygous for a Met allele, in which exon 16 is 
flanked by loxP sites (Huh, et al., 2004; Metfx/fx, courtesy of Dr. Snorri 
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Thorgeirsson, NIH/Center for Cancer Research, Bethesda, MD) to Villincre 
transgenic mice (El Marjou et al., 2004; courtesy of Dr. Brent Polk, Children’s 
Hospital Los Angeles, Los Angeles, CA) that were also heterozygous for the 
floxed Met allele (Villincre/+; Metfx/+). Animals were genotyped by polymerase 
chain reaction (PCR) as previously described (Judson, et al., 2009). In brief, 
Villincre primers were: forward 5’-TTCGGCTATACGTAACAGGG-3’, reverse 5’-
TGCATGCAACGAGTGATGAG-3’. Metfx primers were: forward 5’-
GCAACTGTCTTTTGATCCCTGC-3’, reverse 5’-
TGTCCAGCAAAGTCCCATGATAG-3’. PCR thermal cycling conditions were as 
follows: Villincre, 5 m at 94°C, 35  cycles of 94°C for 45 s, 55°C for 30 s, 72°C for 
1 m, and a final 7 minutes at 72°C; Metfx, 5 m at 94°C, 35 cycles of 94°C for 1 m, 
60°C for 1 m, 72°C for 2 m, and a final 5 minutes at 72°C. For the studies 
reported here, the term “wildtype” refers to both Villin+/+; Metfx/fx homozygous and 
Villin+/+; Metfx/+ heterozygous control animals, as they are both considered 
equivalently unaffected at the Met locus. Developmental weight growth of 
conditional null and wildtype control animals was measured by weighing pups on 
the day of birth (postnatal day 0, P0), P4, P7, P14, and day of weaning on P21. 
Adult male animals ranged in age from P60 to P125. Studies were completed 
according to experimental protocols approved by Institutional Animal Care and 
Use Committee at the University of Southern California. Animal suffering and 




LoxP Recombination Assay 
As previously described (Eagleson, Campbell, Thompson, Bergman, & Levitt, 
2010), genetic recombination of the floxed Met allele was confirmed in a PCR-
based assay on genomic DNA isolated from colon and brain tissue. Cre-
mediated excision of floxed Met exon 16 generates a unique DNA sequence 
which acts as template for amplification of a 650 bp amplicon using 5’-
CCAGGTGGCTTCAAATTCTAAGG-3’ and 5’-CAGCCGTCAGACAATTGGCAC-
3’ primers. Non-excised floxed exon 16 acts as template for amplification of a 313 
bp amplicon using 5’-CCAGGTGGCTTCAAATTCTAAGG-3’ and 5’-
TTAGGCAATGAGGTGTCCCAC-3’ primers.  
 
Histology 
Mice were sacrificed by cervical dislocation under anesthesia (isoflurane), and 
tissue was harvested and immersion-fixed in 0.1 M sodium phosphate-buffered 
4% paraformaldehyde (PFA) overnight at 4ºC. Embryonic tissue was fixed intact 
and adult tissue was flushed with ice-cold PBS and then prepared as Swiss rolls 
prior to fixation (Moolenbeek & Ruitenberg, 1981). Tissue was cryoprotected by 
serial incubations in 10%, 20% and 30% graded sucrose solutions (% w/v in 0.1 
M sodium phosphate buffered 0.9% saline, PBS) for approximately 12 hours 
each, and then frozen over liquid nitrogen in TFM embedding medium (Triangle 
Biomedical Sciences, Durham, NC). Tissue was stored at −80ºC until sectioning 
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on a cryostat at 14 to 25 μm. Slides were processed for staining with either 
hematoxylin and eosin (HE) or anti-Met immunohistochemistry (described below). 
Mucosal thickness was measured in HE stained slides at the proximal and 
distal ends of the Swiss roll, measuring from the basal extent of the muscularis 
mucosae to the apical extent of the epithelium. For each animal, four 
measurements were made (two per end of the roll) and averaged. 
 
Immunohistochemistry 
Immunohistochemical staining of Met protein expression was performed as 
described previously (Judson, et al., 2009), with minor modifications noted below. 
Sections on slides were dried overnight at room temperature, fixed for 15 m with 
4% PFA and rinsed with PBS. Slides were incubated for 5 m in 0.3% H2O2 in 
methanol, rinsed in 0.2% Triton-X-100 in PBS (PBS-0.2Tx), incubated in 0.1 M 
Tris-glycine (pH 7.4), rinsed again in PBS, and then incubated in Blotto-Tx (4% 
Carnation dried milk in PBS-0.2Tx) for at least 1 h. Sections were subsequently 
incubated in polyclonal goat anti-Met primary antibody (HGFR, catalog #AF527, 
R&D Systems, Minneapolis, MN), diluted 1:250 in 0.1% Triton-X-100 in PBS 
(PBS-0.1Tx), for 2 h at room temperature. Sections were then washed several 
times in 0.2% Tween-20 in PBS (PBS-0.2Tw), and incubated with Biotin-SP-
conjugated donkey anti-goat IgG secondary antibody (Jackson 
Immunoresearch), diluted 1:500 in PBS-0.1Tx, for 1 h at room temperature. 
Sections were then washed in PBS-0.2Tw before processing with the ABC Elite 
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kit (Vector, Burlingame, CA), followed by a 5 m incubation in 0.5% 3,3’-
diaminobenzidine with 0.015% H202. Finally, slides were dehydrated in ethanol, 
cleared in d-limonene (VWR, Radnor, PA), and cover-slipped in DPX mounting 
medium (EMS, Hatfield, PA). 
 
Dextran Sulfate Sodium Treatment 
Dextran Sulfate Sodium (DSS) was administered to male adult null and 
wildtype animals to induce acute gastrointestinal epithelial injury (Kimura et al., 
1993; Whittem, Williams, & Williams, 2010). Several days before DSS treatment, 
adult (P60-125) male animals were separated to individual cages in which Lixit 
valves were removed and water bottles were the only source of water in the 
cage. At approximately 12 pm on day 0, the water bottle was replaced with an 
equivalent bottle containing 200 mL of 0.45 μm cellulose acetate-filtered 3% DSS 
(w/v in drinking water; molecular weight 36 – 50 kilodaltons; MP Biomedicals, 
Solon, OH). Chow weight was also recorded on day 0. DSS volume and chow 
weight were recorded at the end of the treatment period on day 8, when animals 
were sacrificed and tissue was collected. Colon tissue was collected as a single 
specimen from cecum to rectum, flushed, weighed and measured, filleted and 
prepared as a Swiss roll. During the experiment, animals were weighed and stool 
samples were collected daily to calculate the Disease Activity Index (DAI) 
(Cooper, Murthy, Shah, & Sedergran, 1993) for each day of treatment. Fecal 
occult blood was detected by guaiac-based Coloscreen-ES tests (Helena 
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Laboratories, Beaumont, TX). During the DSS administration, food and DSS 
solution were available to animals ad libitum. DSS was administered in two 
paradigms, as follows: chronically for 8 days; and for 4 days followed by 4 days 
of recovery in which fresh, non-DSS water replaced DSS in the cage. 
Additionally, water-only control experiments were performed, with tissue 
harvested in the same manner for DSS-treated tissue. For the duration of the 
experiments, from initial cage separation, through harvesting, tissue processing, 
and analysis, the investigator was blinded to animal genotype. 
 
Histologic Colitis Scoring 
HE stained sections were scored by an expert pathologist who was blinded to 
genotype and DSS condition (chronic, recovery, water-only control), using a 
previously-described and commonly-used histologic colitis score (Dieleman et al., 
1998). Using this scoring system, and with the investigator blind to treatment 
category and genotype, 3 individual scores were generated independently: an 
inflammation score (from 0/none to 3/severe); an inflammation extent score (from 
0/none to 3/transmural); and a crypt damage score (from 0/none to 4/entire crypt 
and surface epithelium lost). Percent involvement, for inflammation and crypt 
damage, was also assessed (from 1/less than 25% to 4/greater than 75%). A 
final score of colitis extent and severity was calculated by multiplying the percent 
involvement of inflammation times the inflammation scores, and the percent 
111
  
involvement of crypt damage times the damage score, and summing the results 
for a total injury and inflammation score, which is reported here. 
 
Microscopy 
An Axioplan II microscope and AxioCam HRc and MR3 cameras (Zeiss, Jena, 
Germany) were used for micrograph acquisition. Image annotation, resizing, de-
skewing and distance measurements were completed using Axiovision software 
version 4.1 (Zeiss). 
 
Data Analysis 
Study data were managed using REDCap, a secure, research-oriented, web-
based application (Harris et al., 2009). Statistical analyses were computed using 
SPSS version 18.0.3 (IBM, Somers, NY) and Prism version 5.0d (GraphPad, La 
Jolla, CA). Prism was also used for generating plots. Continuous measures 
(developmental weight, mucosa thickness, colon length ratio, histological colitis 
score) were plotted as mean and 95% confidence intervals (CIs) and were 
compared between wildtype and conditional nulls with two-tailed t-tests. Weight 
loss and DAI during the course of DSS experiments were compared with a 
repeated measures two-way ANOVA for time and genotype. For all statistical 







Normative Met Gastrointestinal Expression 
Met protein expression in the GI system was mapped in wildtype animals 
using immunohistochemistry. Three ages were selected for study: embryonic day 
15 (E15), P21, and adulthood (Figure 1). E15 is a time of rapid GI epithelium 
development, and Met expression was seen primarily in cells lining the lumen, 
precursors to the mature mucosa. By P21, colonic crypts are near maturity, and 
Met expression is still apparent. In the adult, Met expression was still apparent in 
epithelial cells, with a preponderance of staining in the lower portion of the 
colonic crypts, a site of continual cellular proliferation in the adult.  
 
Genetic Recombination in Conditional Nulls 
Villincre mice express Cre recombinase protein specifically in the GI 
epithelium, from early embryogenesis through adulthood (El Marjou, et al., 2004). 
The expression studies in Figure 1 suggested that the Villincre line would be an 
appropriate tissue-specific Cre line for Met conditional deletion from the GI 
epithelium. Villincre-mediated recombination of the floxed allele of Met exon 16 in 
colons of conditional null mice was confirmed by a PCR-based assay (Figure 2). 
Genomic DNA from colons and brains of wildtype and null animals was extracted. 
DNA from both tissues and both genotypes amplified a control amplicon, the 
template for which is the non-recombined floxed Met allele. The band for the  
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Figure 1. Immunohistochemical stain for Met expression in the mouse 
gastrointestinal system. A, E15; B, E15 without primary antibody. Met 
expression is seen in the developing epithelium, preceding the development of 
mature crypts. C, P21; D, P21 without primary. At P21, colonic crypts are nearly 
mature, and Met signal is still apparent in epithelial cells lining the crypts. E, 
adult; F, adult without primary. Met expression persists into adulthood in crypt 










Figure 2. Genetic recombination in Villincre/+; Metfx/fx animals, specifically in 
the colon. Genomic DNA was extracted from colon and brain tissue from Villin+/
+; Metfx/fx wildtype and Villincre/+; Metfx/fx conditional null animals and assessed 
with a PCR-based recombination assay. At left, all tissues show amplification of 
the fx-control amplicon. At right, only colon in Villincre/+; Metfx/fx null animals shows 
a specific band indicating recombination.
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Villin+/+; Metfx/fx wildtype (lane 1) is faint, but present. Cre protein in Villincre mice 
is expressed specifically in GI epithelial cells, leaving other GI cell types (such as 
smooth muscle, immune, enteric nervous) untargeted for recombination. As such, 
non-recombined floxed Met DNA persists in DNA extracted from a heterogenous 
GI cell population (such as that from whole colon); the control amplicon is also 
generated from Villincre/+; Metfx/fx colon tissue (lane 3). Importantly, the 
recombination-specific amplicon is only generated from colon DNA of Villincre/+; 
Metfx/fx animals, demonstrating specific Villincre-mediated recombination of the 
floxed Met allele only in colon tissue. As previously reported, genetic excision of 
this floxed Met allele is sufficient to preclude Met receptor phosphorylation in 
response to HGF stimulation, indicating that recombination successfully 
incapacitates Met receptor signaling function (Judson, et al., 2010b). 
 
Developmental Growth in Conditional Nulls 
As the GI epithelium is critical for nutrient absorption, the developmental 
weight gain of conditional null pups was measured (Figure 3). Five to 10 animals 
at each age, for each genotype and sex, were weighed on day of birth (P0), P4, 
P7, P14 and day of weaning (P21). Comparing wildtype versus nulls in pre-
weaning males and females, as well as adult males, showed no significant 
































Figure 3. Comparing wildtype versus conditional null animals for weight 
gain during adolescence and in adulthood. A, pre-weanling females; B, pre-
weanling males; C, adult males. No significant differences were found between 
genotypes, for either sex, at any age. Horizontal bars indicate means; vertical 
bars are 95% CIs.
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Histology in Conditional Nulls 
As Met signaling is important in the development of other organs (Schmidt, et 
al., 1995; Uehara, et al., 1995), it was hypothesized that loss of Met signaling in 
GI epithelial cells could alter development of the colonic mucosa. Qualitative 
histological examination of Swiss roll preparations of mouse colon (wildtype n = 
5, null n = 6) showed no gross differences between genotypes (Figure 4). 
Quantitative analysis of mucosal thickness showed no difference between 
genotypes (Figure 5; mean thickness in μm ± SD: wildtype 251.8 ± 18.4; null 
242.3 ± 18.1).  
 
Systemic Effects of DSS Treatment 
Although conditional null animals did not have a measurable histological 
difference in mucosal thickness (Figure 5), because Met signaling is involved in 
repair and regeneration of other tissues (Borowiak, et al., 2004; Chmielowiec, et 
al., 2007; Huh, et al., 2004) and HGF administration augments GI epithelial repair 
(Numata, et al., 2005; Oh, et al., 2005; Tahara, et al., 2003), Met conditional null 
animals were subjected to acute injury experiments to directly assess the 
response of null animals to GI injury. DSS is a commonly used model for acute 
GI epithelial injury and repair, and was the paradigm used in these studies. As is 
well known, DSS treatment causes colonic shortening, due to inflammation and 
edema (Figure 6A). For both wildtype (n = 14) and null (n = 11) animals, colon 
length (relative to the animal’s total body weight) was significantly decreased with 
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Figure 4. Swiss roll preparation of mouse colon, comparing wildtype and 
null mice. A, Villin+/+; Metfx/fx wildtype. B, Villincre/+; Metfx/fx conditional null. In both 




Figure 5. Mucosa thickness in conditional null mice. A, Micrograph of 
wildtype tissue showing an example measurement of mucosa thickness, 265 
μm. Scale bar 100 μm. B, No significant difference in mucosa thickness between 













DSS treatment relative to water-only control treatment (Figure 6B; P ≤ 0.01). 
Within DSS and water-only treatment groups, no difference was seen between 
genotypes (group mean ratios in cm/g ± SD were as follows: wildtype, water 
0.368 ± 0.024, DSS 0.312 ± 0.040; null, water 0.375 ± 0.044, DSS 0.288 ± 
0.025). During the course of DSS treatment over 8 days, animal body weight was 
measured daily (Figure 7A). On day 5 of treatment, animals of both genotypes 
begin rapidly losing body weight (Figure 7B, which has an enlarged y-axis of data 
in Panel A). No significant differences in total weight lost were seen between 
genotypes (mean in percent of day 0 weight lost ± SD: wildtype 12.7 ± 6.3; null 
11.5 ± 2.7). DAI (Cooper, et al., 1993) was also calculated for each day of DSS 
treatment. DAI is a composite score of weight loss, fecal occult blood, and stool 
consistency, with higher numbers indicating increased disease activity. No 
significant differences in DAI were seen between genotypes (Figure 7C). No 
significant differences were seen between genotypes for chow (mean in g ± SD: 
wildtype 30.2 ± 4.5; null 29.6 ± 4.5) or DSS (mean in mL ± SD: wildtype 52.4 ± 
22.7; null 48.0 ± 4.9) consumed over the 8 days of DSS treatment. 
 
Histologic Colitis Score After Chronic DSS 
Pathological effects of DSS-induced acute injury are commonly scored using 
a composite histologic colitis score, which rates extent and severity of 
inflammation and extent of crypt damage (Dieleman, et al., 1998). In this metric, 
higher scores indicate worse injury and inflammation, and the maximum score is 
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Figure 6. DSS treatment causes colonic shortening. A, Examples of 
harvested colons from wildtype animals, comparing animals fed drinking water 
versus 3% DSS for 8 days. B, Group data for wildtype and null animals on water 
versus DSS. No differences between genotypes in either water or DSS treatment 
groups. Both genotypes showed significant shortening with DSS treatment. 
Group mean ratios in cm/g ± SD were as follows: wildtype, water 0.368 ± 0.024, 
DSS 0.312 ± 0.040; null, water 0.375 ± 0.044, DSS 0.288 ± 0.025. Horizontal 















































Figure 7. Systemic effects of DSS treatment, comparing wildtype versus 
null animals. A, Percent of weight relative to Day 0 of 3% DSS treatment for 8 
days. B, Focused view of weight loss from A showing days 4 to 8 of DSS 
treatment on a enlarged vertical scale. C, Disease Activity Index over DSS 




40 for a single animal. An expert pathologist (Dr. Kay Washington, Vanderbilt 
University Medical Center), blinded to genotype and DSS versus water-only 
treatment, scored tissue for colitis (Figure 8). At low power magnification, no 
gross differences were readily apparent between genotypes (Figure 8A-B). 
Higher power magnification showed dense infiltration of basophilic inflammatory 
cells and obliteration of the normal crypt axis and architecture, although with no 
apparent qualitative differences between genotypes (Figure 8C-D). Statistical 
comparison of total histologic scores between genotypes showed no difference 
after DSS treatment (Figure 8E; group mean score ± SD: wildtype 29.4 ± 6.1; null 
31.7 ± 7.3). Water-only controls showed no injury or inflammation, for either 
genotype (Figure 8E). 
 
Histologic Colitis Score After Recovery From DSS 
Because Met signaling has been implicated in tissue repair and regeneration, 
Met conditional null animals were tested for repair capacity in response to acute 
DSS-induced injury. In this recovery paradigm, rather than a chronic 8-day 
administration of DSS, animals were exposed to DSS for 4 days and then 
allowed to recover for 4 days on water. Similar to chronic DSS administration, no 
gross histological differences were seen between genotypes at low magnification 
(wildtype n = 6; null n = 6; Figure 9A-B). At higher magnification, tissue repair is 
readily apparent with normal crypt architecture reappearing in both genotypes 
(Figure 9C-D). Infiltrating cells are still seen, however. In contrast to the 8-day  
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Figure 8. Colitis after DSS administration in wildtype compared to null 
animals. A, Villin+/+; Metfx/fx wildtype and B, Villincre/+; Metfx/fx null low power 
micrographs of Swiss rolled-colon after 8 days of 3% DSS treatment, HE 
stained. C, wildtype and D, null high power micrographs of representative tissue 
with histologic colitis scores similar to group means seen in E. E, Total histologic 
colitis score, comparing wildtype and null animals in water-only control 
experiments and DSS experiments. No significant differences between 
genotypes in either treatment condition (for DSS, group mean score ± SD: 
wildtype 29.4 ± 6.1; null 31.7 ± 7.3). Total histologic colitis score includes 
inflammation severity and extent, crypt damage, and percent involvement. 
Abbreviations: L, lumen; S, submucosa.
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Figure 9. Colitis after DSS administration and subsequent recovery period 
in wildtype compared to null animals. A, Villin+/+; Metfx/fx wildtype and B, 
Villincre/+; Metfx/fx null low power micrographs of Swiss rolled-colon after 4 days of 
3% DSS treatment followed by 4 days of recovery on water, HE stained. C, 
wildtype and D, null high power micrographs of representative tissue with 
histologic colitis scores similar to group means seen in E. E, Total histologic 
colitis score, comparing wildtype and null animals after DSS treatment and 
recovery. Null animals maintain a significantly increased score after DSS 
recovery (group mean score ± SD: wildtype 6.7 ± 3.6; null 18.0 ± 9.4). Total 
histologic colitis score includes inflammation severity and extent, crypt damage, 














Colitis  Score P  = 0.02
126
  
treatment results, quantitative analysis of total histologic score in the recovery 
experiment showed a significant difference between wildtype and null animals 
(Figure 9E, P = 0.02; group mean score ± SD: wildtype 6.7 ± 3.6; null 18.0 ± 9.4). 
Null animals had higher scores in this recovery paradigm, indicating increased 
inflammation and injury, compared to wildtype animals. The high power 
exemplary micrographs (Figure 9C-D) depict tissue with scores approximating 
group mean scores. However, due to the apparent bimodal distribution of scores 
in null animals, a single animal with a score approximating the null mean score 
was not available. Additionally, one null animal had a total score of 0, which was 
greater than two standard deviations from the group mean, and was thus 
excluded as an outlier. 
 
Met Expression After DSS 
Met protein expression in wildtype animals after DSS treatment was studied 
by immunohistochemistry. Compared to water-only control experiments in which 
Met is expressed at modest levels in the lower compartment of crypts (Figure 
10A), Met expression was dramatically increased after both chronic DSS 
treatment (Figure 10C) and DSS treatment followed by recovery (Figure 10D). 
Met expression was increased in both the lower portion of crypts where cellular 





Figure 10. Immunohistochemical stain for Met expression in wildtype 
animals after water compared to DSS treatments. A, Water. B, Water, stained 
without primary antibody. C, 3% DSS treatment for 8 days. D, DSS treatment for 
4 days, followed by 4 days of recovery on water. Met expression dramatically 










The results of the studies reported here provide the first data from a genetic 
model implicating Met signaling in gastrointestinal physiology. The findings are 
consistent with existing reports in the literature implicating HGF treatment for 
enhancing gut epithelial repair after experimental injury. Our protein expression 
studies corroborate what has been previously reported, and contribute additional 
details regarding cellular specificity. Met protein was detected in the E15 intestine 
primarily in the immature epithelium, which is consistent with a previous report 
that demonstrated Met mRNA expression at E15 in the developing intestine, 
although without cellular resolution (Sonnenberg, Meyer, Weidner, & Birchmeier, 
1993). Similarly, modest protein expression was detected in adult GI epithelial 
cells, similar to what has been previously reported (Boon et al., 2006). The 
relative decrease in Met GI expression during development, from E15 to P21, is 
reminiscent of the temporal expression profile reported in the nervous system 
(Judson, et al., 2009), suggesting that Met signaling is most likely active during 
specified periods of development but then is down-regulated in a mature, 
uninjured epithelium. 
After mapping expression of Met protein in the GI epithelium, the Villincre line 
was chosen to conditionally delete floxed Met specifically in GI epithelial cells. 
Conditional null animals displayed normal development, as weight gain was 
unaffected and adult mucosal thickness was not different relative to wildtype 
animals. As Met was expressed robustly during GI development, this absence of 
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a phenotype in conditional null animals was surprising. Other knockout mice 
lacking genes of interest in the GI system have shown basal phenotypes. For 
example, mice lacking secretory mucin (Muc2-/-), the structural component of the 
mucus layer lining the GI lumen, display growth retardation and spontaneously 
develop colitis (Van der Sluis et al., 2006). However, the absence of a phenotype 
in the null animals reported here is not unprecedented. Mice lacking intestinal 
trefoil factor (Itf-/-), a protein specifically and abundantly expressed in the GI tract, 
were reported to develop normally and be indistinguishable from wildtype 
animals, with normal growth and absence of fecal occult blood (Mashimo, Wu, 
Podolsky, & Fishman, 1996). Itf-/- mice did, however, display increased 
susceptibility to and impaired healing after acute injury induced by DSS. It is 
possible that any altered phenotype due to deletion of Met signaling may be far 
more subtle than the general measures used here were able to detect. This is 
reminiscent of the subtle changes in dendritic and spine structure of neurons that 
normally express Met, which was reported in the mouse brain (Judson, et al., 
2010b). There are, however, far more impactful physiological consequences in 
the brain due to Met signaling disruption (Qiu, Anderson, Levitt, & Shepherd, 
2011). This is consistent with the functional findings here. 
As Met signaling is implicated in injury repair in other tissues, Villincre/+; Metfx/fx 
conditional null animals were assessed for susceptibility to DSS-induced acute GI 
injury. Chronic DSS treatment showed no difference in susceptibility to injury 
between wildtype and null animals, as measured by total histologic colitis score. 
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This finding was surprising, as it was hypothesized that if Met signaling was 
involved in mounting a repair response to epithelial injury, then loss of Met 
signaling would increase an animal’s susceptibility to injury as it would be limited 
in its capacity to respond to the ongoing DSS injury. A possible explanation for 
this lack of increased susceptibility between null and wildtype animals is that the 
8-day DSS paradigm used in these studies may have a ceiling effect. The 
histologic score has a maximum of 40, and both genotype group means were 
approaching this maximum (approximately 30 in both groups). Lower 
concentration of DSS administration, or for a shorter duration, may in future 
studies enable differentiation of susceptibility between genotypes with a less 
robust induced injury. 
We addressed the potential ceiling effect of the chronic treatment by using a 
classic injury/repair paradigm. Met conditional null animals were significantly less 
able to repair in the DSS recovery paradigm, compared to wildtype mice, 
measured by histologic colitis score. This finding is consistent with previous 
studies demonstrating Met signaling system involvement in repair of skin wounds 
(Chmielowiec, et al., 2007) and liver regeneration after injury (Borowiak, et al., 
2004; Huh, et al., 2004). In the context of Met protein expression data, which 
showed up-regulation of Met after DSS administration, an interpretation of these 
findings would be that loss of functional Met signaling, which in wildtype animals 




This report has several limitations and opportunities for future studies. The 
sample size for the recovery experiments needs to be enlarged to clarify if the 
conditional null histological colitis scores truly are bimodal, or instead merely 
represent natural biological variation and heterogeneity. The colitis scoring 
system, while common in the literature, is only semi-quantitative and restricted to 
discrete scores. A continuous measure of damage, for example by staining intact 
actin in enterocytes with phalloidin, would be more sensitive for detecting modest 
effects in null animals. Quantitative analysis of specific classes of infiltrated 
immune-competent cells would also provide additional evidence for differing 
pathology beyond the colitis scores. For example, cell counts for macrophages 
(by F4/80 staining) and CD4+ T cells, and granulocyte infiltration (by 
myeloperoxidase activity assays) would all be important future studies. Moreover, 
the immunohistochemical staining data for Met expression is qualitative in nature, 
and should be augmented by quantitative Western blot studies. Co-labeling 
studies with markers for specific crypt cell types will also be important, to better 
understand the particular role played by Met signaling in response to injury. For 
example, Musashi-1 is a putative marker of the colonic stem cell (Kayahara et al., 
2003; Potten et al., 2003), and co-staining may help to clarify if Met’s role is 







Met signaling is involved in diverse biological processes, by initiating multiple 
signal cascades that possess a degree of overlap and crosstalk (Trusolino, et al., 
2010). The data reported here showing absence of a basal phenotype in Met 
conditional null animals may be explained by this signaling redundancy in the 
context of formidable homeostatic mechanisms, or that Met signaling is not 
critically involved in normal development and function of the GI epithelium. Data 
reported here do, however, demonstrate a critical role for Met in GI epithelial 
repair after acute injury. The data reported here are unable to clarify what specific 
cellular processes are deficient and responsible for impaired responsiveness in 
null animals. Three possible processes are epithelial motility and proliferation 
(both of which Met signaling is implicated in (Dignass, Lynch-Devaney, & 
Podolsky, 1994)), and regulation of infiltrated cells (in which Met signaling is 
involved in both paracrine and autocrine signaling for macrophage functioning 
(Galimi et al., 2001). Future studies may elucidate the relative contributions of 
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Translational in nature, this thesis sought to use a tripartite approach to 
understanding complexity in autism spectrum disorders (ASDs) through the lens 
of co-occurring gastrointestinal dysfunction (GID) in children. With the wealth of 
data analyzed (over 5,000 lines of custom computer code were written for the 
project), rich phenotypes apparent in ASD and GID populations were described. 
Unique behavioral features of co-occurring ASD-GID children (increased 
language and social impairment) were paralleled by elevated levels of 15-F2t-
isoprostane (isoP), a marker of oxidative stress, in a subgroup of ASD-GID 
children. In a mouse model lacking functional signaling of the Met receptor 
tyrosine kinase, a well-established ASD-risk gene, a deficit in epithelial repair 
was described, providing data that will contribute to understanding 
gastrointestinal biology. The findings of this thesis will add to the developing 
literature regarding, and clinical care of, children with ASD and GID.  
In a larger context, the broad goal of this thesis was to use GID as a model for 
how heterogeneity can be leveraged to the investigator’s advantage, by 
appreciating pleiotropy in the context of whole-body physiology, and stratifying 
based on a readily-assessed comorbid condition such as GID. We hope that the 
combined findings reported in this thesis will serve as an inspirational model for 
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future studies, highlighting the advantages of a translational approach and 
stratification to address complexity. Building on this thesis, a number of 
interesting avenues of future study are discussed below. 
 
Characteristics of a Latino Population and Cross-Cultural Comparisons 
Prevalence of ASDs in Latino populations has been reported to be 
significantly lower than in non-Latino white populations, with some suggesting 
that socioeconomic status, access to services, or cultural factors affect the 
likelihood of diagnosis in Latino populations (Liptak et al., 2008; Mandell et al., 
2008). Cross-cultural comparisons that explore similarities and differences 
between Latino and non-Latino populations may thus provide insight into the 
natural history and ecology of ASDs within a Latino context. For logistical 
reasons, this thesis did not include data from the second recruitment site, 
Children’s Hospital of Los Angeles (CHLA). However, similar data to that 
collected at Vanderbilt (Chapters II and III) has been collected from participants 
in Los Angeles. Corresponding to the high prevalence of Latino patients in the 
general patient population of CHLA, approximately 40% of the participants in the 
CHLA cohort recruited for this study are of self-identified Latino ethnicity. We are 
not aware of any studies that have looked rigorously in Latino populations at 
issues involving co-occurring GID and ASD, making data from the CHLA cohort a 
potentially rich opportunity for future analysis. For example, in an exploratory 
analysis of the utilization of gluten-free/casein-free (GFCF) diets in 51 children at 
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CHLA, significant differences exist between Latino and non-Latino white 
populations (M. Miller, P. Gorrindo and P. Levitt, unpublished observations). 
Comparing ethnicities in those 51 children, significantly more white (11 of 31) 
versus Latino (1 of 20) children have tried a GFCF diet (χ2, P = 0.01). Comparing 
ASD and GID status, 10 of 30 ASD-GID children have tried a GFCF diet, 
whereas only 1 of 7 ASD-only and 1 of 14 GID-only children have. Focusing only 
on the 30 ASD-GID children, 52.9% of white children (9 of 17), but only 7.7% of 
Latino children (1 of 13) have tried GFCF diets (χ2, P = 0.009). While these data 
are limited by a small sample size, they do offer a glimpse into the possibilities of 
describing unique differences between Latino and white populations with ASD 
and GID. 
 
Regression Modeling and Potential Predictive Utility of Elevated IsoP 
Levels in ASD-GID Children 
The elevated isoP levels in a subgroup of children with ASD-GID was 
surprising to us, and offers an intriguing line of future research. Active and 
ongoing work seeks to apply advanced analytic techniques, including regression 
modeling, to better characterize the subgroup of individuals with elevated isoP 
levels. The extent to which, if any, isoP levels correlate with behavioral findings in 
the ASD-GID group, such as increased language and social impairment, will be 
interesting. Within the ASD-GID group, determining what, if anything is similar 
amongst the subgroup of individuals with elevated levels, and, related, what is 
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different between that cluster and other children in the ASD-GID group may 
provide insight into the biology of ASD. Additionally, as discussed below, 
integrating isoP measurements in studies of treatment response may 
demonstrate a biomarker sensitive to disease state or prognosis. With a better 
understanding of isoP-phenotype relationships, if a regression model with high 
sensitivity and specificity can be built, we possess the unique opportunity to then 
test the predictive capacity of such a model in the CHLA cohort. Prediction and 
replication of the isoP findings in an independent cohort will provide substantial 
support to the initial findings reported in Chapter III. 
 
Nonverbal Children: A Conspicuous Phenotype with Potential Clinical 
Implications 
The report in Chapter II of a significant portion of nonverbal children in the 
ASD-GID group (30%) was striking and unexpected. The complete absence of 
expressive language capacity is a robust and salient phenotype that warrants 
deeper investigation. Future work may gather a comprehensive characterization 
of language and communication abilities, including a history of language 
development and nonverbal communication strategies. Use of specific, research-
quality instruments (Vineland Adaptive Behavior Scales-II; Kaufman Brief 
Intelligence Test-2) to evaluate communication skills should be incorporated into 
all future studies of the ASD-GID population. 
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Additionally, it will be important to interrogate the relationship between GID 
status and language capacity. One hypothesis is that the co-occurrence of 
nonverbal status with GID and ASD represents a specific syndrome, a complex 
and pleiotropic manifestation of disrupted biology. Human genetic studies of 
larger cohorts stratified by language impairment, in addition to GID status, may 
provide useful data to this end. An alternative hypothesis is that nonverbal 
children, lacking conventional communication abilities, are unable to 
communicate internal states to caregivers and thus are unable to impose any 
control on behavioral or environmental factors that modify GID state. One 
approach to this question is to assess physiological states of children, 
independent of their communication abilities, and correlate changes in state with 
coincident environmental changes. An exploratory collaboration seeks to refine a 
multimodal real-time physiological monitor. In its current incarnation, the non-
invasive device is worn by a study participant for a number of days, enabling the 
device to capture longitudinal data on galvanic skin response (GSR), heart rate, 
and general locomotive and activity level — all independent of the participant’s 
communication ability. Parental reports of time of eating and going to the 
bathroom, for example, can then be combined with physiological measures of 
internal state to specifically test for correlations between acute events and 
heightened arousal.  
Finally, an important clinical implication of the nonverbal findings is that, 
lacking traditional communication abilities, some children may have ongoing, 
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latent GID that has not yet been detected by their caregivers or clinical care 
providers. To this end, an important future area of work would be the 
development of a highly sensitive GID screening tool, independent of verbal 
capacity of the child, which could be used by parents or primary care clinicians to 
determine if evaluation by a pediatric gastroenterologist is warranted (Buie et al., 
2010). 
 
Deeper Characterization of GID: Focus on Constipation 
The relative homogeneity of type of GID in ASD-GID children was somewhat 
surprising (85% constipation, Chapter II). Future studies may benefit from 
focusing specifically on constipation, to develop a richer understanding of GID in 
ASD. The potential causes of constipation in children are myriad, ranging from 
toilet phobia, depression, or dehydration, to anatomical malformations, electrolyte 
imbalances, or connective tissue disorders (Constipation Guideline Committee of 
the North American Society for Pediatric Gastroenterology Hepatology and 
Nutrition, 2006). Some possible causes are rare, and multiple factors can 
combine in complex ways to influence outcome. While many of these possible 
causes were assessed in the study described in Chapter II, future studies would 
benefit from a systematic and comprehensive assessment by pediatric 
gastroenterologists of each potential cause to clarify the relative contributions of 
functional, anatomic, metabolic, infectious, inflammatory, neoplastic, dietary, and 
pharmacological factors to GID status.  
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Moreover, the GID described in Chapter II is not acute, as a study inclusion 
requirement was duration of GID greater than one month. A close examination of 
the natural history and developmental time-course of chronic GID presentation 
may offer insight into etiology and prognosis. As ASDs are neurodevelopmental 
disorders, with a changing biology interacting with a dynamic environment over 
the course of development, some have proposed that biology-behavior-
environment interactions funnel an individual into an increasingly atypical social 
environment (Jones & Klin, 2009). It is possible then, by extension, that GID 
status funnels an individual into a similarly abnormal “gastrointestinal 
environment” — a parallel concept to the social environment, which involves the 
various possible causes and outcomes of GID discussed above. 
 
Functional Implications of Co-occurring GID in ASD 
The language and social impairments reported in a portion of ASD-GID 
children suggested that GID has important implications for the overall functional 
abilities of an individual, with synergistic effects of ASD and GID statuses when 
co-occurring. These findings are corroborated by exploratory analysis of an 
additional dataset. For a subpopulation of children described in Chapter II, we 
serendipitously were able to assess children for functional behaviors on the Child 
Behavior Checklist (CBCL; (Achenbach & Rescorla, 2001). For 17 ASD-GID 
children and 9 ASD-only children, we see significantly higher scores on functional 
impairment metrics in the ASD-GID group compared to ASD-only, including 
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attention problems, rule-breaking behaviors, aggressive behaviors, and anxiety 
problems (P. Gorrindo and P. Levitt, unpublished observations). These findings, 
although in a small cohort, suggest GID status correlates with additional problem 
behaviors that have functional implications on daily living for children (Buie, et al., 
2010). Moreover, it has been reported that family quality of life also is negatively 
impacted by more severely affected children (Herring et al., 2006) which can 
negatively impact family-based intervention strategies (Osborne, McHugh, 
Saunders, & Reed, 2007).  
To further explore the relationship between GID, functional impairment in 
affected children, and parental quality of life, a longitudinal study before and after 
GID treatment is proposed here. On study enrollment, all ASD participants would 
be screened for possible constipation using Rome-III criteria (Drossman, 2006; 
Walker, Caplan-Dover, & Rasquin-Weber, 2000). Standard of care for 
constipation is parental counseling and advised use of over-the-counter stool 
softeners and laxatives (SSL). Participants who screen for high likelihood of 
constipation would be randomized to one of two study arms: (a) treatment with 
SSL beginning immediately, after evaluation by a pediatric gastroenterologist or 
(b) wait-list control, with a one month delay in evaluation by gastroenterologist 
and initiating SSL treatment. Baseline measures of problem behaviors, social 
impairment, and parental quality of life would be assessed at study enrollment for 
both arms. As treatment with SSL would be administered by one parent, during 
this study a requirement would be that a second parent be available to act as an 
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informant blinded to treatment status of the child, completing the CBCL 
(assessing for functional ability and problem behaviors) and SRS (assessing for 
social impairment) regarding the child in the study, and the Questionnaire on 
Resources and Stress (QRS; (Osborne, et al., 2007), an instrument assessing 
quality of life issues for the SSL-administering, non-blinded parent. Additionally, 
blood would be drawn at baseline, to measure isoP levels. These measures 
would be repeated at one month after enrollment. For the treatment arm, at that 
time they would then have completed one month of treatment. For the wait-list 
control arm, they would have not yet received treatment, but would subsequently 
begin treatment at that time. The measures would be repeated again at two 
months after enrollment, which would be two months of treatment for the 
treatment arm, and one month of treatment for the wait-list arm. During the 
course of the study, weekly phone calls with participating parents would assess 
for treatment compliance by ascertaining frequency of use of SSL and stooling 
history during the preceding week. Primary analytic outcomes would be, 
comparing means between study arms, the following: change in isoP levels, as 
well as CBCL, SRS, and QRS scores at one and two months from baseline. It is 
hypothesized that the treatment arm will see significant improvements (lower 
scores on the instruments, and isoP levels) after one month, whereas the wait-list 
arm will not see significant change during the first month, but will see 
indistinguishable improvements during the second month compared to 
improvements seen in the first month of the treatment arm. These findings would 
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be able to objectively and quantitatively address the suggestion that appropriate 
treatment of co-occurring medical conditions in children with ASDs can positively 
impact both the developmental course of the affected child, and the quality of life 
of the family as a whole (Bauman, 2010). 
 
Methodological Refinements To Detect A Subtle Repair Phenotype in 
Conditional Null Mice 
As reported in Chapter IV, Villincre/+; Metfx/fx conditional null animals have a 
deficit in repair capacity in response to an induced acute gastrointestinal (GI) 
epithelial injury. There are two points worth noting regarding these findings. First, 
no phenotype was seen in 8-day chronic administration of dextran sulfate sodium 
(DSS). Second, in a 4-day on/4-day off recovery paradigm of DSS administration, 
while a group effect was seen using a histologic colitis score, there was 
substantial variability within the conditional null group using this metric. While one 
possible explanation of these findings is that they faithfully represent the 
underlying biology of Met in the gastrointestinal system, another possibility is that 
Met signaling has modest effects on cellular biology and the analytic approaches 
employed were of insufficient resolution to detect such differences. For example, 
relatively modest changes in spine and dendritic structure were seen in neurons 
lacking Met (Judson, Eagleson, Wang, & Levitt, 2010).   
To improve our detection ability of modest changes in the GI epithelium, two 
major approaches are possible. First, a less dramatic injury may unmask 
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differences that in the existing paradigm are indistinguishable. A lower 
concentration or shorter duration of administration of DSS may prove useful. 
Additionally, combined with an attenuated DSS treatment, it would be interesting 
to explore additive effects of psychosocial stressors. It has been reported that 
DSS-induced injury can be modulated by environmental stressors, such as cage 
overcrowding (Reber et al., 2006; Veenema, Reber, Selch, Obermeier, & 
Neumann, 2008). One potential future study could be low-dose (1%, instead of 
3%) DSS, with and without a socially-stressful environmental factor to see if 
psychosocial stress can, in the context of low-dose DSS, elicit a phenotype in 
nulls but not wildtype animals.  
Second, more sensitive and quantitative measurements may be better able to 
detect subtle epithelial phenotypes. DSS studies commonly measure 
myeloperoxidase (MPO) activity, as an index of granulocyte infiltration (Beck et 
al., 2010). The tissue harvest protocol for the DSS studies in Chapter IV included 
filleting a narrow longitudinal piece of colon tissue prior to immersion fixation, and 
flash-freezing the sample in liquid nitrogen. These frozen samples could thus be 
used for both MPO activity assays, and Western blots for Met protein levels. 
Additionally, a novel metric of epithelial integrity is proposed here, using 
phalloidin staining of enterocyte actin filaments. Figure 1 shows proof-of-principle 
staining of actin using Alexa 488-conjugated phalloidin (Invitrogen, Carlsbad, 
CA). Panel A shows wildtype tissue exposed to water only, with a bright and 
continuous band of phalloidin signal lining the lumen, as expected. Panel B 
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shows wildtype tissue exposed to 8-days of chronic DSS administration, with 
discontinuous patches of staining signal (arrow), representing patches of intact 
epithelium, interspersed among denuded epithelium which does not stain with 
phalloidin (arrowhead). We propose using an automated image acquisition and 
processing strategy, in which a strong phalloidin signal is distinguished from 
background by signal intensity thresholding, to gather a section-level and 
continuous index of epithelial integrity. Additionally, in response to DSS injury, 
colonic restitution includes up-regulated cellular proliferation (Edelblum et al., 
2008). Figure 2 shows preliminary staining for Ki67, a marker of proliferating 
cells, in wildtype tissue treated with water (Panel A) compared to 8-day DSS 
(Panel B). As seen in the figure, response to DSS includes a dramatic increase in 
proliferating cells; cell counts of Ki67-positive cells may evince a modest 
genotype effect in Met conditional null animals. Finally, staining for markers of 
specific classes of immune-competent infiltrating cells in response to DSS may 
reveal differences in null animals. Two important classes of cells in the DSS 
paradigm include macrophages and CD4+ T cells. Figure 3 shows preliminary 
staining for both cell types, in wildtype tissue treated with water (Panels A and C), 
and dramatically increased staining signal in wildtype tissue after 4-day on/4-day 
off DSS administration (Panels B and D). Ongoing work seeks to refine the 
immunohistochemical protocol for these markers, after which rigorous cell count 




Figure 1. Apical actin filaments in enterocytes lining the gastrointestinal 
lumen stained with phalloidin. A, Wildtype tissue after water-only control 
treatment, with intense phalloidin-staining signal apparent in cells lining the 
lumen. B, Wildtype tissue after 8-day 3% DSS treatment, resulting in significant 
epithelial and crypt damage. Patches of intact staining, representing presumably 
intact epithelium, are apparent (arrow), compared to stretches of denuded 
epithelium lacking any phalloidin staining (arrowhead). Abbreviations: L, lumen; 








Figure 2. Immunohistochemical stain for Ki67 as a measure of active 
cellular proliferation in colon tissue. A, Low basal signal for Ki67 in wildtype 
tissue on water. B, Although the crypt architecture is significantly damaged, there 
is a robust increase in Ki67 staining in wildtype tissue after 3% DSS treatment 








Figure 3. Immunohistochemical staining for infiltrated immune-competent 
cells in response to DSS administration. A and B, F4/80 staining for 
macrophages. C and D, CD4 staining for CD4+ T cells. A and C, wildtype tissue 
treated with water. B and D, wildtype tissue after 4-day on/4-day off DSS in the 
recovery paradigm. Dramatic increases in staining for both markers are apparent 
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